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mri
Abstract
To expand the utility of hyperpolarized (hp) 129Xe NMR for sensitive biodetection, a cryptophane host
molecule can be specifically targeted to analytes of interest. This system has the potential to be used in
conjunction with proton MRI for the diagnosis and staging of disease. Xenon was found previously to
have high affinity (KD = 20-30 µM at room temperature) for trifunctionalized, water-soluble cryptophanes.
Cryptophanes have been designed for increased water solubility and xenon affinity, and provide a broad
(~300 ppm) chemical shift window. Importantly, new synthetic methods have enabled conjugation of a
variety of targeting and solubilizing ligands, and increased access to enantiopure cryptophane. This
dissertation reports my progress in three areas. The first involves studies with carbonic anhydrase, a
useful model system for the design and characterization of xenon biosensors targeted to enzymes
indicated in disease progression. Cryptophane functionalized with a benzenesulfonamide ligand and two
water-solubilizing moieties bound to carbonic anhydrase II (CAII) with nanomolar affinity; Zn2+
coordination in the active-site channel was confirmed by X-ray crystallography. Using xenon biosensors
tailored for CA, progress has been made in manipulating and better resolving the 129Xe NMR chemical
shift, as required for multiplexing studies. The second study details the development of a biosensor that
labels cells in an acidic microenvironment. Cryptophane was conjugated to a peptide that undergoes a
conformational change from random coil to alpha-helical as the pH decreases from 7.5 to 5.5. This
conformational change stimulates membrane insertion, as validated with HeLa cell studies. With this
compound we demonstrated the engineering of the largest published chemical shift change for
cryptophane biosensor. We also utilized hp 129Xe chemical exchange saturation transfer (Hyper-CEST)
NMR methods to achieve low-picomolar cryptophane detection, which creates new opportunities for bioanalysis and molecular imaging. Finally, a peptido-cryptophane was developed that binds to calmodulin
(CaM) protein. With this work we hope to not only demonstrate the development of a biophysical probe
sensitive to changes in protein conformation but also generate a Ca2+ sensor. These three studies
highlight the broad utility of cryptophane-129Xe NMR biosensors, and synthetic methods described herein
lay the groundwork for future in vivo studies.
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Out of sheer luck and many footsteps, I made it.
-Markus Zukus, The Book Thief

“Do you think things always have an explanation?”
"Yes. I believe that they do. But I think that with our human limitations we're not always
able to understand the explanations. But you see, Meg, just because we don't understand
doesn't mean that the explanation doesn't exist.”
Madeleine L’Engle, A Wrinkle in Time
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ABSTRACT
DESIGN AND SYNTHESIS OF TARGETED CRYPTOPHANE BIOSENSORS FOR
XENON-129 NMR/MRI
Brittany A. Riggle
Ivan J. Dmochowski

To expand the utility of hyperpolarized (hp)

129

Xe NMR for sensitive biodetection, a

cryptophane host molecule can be specifically targeted to analytes of interest. This system
has the potential to be used in conjunction with proton MRI for the diagnosis and staging
of disease. Xenon was found previously to have high affinity (KD = 20-30 µM at room
temperature) for trifunctionalized, water-soluble cryptophanes. Cryptophanes have been
designed for increased water solubility and xenon affinity, and provide a broad (~300 ppm)
chemical shift window. Importantly, new synthetic methods have enabled conjugation of a
variety of targeting and solubilizing ligands, and increased access to enantiopure
cryptophane. This dissertation reports my progress in three areas. The first involves studies
with carbonic anhydrase, a useful model system for the design and characterization of
xenon biosensors targeted to enzymes indicated in disease progression. Cryptophane
functionalized with a benzenesulfonamide ligand and two water-solubilizing moieties
bound to carbonic anhydrase II (CAII) with nanomolar affinity; Zn2+ coordination in the
active-site channel was confirmed by X-ray crystallography. Using xenon biosensors
tailored for CA, progress has been made in manipulating and better resolving the

129

Xe

NMR chemical shift, as required for multiplexing studies. The second study details the

viii

development of a biosensor that labels cells in an acidic microenvironment. Cryptophane
was conjugated to a peptide that undergoes a conformational change from random coil to
alpha-helical as the pH decreases from 7.5 to 5.5. This conformational change stimulates
membrane insertion, as validated with HeLa cell studies. With this compound we
demonstrated the engineering of the largest published chemical shift change for
cryptophane biosensor. We also utilized hp

129

Xe chemical exchange saturation transfer

(Hyper-CEST) NMR methods to achieve low-picomolar cryptophane detection, which
creates new opportunities for bio-analysis and molecular imaging. Finally, a peptidocryptophane was developed that binds to calmodulin (CaM) protein. With this work we
hope to not only demonstrate the development of a biophysical probe sensitive to changes
in protein conformation but also generate a Ca2+ sensor. These three studies highlight the
broad utility of cryptophane-129Xe NMR biosensors, and synthetic methods described
herein lay the groundwork for future in vivo studies.
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Chapter 1: Introduction

1

§ 1.1 Preamble
Medical imaging is widely employed for visualizing normal and abnormal anatomy
and physiology. The importance of imaging in the diagnosis and subsequent treatment of
diseases like cancer has resulted in the development of a wide variety of imaging
techniques. At the nexus of medicine and the physical sciences, the imaging field includes
x-ray, ultrasound, positron emission tomography (PET), computed tomography (CT),
single photon emission computed tomography (SPECT) and magnetic resonance imaging
(MRI) as well as optical imaging and many more recent imaging modalities. Each of these
techniques offers specific attributes with regard to spatial and temporal resolution,
sensitivity, contrast, and level of radiation exposure. One important area of medical
imaging—molecular imaging—overlaps with drug discovery efforts and focuses on
targeting biomarkers with specific roles in disease pathology. Thus, by monitoring changes
in number and distribution of specific biomarkers of interest, clinicians can monitor disease
progression and tailor treatment appropriately. This thesis describes my research into the
design of xenon-binding cryptophane biosensors, and additional steps on the path to
developing hyperpolarized

129

Xe MRI as a molecular imaging modality. This general

introduction is meant to provide overall motivation for the development of targeted 129Xe
biosensors as well as describe in broad strokes the chemistry previously accomplished by
our research group and others. These studies culminated in the work described in Chapters
2-4, and a consideration of future studies is provided in Chapter 5. Brief discussions of the
techniques used to observe and characterize both Xe-cryptophane and biosensor-target
interactions are first provided here in Chapter 1.

2

Authors Note: The sections of Chapter 1 denoted with an asterisk (*) were originally
published in the chapter: Cryptophane-Based

129

Xe NMR Biosensors and have been

adapted here with permission from the Royal Society of Chemistry:
Adapted from Riggle, B. A.; Wang, Y.; Roose, B. W.; Dmochowski, I. J., CryptophaneBased

129

Xe NMR Biosensors. In Hyperpolarized Xenon-129 Magnetic Resonance:

Concepts, Production, Techniques and Applications, Meersmann, T.; Brunner, E., Eds.
Royal Society of Chemistry: Cambridge, 2015; 272-287.
§ 1.2 Nuclear Magnetic Resonance Spectroscopy†
Nuclear magnetic resonance (NMR) spectroscopy and magnetic resonance imaging
(MRI) are a form of absorption spectroscopy in which nuclei in a magnetic field absorb
and reemit electromagnetic radiation at radiofrequencies specific to the characteristics of a
sample. In more general terms, NMR spectroscopy is a technique used to characterize the
chemical structure and composition, as well as biological properties, of a sample. NMR, as
it is applied to medical imaging, typically employs concepts of proton NMR. The long term
goal of this work is to simultaneous employ proton MRI with xenon MRI to achieve both
high resolution spatial context and ultrasensitive disease identification. Thus, this section

†

Material in this section follows references: 1-3 Figures are adapted from: 1, 2

3

of the introduction will introduce the concept of proton NMR as well as compare and
contrast it with the use of exogenously supplied xenon-129 nuclei.

Figure 1.1. The two allowed spin states for a spin ½ nucleus.

NMR exploits the magnetic properties of nuclei. Nuclei with either or both an odd
atomic number or odd mass have a charge that spins on the nuclear axis thus generating a
magnetic dipole along that axis. The quantum spin number I describes the angular
momentum of this spinning charge where I is a physical constant corresponding to a given
nucleus. There are 2I + 1 allowed spin states from -I to I which denote the number of
orientations a nucleus may assume in an external and uniform magnetic field.2 When the
nucleus has a non-spherical charge distribution that results in a magnetic moment (µ). For
protons I = ½ and the allowed spin states are +½ and −½ which are clockwise and
counterclockwise, respectively, as shown in Figure 1.1. For xenon-129 I = ½, but this spin
state arises from an unpaired neutron.4 Because each nucleus is a charged particle, in an
applied magnetic field any moving charge generates its own magnetic field, thus these spin
states are not equal in energy. For protons, the lower energy spin state is +½ because it is

4

aligned with the applied magnetic field (B0) and −½ is higher in energy as it is counter
aligned with the field, see Figure 1.2a.

Figure 1. 2. Spin-state energy separation as a function of the applied magnetic field. For protons
(a) and xenon-129 (b).

These two energy states are populated in accordance with the Boltzmann
distribution where a slight excess of nuclear spins is found in the lower energy state.
Nuclear magnetic resonance occurs when the nuclei aligned with an applied magnetic field
absorb energy and change their spin orientation with respect to the applied field. The
energy absorbed is equal to the energy difference as given by the equation:
𝐸𝑎𝑏𝑠 = (𝐸−1⁄ − 𝐸+1⁄ ) = ℎ𝜈
2

(1.1)

2

The magnitude of the energy level separation is directly dependent on the nucleus in
question and the strength of the magnetic field. As Figure 1.2 depicts, the energy difference
between the two spin states increases as a function of the magnetic field strength as
described by the equation:
5

ℎ𝛾
Δ𝐸 = ( ⁄2𝜋) 𝑩0

(1.2)

Where the change in energy is proportional to the magnetic field strength because h
(Planck’s constant), γ (the gyromagnetic ratio), and π are all constants. The gyromagnetic
ratio is a constant for a given nucleus, in the case of protons γ = 42.6 MHz/T.5 However,
in xenon-129, γ = -11.8 MHz/T.4 The negative value of the gyromagnetic ratio accounts
for the different energy for the +½ and −½ spin states. As shown in Figure 1.2b, the −½
spin state is lower in energy than the +½ spin state for xenon-129. Thus, with protons the
spin and magnetic moment are pointed in the same direction but with xenon the spin and
magnetic moment point in opposite directions, but the understanding of how these nuclei
function in an applied magnetic field is consistent. The term given in 1.2 can also be
described with respect to frequency as:
𝛾
𝜈 = ( ⁄2𝜋)𝑩𝟎

(1.3)

Δ𝐸 = ℎ𝜈

(1.4)

Since:

The system is said to be in resonance when the frequency equals the applied B field and
the energy is then absorbed by the proton raising it to the higher energy state. To describe
it in another way, nuclei absorb energy because, as a result of the earth’s gravitational field,
they precess in the applied magnetic field of the NMR spectrometer. This precession is
usually likened to a spinning gyroscope (as shown in Figure 1.3) as the nucleus ‘wobbles’
about its axis. The angular velocity ω by which the nuclei precess is termed its Larmor
frequency and is directly proportional to the strength of the applied magnetic field. Only
6

when the applied radiofrequency waves (ν1) are equal to the Larmor frequency (νL) can
energy be absorbed and a spectrum be recorded. The radio frequency energy is introduced
with a single burst covering the entire range of available frequencies for a given nuclei of
interest thereby exciting the entire sample. As the excited nuclei return to the ground energy
state, they radiate the previously absorbed energy which is recorded by a detector as a free
induction decay (FID). The FID represents the entire energy radiated over time and can be
converted to a spectrum as a function of frequency by a Fourier transform.

Figure 1. 3. The precession of a spinning nucleus can be equated to that of a spinning toy top or
gyroscope.

It is helpful to consider the precessing nuclei in terms of Cartesian coordinates with
a rotating reference frame. As the Boltzmann distribution of spins precesses about the z
axis, aligned with the applied magnetic field, a net magnetization M0 is generated as shown
in Figure 1.4. Again considering our Cartesian reference, the detection coil is in the xy
plane thus M0 must be tipped into the xy plane for detection. To achieve this, ν1 is applied
in the xy plane such that the applied magnetic field B1 is orthogonal to the main magnetic
field B0. The signal is recorded after the applied pulse. The caveat being that the signal can
only be detected until the nuclei relax back to their ground state.
7

There are two main types of relaxation processes termed longitudinal or spin-lattice
relaxation (T1) and transverse or spin-spin relaxation (T2), shown in Figure 1.5. As the
name implies, T1 relaxation results in the transfer of absorbed energy to the surrounding
nuclei as thermal energy. This is indicated in the return of magnetization (M) to M0 in a
decreasing spiral as depicted in Figure 1.5a, T1 relaxation results in a loss of signal
intensity. The rate equation for the decay of magnetization (M) with time (t) is given by:
𝑴 = 𝑴0 (1 − 𝑒 −𝑡 /𝑇1 )

(1.5)

Thus the magnetization giving rise to the signal decays faster with decreasing T1. We can
refer back to the rotating frame of reference where the M is represented by a single
stationary arrow in the yz plane with θ representing the angle between the magnetization
vector and the applied field, thus as θ decreases the signal intensity decreases until M has
relaxed to alignment with the applied magnetic field, Figure 1.5a. Variation in T1 is
observed in different compounds and materials and is reduced by thermal motion
increasing energy transfer in the sample, thus T1 is inversely proportional to temperature.
Conversely, T2 transverse relaxation is an entropic process that results from the
dephasing of nuclear spins, see Figure 1.5b. The components of the precessing nuclear
spins begin to spin at slightly different frequencies. This fanning out reduces the net M
along the y axis resulting is signal decay. T2 relaxation results in line-broadening, the rate
of which is described by:
𝑰 = 𝑰0 (𝑒 −𝑡 /𝑇2 )

8

(1.6)

It is worth noting again that T1 and T2 are highly dependent on chemical composition and
chemical structure and that T2 can approach, but not exceed T1.

Figure 1. 4. The sum of the precessing nuclei in an applied magnetic field have a net magnetic
moment, M0 aligned with the stationary magnetic field, B0.

Proton NMR
For 1H NMR sample acquisition, the sample is typically pure and well solubilized
in a solvent containing no protons, is inert, has a low boiling point and is inexpensive.
Deuterium labeled solvents are used to negate solvent proton signal. NMR spectrometers
have a deuterium channel that can be locked on the B0 field. The field inhomogeneties are
minimized by either manually or automatically adjusting 20-30 small “shim” magnets to
bend the main magnetic field thereby tuning the field.
The spectrum of a given compound is measured in frequency and is usually given
either in hertz (Hz) or parts per million (ppm). The frequency of a nucleus is given by
equation 1.3. While this represents the resonant frequency of a specific nuclei, the
frequencies of various protons within a sample are complicated by shielding and
deshielding effects. Thus the chemical shift of a specific nucleus in a sample is given by:
9

𝛾
𝜈𝑒𝑓𝑓 = ( ⁄2𝜋)𝑩𝟎 (1 − 𝜎)

(1.7)

Where σ is the shielding constant. This shielding constant arises from the fact that electrons
within a magnetic field circulate and generate their own magnetic field. Thus, the degree
of shielding is directly reflective of the density of circulating electrons along with the
inductive effect of other groups attached to, in the case of proton NMR, the primary carbon.
The difference in the frequency of a proton from the frequency of a reference proton is
termed chemical shift.

Figure 1. 5. Stationary Cartesian reference of A. spin-lattice and B. spin-spin relaxation.

Xenon NMR
For

129

Xe NMR sample acquisition, background signal from the buffer/sample is

not an issue since 129Xe is not typically found in laboratory or medical settings. Similar to
proton NMR, field inhomogeneities are minimized with the shim magnets, however,
because of the lack of deuterium in buffered samples a standard is shimmed to generate a
shim file that can then be applied to the xenon experiment.6 Unlike 1H NMR, 129Xe has a
much larger frequency window approaching 300 ppm in water, which is highly dependent
10

on solvent and local environment (to be described in greater detail in Section 1.5 of this
chapter). 129Xe is also highly sensitive to pressure (Δδ = 0.9 ppm/atm) and temperature (Δδ
= 0.4 ppm/K).7 These attributes make xenon an excellent probe of solution physical
properties. Exploiting environmental sensitivity is a key feature of hyperpolarized 129Xe as
a contrast agent for MRI. Thus understanding shielding effects on xenon chemical shift is
key for designing xenon based probes.
Relaxation mechanisms in

129

Xe NMR are somewhat different from the standard

T1 and T2 of proton NMR. For the longitudinal relaxation of xenon there are 5 component
factors in non-solid phases that add up to give the overall T1:
1
1
1
1
1
1
=( ) +( ) +( ) +( ) +( )
𝑇1
𝑇1 𝐼𝑡
𝑇1 𝐼𝑝
𝑇1 𝐸𝑤
𝑇1 𝐸𝑔
𝑇1 𝐸𝑜

(1.8)

Where E and I refer to extrinsic and intrinsic mechanisms which are further categorized as
transient Xe2 dimers, persistent Xe2 dimers, wall collisions, magnetic field gradients, and
oxygen interactions. For solution phase 129Xe NMR we can ignore the second term in the
above equation and it is generally held that both intrinsic terms can be disregarded in spinexchange optical pumping experiments (described later). The two main sources of T1
relaxation are terms 3 and 5, wall and oxygen relaxation for gaseous xenon in a chamber.
For biological NMR experiments, however, the most important factor is Xe-solvent
interactions where by the presence of paramagnetic species, including O2 attenuate xenon
signal. Table 1.1 details variations in T1 values in different solvents and biological fluids.
Molecular oxygen serves to catalyze xenon relaxation via collisional dipolar coupling
because of its permanent electronic magnetic dipole.8 Counterintuitively, Albert et al.
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found the blood oxygenation increased T1 values relative to deoxygenated blood whereas
in plasma oxygenation decreases the T1 value as a result of the paramagnetic nature of
oxygen. This unexpected finding is a result of the strong paramagnetic properties of
deoxyhaemoglobin which serve to induce attenuated relaxation times.9 The reverse
findings in blood foam was attributed to hyperpolarization exchange dynamics.9, 10 Due to
their long xenon relaxation times, the use of Intralipid solutions (20%), T1 = 40 s,11 or
perfluorooctyl bromide (PFOB) emulsions, T1 = 110 s, have been proposed for in vivo
imaging.12-14 That being said, transport times from areas of initial xenon introduction, such
as the lungs, to areas of interest, e.g. the brain, are in the range of 5-7 s, thus T1 values in
various tissue types and in both oxygenated and deoxygenated blood should be sufficiently
long for imaging purposes.9
T1 values are longer at higher fields which serve to better resolve different chemical
shifts resulting from xenon exchanging between different environments (i.e. blood vs
lipids).15 However, a strong field is not needed to detect a signal from hyperpolarized 129Xe
because the polarization level is independent of field strength.15 This allows for “one-shot”
imaging experiments with large signal-to-noise ratios at field strengths on par with that of
Earth’s.15 This attribute has cost advantage where inexpensive spectrometers can be used
to detect xenon signal even though field strength requirements would preclude the
detection of proton signal on reasonable timescales.15 Aside from cost effectiveness, ultralow field MRI could expand the field for patients with pacemakers and other metal implants
for whom this imaging technique is currently not available.15
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Transverse relaxation in xenon-129 NMR is typically described by T2* to account
for all sources of dephasing.16 As with proton NMR there are static field effects from field
inhomogeneities that result in the xenon dephasing with increased rates of dephasing being
observed at higher field strengths.16 Additionally, the rapid exchange of xenon between
different sites (such as a host molecule and the bulk) also effects transverse relaxation.16 A
final point of note on different aspects affecting xenon relaxation is that if this system is
used in vivo different considerations have to be made depending on what area of the body
a clinician is imaging. Xenon can dissolve in tissue (solid-phase considerations), blood
(solution-phase considerations), and air pockets, like in the lungs, (gas-phase
13

considerations). Thus a variety of pulse sequence programs will be needed to tune the
resulting signal from different areas of interest.
§ 1.3 Magnetic Resonance Imaging‡
Magnetic resonance imaging (MRI) is a versatile and commonly employed
technique for the diagnosis and staging of disease. More than 30 million scans are
performed in the United States every year. Importantly, MRI utilizes non-ionizing radiation
and offers sub-millimeter spatial resolution and excellent soft tissue contrast and depth
penetration. In the late 1960’s Raymond Damadian observed by NMR that malignant tissue
had a different spectrum than normal tissue. Then, in 1973, Lauterbur proposed a method
of converting NMR signal into an image. Magnetic resonance imaging is characterized by
high spatial resolution, which is the ability to readily discern one object as separate from
another object. There are three main factors that determine the chemical shift of a given
proton in NMR: spin-density, longitudinal relaxation, and transverse relaxation. Images
can be measured by changing pulse programs to weight these contributing factors
differently. When considering tissues in general and humans (or animals) specifically, the
proton concentration is directly affected by the water and lipid content of a given area. The
relative differences are only on the order of 10-15% and thus these “spin-density” images
suffer from poor contrast. It should be noted, however, that grey-white matter

‡ This section follows discussions in references: 5, 17-19
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differentiation achieved in spin-density images is superior to that of computed tomography
(CT) images. For T1 weighted images, increasing rigidity of the tissue reduces atomic
collisions and typically leads to longer spin-lattice relaxation times. Because most tissues
have high water content, typical T1 values are in the hundreds of milliseconds range. T2
depends on local non-uniformities in the magnetic field. Molecular motion disturbs the
distribution of non-uniformities thus increasing T2 relative to that of bulkier
macromolecules. It may be helpful to compare the relative effects of different disease
processes on the three variables influencing proton signal as seen in Table 1.2.18
The signal generated in NMR spectroscopy can be converted into an image in a
variety of ways. Initially, it is important to understand how the signal of one type of tissue
in one part of the body can be differentiated from the signal from the same tissue in a
different part of the body. The principle first proposed for spatial localization was described
by Lauterbur. Simply put, he proposed making the frequency of the emitted radio waves
reflect the position of the emitting protons. To do this, MR imaging instruments contain
gradient coils which cause variations in the linear field. Using these gradient coils, spatial
localization can be achieved in a variety of manners but the most straightforward is slice
selection.
Slice selection is achieved by applying a gradient field across the body along a
coronal plane (orange gradient, Figure 1. 6). This generates an inhomogeneous field
resulting in resonance frequency variations in the direction of the field gradient. The result
is that each spin will each turn on an angle that is linearly dependent on the nucleus’
position, termed a phase roll. Thus, the frequency needed for the applied radiowave to be
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in resonance changes resulting in selective excitation of the protons within the selected
sagittal slice (blue bar, Figure 1. 6). Then, different signals are generated for different
positions within the sagittal plane by employing gradients.

Figure 1. 6. Depiction of slice selection where a gradient (orange wedge) is applied along the
plane orthogonal to the imaging slice. A rf pulse that matches the narrow range of frequencies
(generated by the gradient) is simultaneously applied (blue rectangle) along the desired imaging
slice.

The use of gradients to generate this phase roll results in a net decrease in signal. Because
there are void areas from which there is no water signal (e.g., bone), the “wave length” of
the phase roll directly corresponds to the distance between the areas generating water
signal. Thus the magnitude of the signal for a particular phase roll pattern determines
whether there is structural similarity between imaged areas. This description is simplified
a bit to understand imaging in a one-dimensional plane but to extend the image to the 2-D
images with which doctors are familiar, k-space must be considered. Spin patterns are
generated from phase rolls and a vector k is assigned in the direction of change, the
magnitude of which is indicative of spin density. Thus, the radio wave signal is presented
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as a function of k, a Fourier technique. In this manner images within a 2-D plane are
generated but by applying gradients in different directions and strengths and then
overlaying the slices it is possible to generate a meaningful image in a process termed
signal reconstruction. For the generation of MR images then, the spatial limitation is
determined by the movement of water molecules, gradient strengths, and relaxation times.
To mitigate these limitations then a variety of gradients are used in addition to the
introduction of compounds which function to perturb relaxation times, namely, contrast
agents.

§ 1.4 Contrast Agents in Magnetic Resonance Imaging
Proton (1H) magnetic resonance signals are abundant based on the high
concentration of water, fat, and other biomolecules in vivo. Technicians can modulate the
signal and contrast of the images with different pulse sequence programs in order to obtain
drastically different images; highlighting differences in proton density, relaxation times,
and chemical shift (lipids vs water).20 However, high background, coupled with the very
small magnetic resonance signals obtained from individual proton nuclei, generally limit
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the sensitivity of this technique.20 One consequence is that molecular signatures from
protons in discrete environments (e.g., from specific biomolecules or acidic compartments
in cells) are not readily detected. These challenges have motivated the development of MRI
contrast agents to perturb the endogenous proton signals. All contrast agents decrease the
longitudinal (T1) relaxation time and the transverse (T2) relaxation time, thereby increasing
the relaxation rate. If an agent increases the longitudinal relaxation rate (1/T1) more than
the transverse relaxation rate (1/T2) they are said to be T1 weighted and are termed positive
contrast agents because they give rise to increased signal intensity. Conversely, T2
weighted images result from the negative contrast achieved by an increase in 1/T2, usually
with ferromagnetic iron oxide particles. The majority of contrast agents, however, are
chelated gadolinium compounds whose paramagnetic properties reduce T1. Indeed, four of
the six clinically approved intravenous contrast agents are gadolinium chelates. A
relaxation rate change of 0.5 s-1 can produce observable contrast; thus, gadolinium contrast
agents with typical relaxivities (r1 = 3-10 mM-1s-1) require minimum concentrations ~ 100
µM, shown in Figure 1. 7.20 The design strategies employed for gadolinium-based agents
must balance the need for strong organic ligand coordination (to mitigate toxicity) with the
desire to markedly perturb relaxation times.21 Gadolinium serves to perturb water relaxivity
by either directly (inner sphere) or indirectly (outer sphere) coordinating water molecule(s).
Thus, an increase in the number of inner sphere waters coordinated (q) tends to increase
relaxation rates. Again, because of the need to fully chelate the gadolinium ion, q is
limited.21 One way to decrease longitudinal relaxation time is to slow the molecular
rotational correlation time because slower tumbling leads to faster relaxation rates.20, 21
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Thus, to slow tumbling times a wide variety of bulky scaffolds have been appended to the
chelation complexes.22 In order to allow the detection of much rarer analytes, “superstoichiometric” strategies have been explored, which include incorporating numerous
gadolinium agents within a single particle, as well as engineering enzyme reporters, where
a single enzyme can change the coordination environment of many gadolinium agents.20-25
Targeted contrast agents are typically bifunctional ligands with the cyclen or
diethylenetriamine Gd3+ chelating core with nitrogen or oxygen donor atoms that are then
appended with a ligand specific to the protein or enzyme of interest.25 Protein binding can
serve to retard the tumbling time but can also affect the metal hydration by blocking the
inner coordination sphere. The targeting must be achieved with high specificity while the
complex must be inert and fully clear the body.25 Thus, these smart agents have the
potential to strongly improve contrast, but remain limited both because they modulate
endogenous signal and because the use of a heavy metal necessitates strong chelation. A
parallel and potentially complementary strategy involves the use of exogenously supplied
“hyperpolarized” nuclei, which include 13C, 3He, and 129Xe.

Figure 1. 7. DOTA and DPTA gadolinium chelates for magnetic resonance imaging.21
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§ 1.5 Exogenous Nuclei in NMR/MRI: Advantages of 129Xe*
The intrinsic NMR chemical shift sensitivity, exceptional signal-to-noise, and
chemical inertness of hyperpolarized xenon-129 (hp

129

Xe) make it attractive for many

magnetic resonance applications, and a natural complement to proton magnetic resonance
imaging (MRI). For imaging studies, 129Xe is a viable alternative to 3He, which is rare and
nonrenewable; moreover, among the noble gases,

129

Xe (with 54 electrons) possesses

unique capabilities for host-guest chemistry based on its volume (~40 Å3), significant
polarizability (which yields high affinity for void spaces and good water solubility, as well
as local environment sensitivity),26 and lack of radioactivity. These applications are
enhanced by recent improvements in spin-exchange optical pumping methods that yield
near unity 129Xe hyperpolarization.27 Pioneering biological imaging studies with hp 129Xe
targeted the pulmonary void spaces in rat lungs.28 There have since been many additional
xenon studies in the lungs, brain, and other tissues in both rat and humans, shown in Figure
1. 8.29-33

Figure 1. 8. Representative 129Xe MR images from living rat brain and lungs. Reprinted with
permission from references:34, 35

20

These successes motivate greater use of hp 129Xe in human imaging, with the caveat
that xenon is limited to areas where the gas will readily diffuse, after inhalation or direct
injection. Although very soluble in organic solvents and lipid environments, xenon exhibits
low affinity for endogenous proteins and other biomolecules; attempts to engineer highaffinity xenon-binding sites into proteins have thus far been unsuccessful.36 Therefore,
xenon should not localize to biomolecular targets in vitro or in vivo, unless biosensors with
high xenon affinity are employed. Here, we summarize lessons learned over the past decade
as we have worked to develop cryptophane-based hp 129Xe NMR biosensors for biological
imaging applications.
§ 1.6 Hyperpolarization of 129Xe
Exogenously supplied nuclei that are not found in vivo, like xenon, already
demonstrate an advantage over proton signal in that there is no “background”. Increasing
the utility of this nucleus specifically is the ability to generate a pool of “hyperpolarized”
nuclei. The hyperpolarized state is differentiated from Boltzmann spin distribution (see
Figure 1. 9) and from a polarized state which refers to electron cloud perturbation as a
result of local electric fields. While there are a variety of methods used to achieve a
hyperpolarized state of various nuclei, spin exchange optical pumping (SEOP) is highly
efficient for 129Xe.
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Figure 1. 9. Boltzmann spin distribution compared to hyperpolarized spin of

129Xe.

SEOP was originally developed in the 1960s for hyperpolarization of noble gases.37
This method embeds rubidium in a high pressure gas mixture, at 64 psi, containing 89%
helium, 10% nitrogen, and 1% xenon-129 (natural abundance). The helium acts as a buffer
and the nitrogen acts as a quencher. The percentage of xenon can be increased but this
results in a significant cost increase. The elevated pressure of this gas mixture significantly
broadens the optical transition of rubidium, which is compatible with the use of a
broadband, high-powered, semiconducting laser (typically 50 W or greater) with line
widths at 1-3 nm to excite the alkali metal. More recently, much narrower line width lasers
centered on 795 nm have been developed that make it possible to work more safely with
lower pressure (non-broadened) Xe gas mixtures. This process, termed optical polarization,
relies on the absorption of circularly polarized light photons (σ+) by Rb. The laser provided
circularly polarized light is tuned to the D1 transition of Rb at 794.7 nm. The quenching
nitrogen gas prevents rubidium depolarization. The laser is directed through a beam
expander and a λ/4 wave plate to generate circularly polarized light.38 This process results
in a ground state electron spin polarization of Rb. Next, as a result of the high pressure
conditions, there are increased collisions between polarized Rb and Xe. These collisions
22

result in short-lived complexes generating isotropic hyperfine coupling or Fermi contact
interactions which result in xenon spin polarization. This is depicted in Figure 1. 10,
prepared by Yanfei Wang.

Figure 1. 10. Hyperpolarization of 129Xe achieved via spin-exchange optical pumping.

§ 1.7 Host-Guest Chemistry and the Synthesis of Cryptophane-A Derivatives*
Most xenon biosensors developed to date employ an organic host molecule with a
hydrophobic cavity that can reversibly bind xenon in aqueous solution. Host candidates
with modest room-temp xenon association constants include: hemicarcerand (KA ≈ 200 M1

), α-cyclodextrin (KA ≈ 20 M-1), and calix[4]arene derivatives (KA ≈ 14 M-1), shown in
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Figure 1. 11.39-41 These affinities are on par with xenon-protein association constants (the
highest being myoglobin at 200 M-1),42 which has limited their utility for most applications.
Water-soluble cucurbit[6]uril has significantly higher xenon affinity (KA ≈ 3000 M-1) but
presents synthetic challenges to achieve single-site functionalization for biomolecular
targeting.43 Cucubitr[6]uril itself has a xenon affinity of only 490 M-1 but is commercially
available in gram quantities.44 The most studied xenon-binding molecule to date is
cryptophane-A (Figure 1. 12), in which two cyclotriguiacylene caps are tethered by three
ethylene linkers generating an approximately 1 nm diameter cage molecule with an internal
volume of approximately 85-89 Å3.45 Cryptophane-A was first synthesized in 1981 but it
was not until 1998 that it was determined to have a room-temp xenon association constant
of 3000 M-1 in a noncompeting organic solvent, C2D2Cl4 (deuterated 1,1,2,2tetrachloroethane).45, 46 Notably, cryptophane-A exhibits helical chirality (along the red
axis depicted in Figure 1. 12) but is usually isolated and used as the racemic mixture of
stereoisomers.

Figure 1. 11. 129Xe host molecules with weak affinity. Hemicarcerand: KA≈ 200 M-1; αcyclodextrin: KA≈ 20 M-1; Calix[4]arene: KA≈ 14 M-1; and Cucubit[6]uril KA= 490 M-1 44
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The design of xenon-binding molecules is informed by the work of Mecozzi and
Rebek, who tabulated the known host-guest interactions dominated by dispersion forces
and determined that a guest-to-host volume ratio of 0.55 ± 0.09 optimally balances
favorable van der Waals (enthalpic) contributions with the entropic cost of host crowding.47
[Notably, this empirical formula was not derived for host-guest interactions in water, where
the hydrophobic effect yields favorable entropic contributions.]

Figure 1. 12. Cryptophane-A. Macromolecular cage host molecule with axial chirality.

Indeed, in work using hexa-carboxylic acid cryptophane derivatives in D2O, it was
shown that increasing the size of the cryptophane cavity, going from two-carbon linkers
(2,2,2) to three-carbon linkers (3,3,3), decreased the xenon association constant (KA ≈ 6800
M-1 for cryptophane-222 and KA ≈ 1000 M-1 for cryptophane-333, Figure 1. 13) but also
shifted the Xe@cryptophane peak by 30 ppm upfield.48, 49 Conversely, decreasing the cage
internal volume to 81 Å3 using one-carbon (i.e., methylene) linkers, increased the roomtemp association constant to 10,000 M-1.50 These cryptophane derivatives have promising
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features for use as xenon biosensors, including high xenon affinity and ease of
manipulating 129Xe NMR chemical shift through cage design.

Figure 1. 13. Structures and relative sizes and xenon-129 binding affinity of cryptophane-222
(cryptophane-A) and cryptophane-333 (cryptophane-E).51

Synthetic Mechanism of Cryptophane Cyclization
The synthetic mechanisms for generating cryptophane cages have evolved steadily
since their initial conception. In 1981, Gabard and Collet first published a “Synthesis of a
D3-Bis(cyclotriveratrylenyl) Macrocage by Stereospecific Replication of a C3-Subunit”
where they determined that formation of cyclotriguiacylene (CTG) from vanillyl alcohol
could only be achieved with a phenol protected derivative using 65% perchloric acid.
Subsequent formation of a single product, the D3 cage (in preference to the meso cage) was
achieved at 90 ºC in formic acid which they attributed to a “stereospecific replication”
process. This illustrates a “template effect” where the new ring forms in the same chirality
as the parent C3 ring.45 In 1985, Collet and coworkers coined the term “cryptophane”
harkening to the [1.1.1]orthocyclophane structure of the top and bottom components of the
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cage molecule. Cryptophane describes a spherical, hollow host molecule with a lipophilic
cavity formed by two cyclotriveratrylene (CTV) units joined by three alkoxy bridges,
which results in three “windows” into the cage that allow for guest entry. In 1987, they
strove to ascertain how different linkers and R groups affected the cage formation of which
there are two options, syn or anti (Figure 1. 14a). The anti-conformation is chiral and has
D3 symmetry and, when viewed along the C3 axis, the upper and lower CTV units are
staggered by 50-60º whereas in the syn conformation, the CTV units are eclipsed and the
cage has C3h symmetry and is achiral.52 The syn cage is chiral, however, when R ≠ R’. They
found that O(CH2)2O linkers and linker with trans alkenes preferentially led to anticryptophanes whereas O(CH2)3O and cis alkenes yielded syn cages.52 This phenomenon
is attributed to the position of the reactive veratryl ends with respect to the template ring.52
Subsequent studies determined that for many applications, including further derivatization,
the template method is superior (better yielding and applicable to a wider variety of
derivatives) than the direct, or two-step method.53 The direct or two step method relies on
the formation of a bis-vanillyl alcohol derivative followed by treatment with formic acid
to form cryptophane. The template method, on the other hand, first promotes the
intermolecular cyclization reaction between the vanillyl alcohol derivatives to form the
corresponding CTV derivative, a comparison of these two methods is shown if Figure 1.
14, panel B. The direct method has the distinction of being simple and fast. It can be done
on a large scale but is usually low yielding, resulting in large quantities of polymer.
Additionally, only cryptophanes with hexa-symmetrical subsubstituents can be generated.
These cryptophanes have lower xenon affinities the reasons for which will be discussed in
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detail later. The template method, on the other hand, is far more labor intensive with 5-6
step syntheses.54 The final intramolecular cyclization is also low yielding and because it
must be performed at ultra-low concentrations, is not readily scalable. Efficient
intermolecular cyclization (for either method) requires electron-donating groups meta to
the benzyl alcohol. In the template method the initial intermolecular reaction forms the
CTV “cap” molecule that can then be coupled with a wide variety of benzyl alcohols (again
conforming to the need for electron-donating groups at the meta position) before the final
intramolecular, pre-organized cyclization via a Friedel-Crafts like mechanism, shown in
Figure 1. 15.52 It should be noted that the steps depicting cation formation likely do not
proceed in a concerted fashion but are depicted as such for the sake of clarity.
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Figure 1. 14. Possible conformations of cryptophane host molecules either anti or syn shown in
panel A. and the examples of Direct vs Templated cyclization for the synthesis of cryptophane-A
and its derivatives in panel B.52

A limitation of cryptophane host molecules is their poor water solubility. In 2007,
our lab published a templated, 10-step synthesis for a water-soluble tri-functionalized
cryptophane via tripropargyl cryptophane and a subsequent Cu(I)-catalyzed [3+2] azidealkyne cycloaddition (CuAAC) with azido-propionic acid which was prepared in one step
from β-propiolactone (Figure 1. 16e).55 The resulting compound, termed tris-(triazole
propionic acid)cryptophane (TTPC), had a room-temp xenon association constant of
29

17,300 M-1 in water, significantly higher than previously published cryptophane
derivatives (Table 1.3).48, 55

Figure 1. 15. Intramolecular cyclization mechanism to form cryptophane host molecules.

We postulated that desolvation of xenon in water as well as displacement of water
from the cryptophane cavity entropically drives Xe-cryptophane association. In order to
investigate how the solubilizing linkers affect xenon binding, we synthesized, in 13 steps,
a triacetic acid cryptophane-A derivative or TAAC (Figure 1. 16d), with the carboxylates
~5 Å closer to the cavity.56 Interestingly, TAAC exhibited a marked increase in xenon
binding affinity (Table 1.3). To investigate how the charge on the solubilizing groups
affects xenon binding, we synthesized a tris-(triazole ethylamine)cryptophane (TTEC),
following the same protocols as TTPC, while conjugating 3-azidoethylamine in the last
step.57 As shown in Table 1.3, the amine groups afforded a cryptophane host with nearly
1.3-fold improved xenon affinity, producing the highest known xenon affinity for any host
molecule. For all three water-soluble cryptophanes, the Gibbs free energy had very similar
enthalpic and entropic components (Table 1.3).
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The favorable entropy term likely results from the dissolution of the clathrate shell
surrounding xenon in water along with the release of water molecules from the cryptophane
cavity. A key feature of this system is the use of three solubilizing moieties, which helps
to keep the cryptophane in an open, xenon-accessible conformation. Furthermore, the type
of solubilizing moiety and their distance from the cryptophane interior are postulated to
modulate the number of waters binding inside the cavity, which compete with xenon
binding.58

Figure 1. 16. Derivatives of cryptophane-A. a. tripropargyl cryptophane (TPC); b. triallyl
cryptophane (TAC); c. trihydroxy cryptophane (THC); d. triacetic acid cryptophane (TAAC); e.
tris(triazole propionic acid) cryptophane (TTPC); and f. tris(triazole ethylamine) cryptophane
(TTEC).54-57

In 2011, we reported a shorter six-step synthesis of trifunctionalized cryptophanes
shown in Figure 1. 16a and b with an improved yield of 6%.54 This built on the work of
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Brotin et al. who reported a milder Sc(OTf)3 cyclization for cyclotriguiacylene formation,
removing the need for low concentrations and protection/deprotection steps.59 The use of
either tripropargyl cryptophane (Figure 1. 16a) with CuAAC or trihydroxy cryptophane
(Figure 1. 16c) with amide coupling (following acetate addition) affords a facile means of
functionalizing the cage with solubilizing or targeting moieties. It is notable that the trifunctionalized cryptophanes TTPC, TAAC, and TTEC show similar water solubility to the
reported hexa-functionalized cryptophanes and exhibit significantly better xenon-binding
affinities. From our work we have postulated this is a result of cation chelation by the six
carboxylates, which may block xenon entry and also stabilize water inside the cavity. Very
recent work from the Saven laboratory at the University of Pennsylvania has demonstrated
through molecular simulations that a key component in binding equilibrium is the removal
of water confined within the cryptophane cavity.58 By comparing xenon-cryptophane
binding in a variety of cages, they determined that while internal cage volume played a
role, Xe binding was not perturbed by that alone.58 Indeed four cages with identical central
cavities have wide range of Xe affinity with Ka values from 34,000 – 6800 M-1.58
Desolvation of xenon is known to make binding of cryptophane entropically favorable.56,
58

They found that hexa-acid cryptophanes have greater water occupancies in their core

than trifunctionalized cryptophanes. Additionally, having charged groups on either side of
the cryptophane pores seems to promote the formation of water clusters occluding the
cavity.58 The cryptophane work performed to date has yielded a ~300 ppm chemical shift
window for encapsulated xenon in water (by modulating the cage volume or appending
ruthenium, see Figure 1. 29) as well as tens of micromolar xenon dissociation constants.50,
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57, 60, 61

Thus, our research focus involves coupling the use of exogenously supplied xenon

with targeted molecular imaging techniques.
§ 1.8 Binding Characterization*
Methods for measuring xenon binding parameters to host molecules have been
refined in recent years. Early work used either changes in 1H NMR chemical shifts upon
129

Xe binding or integration of bound and free

129

Xe resonances to calculate the binding

affinity of cryptophane.55 These methods, however, suffer from large errors.48 To develop
a more sensitive method for measuring xenon binding affinity for water-soluble
cryptophane, we took advantage of xenon’s ability to quench fluorescence of organic
chromophores by the heavy atom effect.62 This was previously shown by very efficient Xe
quenching of pyrene bound to apomyoglobin.63 Using 15 µM TTPC (Figure 1. 16e),
experiments were conducted at 293 K in 1 mM phosphate buffer at pH 7.2 by titrating a
solution of 1-atm-saturated (5.05 mM) aqueous xenon. Fluorescence maximum intensity
vs. xenon concentration (0-5.05 mM) data were fit to a single-site binding model:
[𝑋𝑒@𝟏𝒆]
[𝑋𝑒]
=
[𝑋𝑒] + [𝟏𝒆] [𝑋𝑒] + 𝐾𝐷

(1.9)

We also demonstrated the utility of isothermal titration calorimetry (ITC) for measuring
xenon-cryptophane association constants, which gives data in excellent agreement with the
fluorescence quenching method.55, 56 ITC has the advantage of providing both enthalpic
and entropic xenon-binding parameters for a single cryptophane concentration, but requires
significantly more cryptophane sample, particularly as the enthalpic contribution to xenoncryptophane binding is only a few kcal/mole.
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We further investigated the interactions between cryptophane and guest molecules
by X-ray crystallography. Cryptophane is known to encapsulate a large size range of guests
from methane (28 Å3) to chloroform (72 Å3), and these guests bind with similar affinity
(KA ≈ 130-230 M-1).47, 64 In an effort to explain why xenon binds with so much higher
affinity, we co-crystallized cryptophane-A derivatives, Figure 1. 16a, and b with methanol,
xenon, and chloroform and found that the cavity internal volume (80–102 Å3) varied with
guest size.65 Importantly, it was observed that in the xenon-bound structure, van der Waals
interactions were nearly optimized, with an interior cavity volume of 85-89 Å3 and
guest:host volume ratio of 0.47-0.49.
§ 1.9 Cryptophane Biosensors: Targeted Detection*
In developing the first xenon biosensor, Pines, Schultz, and coworkers elegantly
demonstrated how to functionalize cryptophane to achieve the dual aims of targeting
streptavidin and improving water solubility. In cryptophane-A, one methoxy group was
replaced with a free hydroxyl group which was then converted to a carboxylic acid.
Coupling of the carboxylic acid with the amino-terminus of a protected peptide on resin
and subsequent coupling with a biotin linker afforded a water-soluble, targeted biosensor.
Avidin binding generated a ~2.3 ppm upfield chemical shift change for hp
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Xe

encapsulated in the biotin-conjugated biosensor.66 In a follow-up study, one resonance was
observed for mono-allyl-substituted cryptophane-A. However, upon conjugating the
cryptophane with a chiral CKR peptide two peaks appeared, 0.15 ppm apart. These peaks
were attributed to the RL and LL diastereomers. After the cryptophane was further
derivatized with the biotin linker through maleimide chemistry a new racemic chiral center
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was formed, generating RLR, RLL, LLR, and LLL combinations for which four “bound”
peaks were assigned.49 The observed sensitivity of xenon to diastereomerism is
problematic for many biosensing applications, as it “dilutes” the xenon-biomarker signal,
and complicates peak assignments as well as efforts to selectively irradiate

129

Xe in a

specific environment, as required for many NMR experiments.

Figure 1. 17. Targeted cryptophane biosensors from the Dmochowski laboratory. Clockwise from
top left: matrix metalloproteinase-7 (MMP-7) targeting, MMP-7 peptido-substrate cryptophane;
carbonic anhydrase targeting, benzene sulfonamide cryptophane; αvβ3 integrin-receptor targeting,
c[RGDyK] cryptophane; and folate receptor targeting, peptide-folic acid cryptophane.67-70

Following up on this research, our laboratory demonstrated the ability of hp 129Xe
to report on an enzyme cleavage event by appending racemic cryptophane with a peptide
substrate for matrix metalloproteinase-7, a known cancer biomarker, shown in Figure 1.
17. The

129

Xe NMR spectra showed two peaks before cleavage and two new peaks after

cleavage < 1 ppm upfield of the original peaks.67 Because the xenon signal was effectively
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split between the diastereomers, a subsequent work, by Dutasta, Berthault, and others,
utilized enantiopure cryptophane-A grafted with a 20-mer oligonucleotide.71

129

Xe NMR

spectra were measured for the biosensor alone, the biosensor with a complementary DNA
strand, and biosensor with non-complementary DNA strand. The biosensor plus
complementary strand was shifted 1.5 ppm upfield of the other two samples, and all three
samples exhibited one bound peak, as expected for single enantiomers.71 Surprisingly,
however, when the concentration was increased, both the biosensor alone and the biosensor
plus noncomplementary strand were seen to foam and exhibit multiple Xe@biosensor
peaks. It was hypothesized that this was the result of increased microemulsions and
micelle/vesicle formation.71 This observation highlights the importance of developing
highly water-soluble xenon biosensors.
A subsequent work appended cryptophane-A with a peptide ligand to major
histocompatibility complex (MHC). Specifically, Schlundt et al. used the hemagglutinin
(HA) peptide which binds human leukocyte antigen (HLA) DR1. The design employed a
solubilizing linker, which acted as a ~35 Å spacer between the cryptophane and the peptide
binding moiety.72
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Xe NMR revealed one peak for the bound and unbound biosensor,

with a Δδ of only 1 ppm.72 While the spacer improved solubility, it positioned the xenon
too far from the peptide to generate a significant chemical shift change upon MHC binding.
Heretofore, targeted xenon biosensors were mono-functionalized derivatives of
cryptophane-A but our work with water-soluble TAAC, TTPC, and TTEC suggested that
we could achieve both better xenon binding and simplified 129Xe NMR spectra with a trifunctionalized cryptophane. Building on earlier work in our lab using mono-functionalized
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cryptophane with a linear (RGD)4 repeat,73 we functionalized tripropargyl cryptophane
(Figure 1. 16e) with a cyclic peptide RGDyK, known to have high affinity and specificity
for αvβ3 integrin, and two 3-azidopropionic acids with CuAAC.74 Interestingly, despite the
cryptophane chirality and potential for diastereomerism, we observed only one
129

Xe@biosensor NMR peak when the biosensor bound to αvβ3 integrin and it was 4.1 ppm

downfield from the free biosensor. This demonstrated that using a well-solubilized
cryptophane, it is possible to engage protein targets using short tethers and still obtain wellresolved 129Xe NMR spectra.
Targeting αvβ3 Integrin*
In order to investigate the cell compatibility of xenon biosensors we fluorescently
labeled our c[RGDyK]-cryptophane (see Figure 1. 17) and performed cell uptake, viability,
and specificity studies. The MTT assay demonstrated  60% viability at 75 µM biosensor
for three cell lines. Confocal microscopy studies with the cancer cell line, AsPC-1, and
normal human fibroblasts, HFL-1, showed preferential biosensor uptake in AsPC-1 and
further demonstrated that uptake could be blocked with antibody or excess c[RGDyK]
peptide (Figure 1. 18). Flow cytometry confirmed 2-3-fold greater uptake over antibody
and c[RGDyK] blocked cells and 4-fold greater uptake in AsPC-1 vs. HFL-1.74 Our studies
also demonstrated targeting of αvβ3 integrin and αIIbβ3 integrin with nanomolar affinity and
specificity and low cytotoxicity at concentrations required for NMR experiments. This
work paved the way for cellular NMR spectroscopy and imaging experiments, which are
now underway in our laboratory and elsewhere.75-77
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Figure 1. 18. Cellular uptake studies using confocal microscopy. Alexa-fluorophore 488-labeled
c[RGDyK]-cryptophane (1 µM) targeting AsPC-1 cells (a) after 1 h incubation and (b) with
blocking co-treatment of 0.15 mg/mL anti-αv antibody. Adapted with permission from Seward et
al.68

Targeting Carbonic Anhydrase*
A concurrent work sought to characterize how the proximity of cage binding
modulated the xenon-129 chemical shift. For this study we synthesized a carbonic
anhydrase-targeting cryptophane where a benzene sulfonamide ligand with three linker
lengths (C6B, C7B, and C8B) was coupled to tripropargyl cryptophane (Figure 1. 17 and
Figure 1. 20). Our laboratory has employed a carbonic anhydrase (CA) model system,
because of its biomedical relevance for cancer detection.78-81 CA is a ubiquitous zinc
metalloenzyme that catalyzes a simple but physiologically important reaction: the
reversible hydration of carbon dioxide to form bicarbonate and a proton.82-84 Five classes
of evolutionarily unrelated CA exist (α-, β-, γ-, δ-, and ζ-CAs), with humans expressing
fifteen isoforms of α-CA.80 All fifteen isozymes share a conserved fold consisting of a
central ten-stranded β-sheet surrounded by helical connections.85 The catalytic active site
of α-CA is positioned at the base of a conical cavity approximately 15 Å wide and 15 Å
deep and is comprised of a catalytic Zn2+ ion exhibiting tetrahedral coordination with three
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conserved histidine residues and a hydroxide ion, see Figure 1. 19. In this work we targeted
CAI and CAII isozymes because unlike the isozymes CAIX and CAXII indicated in cancer,
CA I and II are well characterized and express readily in bacteria, thus providing an ideal
model system. Both are cytosolic isoforms of α-CA with high structural homology.

Figure 1. 19. Highly conserved active site residues of carbonic anhydrase. Shown is the His64
mediated proton shuttle mechanism that aides in the interconversion of carbon dioxide and
bicarbonate plus proton.
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Figure 1. 20. 129Xe NMR of CA targeting biosensors. 129Xe NMR in 50 mM Tris, pH 8.0 of (a) C6B
alone (96 µM); (b) C6B (188 µM) and CAI (141 µM); (c) C6B (148 µM) and CAII (123 µM); (d)
C7B alone (186 µM); (e) C7B (136 µM) and CAI (100 µM); (f) C7B (132 µM) and CAII (105 µM);
(g) C7B alone (121 µM); (h) C8B (189 µM) and CAI (141 µM); (i) C8B (189 µM) and CAII (153
µM). Data from Chambers et al.70

Biosensor binding to CA was characterized by

129

Xe NMR spectroscopy and

isothermal titration calorimetry (ITC).70 ITC measurements of biosensor binding to CAI
and CAII gave dissociation constants in the 10-100 nM range for all three biosensors.
Interestingly, the dissociation constants for the full-length biosensors were comparable to
those of the biosensors lacking the cryptophane. All three biosensors showed distinct and
reproducible 129Xe NMR chemical shifts upon binding CAI and CAII, respectively (Table
1.4). The hp 129Xe NMR spectrum of racemic biosensors bound to CAI and CAII is shown
as in Figure 1. 20. The unique 129Xe NMR chemical shifts for biosensors bound to CAI or
CAII demonstrate the potential of xenon biosensors to discriminate between isoforms of
α-CA. CAI and CAII are structurally homologous, thus it is expected that xenon tethered
in the active-site channel experiences similar steric environments. However, the
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distribution of hydrophobic and hydrophilic residues lining the active-site channels varies
between CAI and CAII; the large electron cloud surrounding the encapsulated xenon
nucleus is sensitive to these differences, and thus the two isoforms are distinguishable by
hp

129

Xe NMR spectroscopy. It is expected that CAIX and CAXII will also report

characteristic 129Xe chemical shifts upon binding xenon biosensor, thereby allowing for the
selective detection of these cancer biomarkers by MRS/MRI. Interestingly, racemic C7B
bound to wild-type CAII reports two 129Xe NMR chemical shifts (Figure 1. 20). C8B also
reports two chemical shifts when bound to CAI and CAII, respectively. It was initially
hypothesized that the two observed
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Xe chemical shifts were the result of single-site

diastereomerism, with the (+) and (−) enantiomers of C7B binding to the same site but
interacting slightly differently with residues in the chiral active-site channel of CAII.86
However, the

129

Xe NMR spectra of enantiopure (+) and (−) C7B both report multiple

“bound” chemical shifts for xenon.86 This highlights the potential for multi-site binding,
with the two enantiomers occupying distinct sites in the active site cleft. The cause of
observed multiple “bound” cryptophane peaks is discussed further in Chapter 2.

The crystal structure of C8B bound to wild-type CAII was determined at 1.70 Å
resolution by Aaron et al. in 2008 and is shown in Figure 1. 21.87 The occupancy of C8B
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was refined to 0.5 (with the MoMo and PoPo enantiomers having occupancies of 0.25,
respectively). An encapsulated xenon atom was confirmed by a Bijvoet difference Fourier
map calculated from anomalous scattering data and refined with occupancy of 0.5. The
overall fold of CAII is largely unperturbed by binding of C8B, and only a few
conformational changes are observed along the active-site rim. Close examination of the
interface between the biosensor and protein revealed only a few cryptophane-protein
interactions, suggesting that the cryptophane experiences a high degree of translational and
rotational freedom. Such biosensor mobility is advantageous for 129Xe NMR spectroscopy
as it yields narrower line widths, thereby increasing the sensitivity of

129

Xe NMR

measurements in solution.87, 88

Figure 1. 21. X-ray crystal structure of xenon encapsulated in C8B (only M 0M0 enantiomer is
shown for clarity) bound to CAII (PDB: 3CYU). The Xe atom is shown in green; the active-site
Zn2+ is grey; C8B is shown with carbon (black), oxygen (red), nitrogen (blue), and sulfur (green).
Reproduced from Aaron et al.89
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Targeting Folate Receptor
A subsequent work sought to further characterize cell targeting and employed a
different method of solubilization to ascertain the significance of types of solubilizing
methods. In this study we used a mono-functionalized, PEGylated cryptophane with a
leucine tethered folate recognition moiety (Figure 1. 17) synthesized in 20 nonlinear steps
from four commercially available starting materials, depicted in Figure 1. 22a and b. The
folate recognition moiety was synthesized in 5-steps as shown in Figure 1. 22a and then
coupled to a PEGylated, azido peptide on solid support which was then “clicked” to monopropargyl cryptophane, Figure 1.20b to yield the folate receptor-targeting biosensor. Here
we again use a long chain to solubilize the compound but have the targeting portion in
close proximity to the binding cage. In this work, two versions of the final compound were
generated, the first, labeled “Folate receptor targeting cryptophane” in Figure 1. 22 is the
compound proposed for use in NMR/MRI studies. A derivative compound for use in
localization imaging studies was generated by TCEP deprotection of cysteine and
conjugation with a maleimide Cy3 dye. Confocal microscopy studies demonstrated
specific targeting of cells over-expressing folate receptor with the biosensor targeting the
receptor and subsequently being taken up by an endocytotic mechanism, Figure 1. 23. Flow
cytometry studies demonstrated a 10-fold specificity for FR overexpressing KB cells over
HT-1080 cells, as shown in Figure 1. 24a while demonstrating low toxicity at
concentrations relevant for 129Xe NMR, Figure 1. 24b. The NMR again demonstrated two
bound peaks, which exhibited unequal intensity. We attribute this to one of the
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diastereomers of the poorly solvated cage maintaining a more collapsed conformation, thus
reducing xenon affinity. The NMR of the folate-biosensor is shown in Figure 1. 25.

Figure 1. 22. Synthetic scheme showing the formation of the folate recognition moiety (top) and
the fluorescently labeled folate receptor targeting cryptophane (bottom). The top scheme depicts
the 5-step synthesis of [2-(trimethylsilyl)ethoxy]-2-N-[2-(trimethylsilyl)-ethoxycarbonyl]folic acid.
The bottom scheme shows the synthesis of folate-targeting cryptophane and fluorescently
labeled folate-targeting cryptophane, respectively. Monopropargyl cryptophane (synthesized in 12
steps with a 3% overall yield) was coupled to the folate conjugated azidopeptide on solid support
via Cu(I) mediated [3+2] azide-alkyne cycloaddion and cleaved from solid support in 80% purified
yield. Subsequent conjugation of the folate targeting cryptophane yielded the fluorescent
derivative in 20-30% purified yield. Adapted with permission from Khan, Riggle et al.69
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Figure 1. 23. Confocal micrographs and corresponding brightfield images of 4 µM Cy3-labeled
biosensor targeting FRα. Uptake was monitored in (a) KB; (b) HeLa; and (c) HT-1080 cells after 4
h incubation at 37 ºC in folic acid depleted media. Uptake was blocked in (d) KB; (e) HeLa, and (f)
HT-1080 cells pre-incubated in folic acid containing media. Adapted with permission from Khan,
Riggle et al.69
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Figure 1. 24. Flow cytometry (top) and MTT viability assay (bottom). Flow cytometry quantified
cell uptake of 4 µM Cy3-labeled folate targeting cryptophane. Uptake in (a) KB (FR+, red) and (b)
HT-1080 (FR-, blue) cells was compared to cells pre-incubated with folic acid (black). Cytotoxicity
assays for folate-conjugated cryptophane (without dye) in KB (blue) and HT-1080 (red). Percent
viability was determined via MTT assay after 24 h incubation with increasing concentrations of the
biosensor. Adapted with permission from Khan, Riggle et al.69
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Figure 1. 25. Hyperpolarized 129Xe NMR spectrum of folate receptor targeting cryptophane.
Biosensor (60 µM) in acetate buffer at pH 5.0 (40 scans; S/N = 30:1 with 50 Hz line broadening).
Adapted with permission from Khan, Riggle et al.69

Paradigm Shift in Biosensor Design
In 2010, the Pines laboratory demonstrated that if they mixed diacid cryptophaneA with varying concentrations of Intralipid® they were able to achieve chemical shift
changes (from that of the diacid cryptophane-A in buffer alone) approaching 10 ppm.90
This work suggested that substantially larger chemical shifts could be obtained when the
targeting biosensor was bound in close proximity to the cellular membrane. Indeed, in
recent work the Schrӧder lab metabolically labeled sialic acid with a bioorthogonal azide.91
Employing a cryptophane scaffold containing a strained alkyne they labeled cell
membranes with cryptophane host molecules. The cages tethered to cells exhibited a strong
downfield chemical shift of 10 ppm relative to the free biosensor. Thus moving forward
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our lab has endeavored to decorate cell membranes with our targeting biosensors, as
demonstrated in Chapter 3.
Advantages of Targeted Xenon Biosensors
As these examples of targeted biosensors demonstrate, this new version of targeted
or “smart” contrast agents can be made specific for bioreceptors or biomarkers of interest.
This is an important consideration in the accurate diagnosis of malignant tissue. For
example, mammography identifies masses that necessitate biopsy to determine whether
they are malignant or benign. With targeted molecular imaging receptors strongly
indicative of an aggressive cancer, like HER-2, could be targeted and invasive procedures
only performed after positive identification. Mammography and other non-specific
techniques also result in over-diagnosis, or the identification of small cancers that would
have otherwise been asymptomatic and non-life threatening over the patient’s natural life
span.92 Identification of these cancers may prompt chemotherapeutic or radiation
treatments which carry their own adverse effects.92 Following this example, in cases where
early positive identification of breast cancer is made, early treatment strongly improves
survival.93 Thus there is a strong need for reliable early diagnosis of cancer such that
treatment efficacy is high but unnecessary treatment exposure is mitigated.
§ 1.10 Ultrasensitive Detection: HP Chemical Exchange Saturation Transfer
The use of exogenously supplied hyperpolarized 129Xe improves detection limits of
cryptophane-MRI contrast agents to the low micromolar range. However, the requirements
of molecular imaging have made our lab and others endeavor to increase detection
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sensitivity even further, approaching picomolar or even femtomolar detection regimes.
One such paradigm, first described by Ward et al., exploited the exchanging populations
for selective saturation and was so named chemical exchange saturation transfer (CEST).94
These experiments employed barbituric acid and 5,6-dihydrouracil, both of which contain
exchangeable protons. A tuned radio frequency (rf) pulse was applied selectively to
saturate the signal from the barbituric acid. As a result of the amide protons exchanging
more rapidly than the time scale of spin relaxation with the bulk solvent (H2O), the water
signal was also depleted to a degree directly proportional to the concentration of the
barbituric acid this is shown in Error! Reference source not found.. Thus, these results
demonstrated an indirect detection method for achieving increased detection sensitivity.

Figure 1. 26. Preliminary chemical exchange saturation transfer (CEST) experiment with
barbituric acid. Direct detection 1H NMR shown (top) and CEST spectrum (bottom) demonstrating
concentration-dependent quenching. Adapted with permission from Bai et al.38
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The utility of this technique for hyperpolarized xenon NMR was first demonstrated
by the Pines laboratory in 2006.95 In this application the detection technique is termed
hyper-CEST to account for the presence of hyperpolarized nuclei. In these experiments,
the Pines group tethered biotinylated cryptophane to agarose beads and collected
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Xe

NMR spectra (Error! Reference source not found.b) and transverse 1H NMR images
(Error! Reference source not found.a) overlaid with transverse 129Xe images (Figure 1.
27c). They demonstrated > 3300-fold reduction in image acquisition time as well as
sensitivity ~10,000 times better than previous CEST methods. While these hyper-CEST
experiments were performed at ~5 µM, they postulate that several straight-forward
optimizations could decrease the detection limit by at least 60-fold; namely, the use of
isotopically enriched xenon and optimized polarization procedures. Thus hyper-CEST is a
promising technique for drastically increasing sensitivity of 129Xe NMR.

Figure 1. 27. Initial hyper-CEST experiment using agarose beads labeled with biotinylated
cryptophane. Adapted with permission from Klippel et al.95

50

Moving forward, advances in our lab and elsewhere produced significant
improvements in detection sensitivity. Using TAAC (Figure 1. 16d), we demonstrated 1.4
pM detection limits in buffered solutions, shown in Figure 1. 28.96

Figure 1. 28. Hyper-CEST experiments demonstrating 1.4 pM detection sensitivity of TAAC.
Adapted from Bai et al.38

§ 1.11 Multiplexing Applications*
Because of the large (~300 ppm)

129

Xe NMR chemical shift window for

129

Xe

bound to cryptophanes in water, Pines et al. postulated in 2001 that hp 129Xe NMR should
be amenable to multiplexed detection using a cocktail of cryptophane biosensors.66 One
should ideally obtain only one “bound” peak for each biosensor, and these should be well
resolved from each other (ideally > 5 ppm away) as well as from the “free” biosensor peaks.
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This general idea is described in Figure 1. 29 where, in an MRI, signal from multiple
targeted cryptophanes would be acquired simultaneously with proton anatomical reference
images. The signal from multiple targets will help to negate false positives in tumor tissue
identification. Already, large chemical shift changes (Δδ = 7.5 ppm) upon target
complexation have been achieved in our laboratory with carbonic anhydrase targeting
cryptophanes as well as the 10 ppm chemical shift obtained from the metabolically
incorporated cryptophane discussed in the previous section.70, 91 However, additional work
is needed to probe how the nature of the xenon biosensor-protein interaction,
diastereomerism, and cryptophane solubility affect the
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Xe NMR spectrum. Recently,

work in the Schrӧder laboratory demonstrated the first practical example of multiplexing
with xenon host molecules where they mixed cryptophane and perfluoroctyl bromide
(PFOB) nanodroplets and were able to label mammalian cells and demonstrate “two-color”
contrast MRI shown in Figure 1. 30.97
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Figure 1. 29. Exploiting 129Xe chemical environment sensitivity for multiplexing applications with
cryptophane host molecules.

Figure 1. 30. First multiplexed detection experiment with cryptophane. Demonstrated the ability
to readily discern between PFOB- and cryptophane-labeled cells. Adapted with permission from
Klippel et al.97
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§ 1.12 Conspectus
This dissertation describes the advances in the development of disease-targeted
cryptophane biosensors for the use in 129Xe MRI/MRS. These biosensors couple targeted
molecular imaging with the use of an exogenously supplied nucleus,

129

Xe. Cryptophane

cages can be readily functionalized via “click chemistry” to target a wide variety of
overexpressed biomarkers indicated in cancer progression. Our work has endeavored to
develop synthetic strategies to generate biosensors with the highest degree of specificity
and largest xenon association constants possible. We have used the biosensors we have
generated to investigate the biological applicability and utility of targeted xenon biosensors
for use as contrast agents in NMR. The results of some of these studies are discussed in the
following chapters.
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Chapter 2: Benzenesulfonamide Biosensor Binding Mechanisms in Carbonic
Anhydrase

Section 3 of this chapter was originally published in Organic Letters. It has been adapted
here with permission from the publisher:
Reprinted with permission from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A. Riggle;
D.N. Haase; and I.J. Dmochowski. Synthesis of Enantiopure, Trisubstituted CryptophaneA Derivatives. Org Lett. 2012, 14, (14) 3580-3583. Copyright 2012 American Chemical
Society.
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§ 2.1 Introduction
Ubiquitous zinc metalloenzymes, carbonic anhydrase isozymes are found in a
majority of living organisms because they serve to catalyze the reversible hydration of
carbon dioxide to bicarbonate and proton. The medical community has a special interest in
carbonic anhydrase, however, because some of the 15 human isozymes are upregulated in
specific disease states and are believed to aid tumor metastasis in certain forms of cancer,
see Table 2.1.80 Because of the high degree of homology in active-site conformation
between the different isozymes of interest, the development of inhibitors and targeting
ligands with isozyme specificity has been an area of considerable research. Our initial
results with a carbonic anhydrase-targeting cryptophane demonstrated promising “bound”
upfield chemical shifts of up to 7.2 ppm (see Chapter 1, Section 9) and a degree of isozyme
discrimination between CAI and CAII. These data were convoluted, however, by the
presence of multiple bound peaks. Thus a portion of my thesis work and ongoing studies
in the laboratory have been devoted to elucidating the precise cause of the chemical shift
variation in order to inform a variety of rationally designed biosensors specific to different
isozymes of interest in the targeted molecular imaging of carbonic anhydrase. Additionally,
this work may prove to further refine design specifications for a large variety of Xecryptophane protein sensors.49, 67
Initial hypotheses for the cause of multiple bound peaks centered on the chiral
nature of the cryptophane host molecule as shown in Figure 1. 12. Due to the chiral nature
of cryptophane-2,2,2 once the biosensor binds to the protein active site, diastereomers are
formed. Xenon, highly sensitive to its local environment, has been shown to be sensitive

56

to a diastereomeric host molecule.49, 67 Thus we first endeavored to develop an enantiopure
synthesis of trifunctionalized cryptophane-A derivatives because although other
enantiopure syntheses have been published these routes were not to the trifunctionalized
cryptophanes, which exhibit superior xenon binding as a result of improved cage solubility
and decreased water encapsulation.56-58 Thus Section 2.2 describes several routes we have
developed to trihydroxy cryptophane which can then be, as described in Section 2.3,
isolated into the corresponding (+) and (–) enantiomers and propargylated for further
conjugation to form the desired carbonic anhydrase biosensor. [It should be noted that this
route is not limited to producing CA biosensors, rather, it results in enantiopure tripropargyl
cryptophane which is the starting material for all of our currently used cryptophane
biosensors.]
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§ 2.2 Synthesis of Trihydroxy Cryptophane§
In order to achieve trifunctionalized, enantiopure cryptophane we use trihydroxy
cryptophane which can be achieved via three more efficient routes than from tripropargyl
cryptophane.

Figure 2. 1. Depropargylation of TPC or TAC precursor to form THC precursor.

Route 1:
Tripropargyl

cryptophane

precursor,

achieved

in

5

steps,

(2,7,12-Tris-[2-[4-

(hydroxymethyl)-2-propargyloxy-phenoxy]ethoxy]-3,8,13-trimethoxy-10,15-dihydro-2Htribenzo[a,d,g]cyclononene) was depropargylated to form trihydroxy precursor (6,6',6''((((3,8,13-Trimethoxy-10,15-dihydro-5H-tribenzo[a,d,g][9]annulene-2,7,12-triyl)tris(oxy))tris(ethane-2,1-diyl))-tris(oxy))tris(3-(hydroxymethyl)phenol)), Figure 2. 1. An
oven dried round bottom flask was changed with TPC Precursor (1.0 eq.), and Pd(PPh3)2Cl
(0.10 eq.) and was dissolved in triethylamine (25 mL), tetrahydrofuran (25 mL), and water

§

This section highlights the work of Taratula et al.54
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(12 mL) and stirred at 80 ºC under inert atmosphere overnight. The work up entailed ethyl
acetate extraction (3x) and the compiled organics were then washed with brine and dried
over sodium sulfate and concentrated to a white powder under reduced pressure. The crude
material was then purified by column chromatography (CH2Cl2 →MeOH:CH2Cl2 6:94,
v/v) to yield 0.495 g (0.546 mmol, yield: 70% as a white solid). TLC (silica gel, 5%
MeOH/CH2Cl2): Rf(7) = 0.16. mp: 89-91 °C. 1H NMR (DMSO-d6) δ(ppm): 8.88 (s, 3H),
7.16 (s, 3H), 7.09 (s, 3H), 6.87 (d, J = 8.2 Hz, 3H), 6.78 (s, 3H), 6.65 (m,3H), 4.95 (t, J =
5.8 Hz, 3H), 4.70 (d, J = 13.3 Hz, 3H), 4.33 (m, 6H), 4.18-4.29 (m, 12H), 3.68(s, 9H), 3.52
(d, J = 13.3 Hz, 3H).

C NMR (DMSO-d6) δ(ppm): 147.6, 146.8, 146.3, 145.3,135.9,

13

132.6, 132.0, 117.1, 115.3, 114.4, 114.3, 114.0, 67.7, 67.5, 62.6, 55.9, 35.0. HRMS (m/z):
[M+Na]+ calculated for C51H54O15, 929.3360; found, 929.3405. This method was very low
yielding in my hands and difficult to purify as a result of the dark brown precipitate formed
(from the catalyst) during the reaction. With the help of a talented undergrad, Mara
Greenburg, it was determined that the reaction worked in an ~50% yield on an 80 mg scale,
see Appendix B for 1H NMR.

Figure 2. 2. Reduction of TPC to form THC precursor.
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Route 2:
From tripropargyl cryptophane, achieved in 6 steps, trihydroxy precursor was synthesized.
For 0.050 g TPC (0.05 mmol, 1.0 eq.) Pd(PPh3)Cl2 (0.1 eq), THF (5 mL), Et3N (5 mL) and
H2O (2.5 mL) was used. The solution was heated to 80 ºC and put to stirring under inert
atmosphere overnight. The reaction was worked up by extracting 3x with ethyl acetate. The
combined organics were washed with water and brine and dried over sodium sulfate. The
resulting solvent mixture was concentrated under reduced pressure. Repeated trials with
this method and then increasing the amount of catalyst up to 1 eq and/or substituting
solvents for DMF/H2O as well as allowing the reaction to run longer universally yielded
only small amounts of product by TLC.

6
Figure 2. 3. Synthesis of THC aldehyde precursor and subsequent reduction to form THC
precursor.

Route 3:
Trihydroxy aldehyde precursor is first achieved in 3 steps, as shown in Figure 2. 3. This
route utilized regioselective protection of the 4-hydroxyl group in the 3,4dihydroxybenzaldehyde as detailed by Plourde et al to couple the 3,4-dihydroxy
benzaldehyde “hydroxyl linker” to the cap.98 This method negates the difficult meta linker
synthesis and purification and the redundancy of first protecting and then deprotecting the
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meta alcohol. Relying on the increased acidity of the para proton for preferential reaction
at this position. The reaction proceeded rapidly in respectable yield (crude, by TLC)
purification and characterization is ongoing. Crude NMR shown in Appendix B. [This
route not previously published]

Figure 2. 4. Cyclization of THC precursor by two routes to form THC.

Cyclization to form trihydroxy cryptophane:
Trihydroxy aldehyde precursor (0.110 g, 0.121 mmol, 1.0 eq.) was dissolved in THF (10
mL) and methanol (250 mL) was added. Perchloric acid (60%, 250 mL) was then added
dropwise into the cloudy solution at 0 °C. Scheme shown in Figure 2. 4. The reaction was
allowed to warm to rt and stirred slowly for 24 h under N2. The reaction mixture was diluted
by CH2Cl2 and neutralized by 1 M NaOH solution at 0 °C. The reaction mixture was
extracted with CH2Cl2. The combined organic extracts were concentrated and washed with
NaHCO3 solution and brine several times. The solution was filtered and dried over MgSO4.
After removal of the solvent under vacuum, the residue was chromatographed on a silica
gel column (CH2Cl2MeOH:CH2Cl2 2:98, v/v) to yield 0.067 g (0.079 mmol, 65% yield) as
a white powder. TLC (silica gel, 5% MeOH/CH2Cl2): Rf(8) = 0.33 mp >200 °C (decomp.).
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1

H NMR (CDCl3) δ(ppm): 6.83 (s, 3H), 6.71 (s, 3H), 6.70 (s, 3H), 6.62 (s, 3H), 4.58 (dd, J

=13.7 Hz, 6H), 4.27-4.24 (m, 12H), 3.79 (s, 9H), 3.42 (d, J = 13.8 Hz, 3H), 3.36 (d, J =
13.8 Hz, 3H). 13C NMR (CDCl3) δ(ppm): 149.9, 148.1, 145.7, 144.8, 134.3, 133.6, 131.7,
130.7, 122.1, 120.9, 115.7, 114.2, 70.1, 69.0, 53.5, 36.3, 36.2. HRMS (m/z): [M+Na]+
calculated for C51H48O12, 875.3043; found, 875.3062. The spectroscopic data matched
those reported in the literature.56 Although Dr. Taratula published two routes to trihydroxy
cryptophane, in my hands only the perchloric acid route has been accessible.
§ 2.3 Synthesis of Enantiopure, Trisubstituted Cryptophane-A Derivatives
The need for imaging agents and analytical tools that can report on the
concentration and activity of various biomolecules in complex media has motivated the
development of

129

Xe NMR biosensors.53, 99 These agents have the potential to detect

cancer and other diseases by localizing hyperpolarized (hp)

129

Xe to a diseased tissue

and/or by multiplexed detection of different protein biomarkers.53, 99 To date, cryptophaneA organic cages, in which two cyclotriguaiacylene (CTG) units are connected by three
ethylene oxide linkers, show the highest xenon binding affinity with dissociation constants
of ∼25 μM at physiological temperature in aqueous solution.53, 55, 99 Functionalized 129Xe
cryptophane biosensors can be targeted to different protein receptors and identified by
changes to the frequency of the bound 129Xe nucleus.66, 71, 72
The use of enantiopure cryptophanes is preferred over racemic mixtures, which
have been shown to produce multiple, diastereomeric peaks upon binding to chiral protein
surfaces.49, 67, 70 Similarly, complex hp

129

Xe NMR spectra are observed when racemic

cryptophanes are modified with chiral small molecules or peptides, based on
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diastereomeric splitting.100-102 For the sensitive detection of chiral biological analytes,
enantiopure cryptophanes that offer well resolved “bound” and “free”

129

Xe NMR peaks

should offer substantial advantages. Enantiopure cryptophanes have also been employed
for chiral recognition of small guests.103 Here, we report a new method for producing
enantiopure cryptophanes for many different applications.
Results and Discussion
Until now, the resolution of chiral cryptophanes and hemicryptophanes has
typically required expensive HPLC methods and yielded only small quantities of optically
pure material.104, 105 Another approach has been the synthesis of enantiopure cryptophanes
from the optically pure CTG units, but one limitation is possible racemization of CTG
during the subsequent synthetic steps.103 Recently, Dutasta and co-workers employed (−)camphanic chloride as a chiral resolving agent to resolve monocryptophanol through
separation of the resulting diastereomers.106 The diastereomers were not separable by
chromatography on silica gel or reversed-phase HPLC, but crystallographic resolution has
recently been improved to give both enantiomers in 25% yield.107 However, this
crystallographic method is time-consuming. The low yield of pure cryptophane
diastereomers limits the production of enantiomerically pure cages for uses in xenon
biosensors and host guest chemistry, broadly defined.
Dutasta et al. previously demonstrated the chromatographic separation of
trifunctionalized hemicryptophanes.108 We hypothesized that a pair of cryptophane-A
diastereomers substituted with three chiral auxiliaries would also result in a significant
difference in polarity. Indeed, substitution with three chiral resolving groups allowed
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efficient separation and isolation of cryptophane diastereomers using silica gel column
chromatography. Deprotection of the isolated diastereomers yielded the enantiopure
trisubstituted cryptophanes, whose chemical and physical properties can be tuned at the
three positions.
According to Figure 2. 5a, diastereomers 2a and 2b were synthesized from
trihydroxy cryptophane 1, (as described in Section 2.2) which was obtained by a previously
published six-step route.54 Trihydroxy cryptophane 1 was reacted with 3.3 equivalents of
(S)-Mosher’s acid in the presence of DMAP/Et3N. The Mosher’s acid moiety was chosen
as a readily available and sterically bulky chiral resolving agent. The reaction proceeded
relatively slowly and went to ∼70% completion after stirring for two days at 70 ºC in DMF.
The resulting cryptophane-A diastereomers 2a and 2b were successfully separated by
column chromatography (silica gel, Et2O/ CH2Cl2, 0.5:99.5, v/v) to give each enantiomer
in 35% yield. Resolved diastereomers 2a-(S)-(−) and 2b-(S)-(+) were easily distinguished
by 1H NMR spectroscopy (Figure 2. 5b), each showing four singlets with different
chemical shift values for aromatic protons. In contrast, the aromatic region of the
diastereomeric mixture exhibited eight singlets in the same region (Figure 2. 5b). The
enantiopurity of the isolated diastereomers was confirmed by electronic circular dichroism
(ECD) spectroscopy showing the same peaks with opposite signs (Figure 2. 6a).

64

Figure 2. 5. Synthesis of trisubstituted cryptophane diastereomers of cryptophane from trihydroxy
cryptophane (a) and aromatic region of 1H NMR spectra for i. mixture of diastereomers; ii. 2a; and
iii. 2b. Reprinted with permission from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A. Riggle;
D.N. Haase; and I.J. Dmochowski. Synthesis of Enantiopure, Trisubstituted Cryptophane-A
Derivatives. Org Lett. 2012, 14, (14) 3580-3583. Copyright 2012 American Chemical Society.
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Figure 2. 6. ECD spectra of diastereomers 2a and 2b (~0.5 mM) in 1,4-dioxane (a) and hp 129Xe
NMR spectrum of diastereomers 2a and 2b ~10 mM in C2D2Cl4 at 299 ± 2 K (b). Reprinted with
permission from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A. Riggle; D.N. Haase; and I.J.
Dmochowski. Synthesis of Enantiopure, Trisubstituted Cryptophane-A Derivatives. Org Lett.
2012, 14, (14) 3580-3583. Copyright 2012 American Chemical Society.
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Figure 2. 7. 129Xe NMR of a) 2a-(S)-(−); and b) 2a-(S)-(+). Reprinted with permission from O.
Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A. Riggle; D.N. Haase; and I.J. Dmochowski. Synthesis
of Enantiopure, Trisubstituted Cryptophane-A Derivatives. Org Lett. 2012, 14, (14) 3580-3583.
Copyright 2012 American Chemical Society.
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The interaction between xenon and the trisubstituted cryptophane diastereomers 2a
and 2b was investigated by hp

129

Xe NMR spectroscopy in a nonintercalating organic

solvent, 1,1,2,2-tetrachloroethane-d2 (C2D2Cl4). Hyperpolarized

129

Xe was mixed with a

sample solution in an airtight NMR tube, and spectra were taken quickly with
four transients (Figure 2. 6b). Standardized by the signal from dissolved hp
C2D2Cl4,46 hp

129

129

Xe in

Xe NMR chemical shifts for the mixture of diastereomers 2a-(−) (67.5

ppm) and 2b-(+) (77.0 ppm) in C2D2Cl4 at 299 K were recorded 9.5 ppm apart (Figure 2.
6b), which is the largest chemical shift difference reported for cryptophane diastereomers.
Peaks were assigned by collecting the hp 129Xe NMR spectrum for both of the individual
diastereomers (Figure 2. 7). Previously, for the mono-(−)-camphanic acid cryptophane
diastereomers, a chemical shift difference of ∼7 ppm was observed for the two
diastereomers.109

Notably,

for

the

camphanic

acid

derivative,

the

more

downfield peak arose from the cryptophane-(−) diastereomer, whereas with three Mosher
acids it was the cryptophane-(+) diastereomer. With a 1:1 mixture of diastereomers 2a and
2b, the two resonances are clearly resolvable (Figure 2. 6b) by hp

129

Xe NMR

spectroscopy. The isolated cryptophane diastereomers are useful precursors for preparing
various enantiopure functionalized cryptophanes. Removal of the Mosher moieties occurs
without loss of optical activity. Diastereomers 2a and 2b were deprotected via basic
hydrolysis at 70 ºC, affording enantiopure trihydroxy cryptophanes 3a-(−) and 3b-(+)
(Figure 2. 8). The recorded ECD spectra were mirror images (within experimental error)
of each other, as expected for a pair of enantiomers (Figure 2. 9a). In the absence of an Xray crystal structure for the isolated enantiomers, the structural assignment for the two
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enantiomers was made by reacting cryptophane 3b-(+) with methyl iodide to yield (+)cryptophane-A, Figure 2. 10. The recorded ECD spectrum (Figure 2. 9c) was found to be
opposite of the previously reported spectrum for (−)-cryptophane-A.110

Figure 2. 8. Synthesis of enantiopure, trifunctionalized cryptophanes 3-(−), 3-(+), 4-(−), and 4-(+).
Reprinted with permission from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A. Riggle; D.N.
Haase; and I.J. Dmochowski. Synthesis of Enantiopure, Trisubstituted Cryptophane-A
Derivatives. Org Lett. 2012, 14, (14) 3580-3583. Copyright 2012 American Chemical Society.

69

Similarly to (+)-cryptophane-A, various trisubstituted enantiopure cryptophane
derivatives could be easily synthesized from trihydroxy cryptophane enantiomers 3a-(−)
and 3b-(+). For example, reaction with excess propargyl bromide gave the
enantiomerically pure tripropargyl cryptophanes 4a-(−) and 4b-(+) (Figure 2. 8; Figure 2.
9b).111, 112 We previously showed that alkyl azides can react with tripropargyl cryptophane
in nearly quantitative yields via the Cu(I)-catalyzed Huisgen [3 + 2] cycloaddition reaction.
This route gave enantiopure tripropargyl cryptophanes 4a-(−) and 4b-(+), each in 15%
overall yield starting from racemic trihydroxy cryptophane 1-(±).

Figure 2. 9. Electronic circular dichroism for a) 3a-(−) and 3a-(+); b) 4a-(−) and 4a-(+); c) (+)cryptophane-A. Reprinted with permission from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A.
Riggle; D.N. Haase; and I.J. Dmochowski. Synthesis of Enantiopure, Trisubstituted CryptophaneA Derivatives. Org Lett. 2012, 14, (14) 3580-3583. Copyright 2012 American Chemical Society.
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Figure 2. 10. Synthesis of Cryptophane-A (+)

In conclusion, an efficient synthesis of enantiopure trifunctionalized cryptophanes
was

developed

using

chromatographically

resolved

trisubstituted

cryptophane

diastereomers. ECD spectroscopy confirmed the expected chiroptical properties of the
isolated diastereomeric and enantiomeric pairs. Hyperpolarized 129Xe NMR chemical shifts
were recorded at 9.5 ppm apart for the cryptophane diastereomers. The potential for
synthesizing gram-scale quantities of enantiomerically pure cryptophane would provide
access to the various functionalized cryptophanes, precursors for many cryptophane-based
enantiopure biosensors. Particularly, enantiopure Xe biosensors are desired to facilitate
high-resolution X-ray crystallographic studies53, 65, 70, 71, 113 and to simplify the assignment
of peaks in 129Xe NMR spectra. These methods are currently being applied to synthesizing
enantiopure C8B.
Materials and Methods
General Methods. 1H NMR (360 and 500 MHz) and 13C NMR (90 and 125 MHz) spectra
were obtained on Bruker DMX 360 and AMX 500 spectrometers at the University of
Pennsylvania NMR facility and were recorded at room temperature in deuterated
chloroform (CDCl3) or dimethyl sulfoxide (DMSO-d6) unless otherwise noted. The 1H and
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C NMR spectra were referenced to the central line of the residual solvent. 1H NMR and
C NMR chemical shifts (δ) are given in parts per million (ppm) and reported to a precision

13

of ± 0.01 and ± 0.1 ppm, respectively. Proton coupling constants (J) are given in Hz and
reported to a precision of ± 0.1 Hz. Column chromatography was performed using silica
gel (60 Å pore size, 40-75 µm particle size) from Sorbent Technologies. Thin layer
chromatography (TLC) was performed using silica gel plates (60 Å pore size, Whatman)
with UV light at 254 nm as the detection method. High resolution mass spectrometry
(HRMS) data were obtained using electrospray ionization (ESI) mass spectrometry on a
Micromass Autospec at the Mass Spectrometry Center in the Chemistry Department at the
University of Pennsylvania. Electronic circular dichroism (ECD) spectra were recorded at
room temperature on a Chirascan™ Circular Dichroism Spectrometer using cells with a
pathlength of 0.1 cm. UV-visible spectra were measured using a diode-array Agilent
89090A spectrophotometer.
Hyperpolarized

129Xe

NMR spectroscopy. We utilized an in-house

129

Xe hyperpolarizer

based on the IGI.Xe.2000 system made by the former Nycomed-Amersham (now GE).
Hyperpolarized gas supply (Concorde Gases) was a mixture of 89% N2, 10% He, and 1%
natural abundance Xe (29.4%

129

Xe).

129

Xe nuclei were hyperpolarized to 10-15% after

being cryogenically separated, accumulated, thawed, and collected in degassed airtight
NMR tubes (CAV5, New Era).70 This traps ~2 atm of hyperpolarized Xe in the tube. After
hyperpolarized Xe was retrieved, NMR tubes were shaken vigorously to mix Xe with
cryptophane solutions. All

129

Xe NMR measurements were made on a 500 MHz Bruker

BioDRX NMR spectrometer at the University of Pennsylvania NMR Facility. RF pulse
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frequency for

129

Xe was 138.12 MHz. Samples were observed using a Bruker 5 mm

PABBO NMR probe.

129

Xe spectra were processed using standard protocols, and

129

Xe

NMR spectral calibration was performed as previously reported for cryptophane solutions
in C2D2Cl4.54 All air- and moisture-sensitive reactions were performed under inert
atmosphere in glassware flamed under vacuum, and using anhydrous solvents. Standard
workup procedures involved multiple (~3) extractions with the indicated organic solvent,
followed by washing of the combined organic extracts with water or brine, drying over
Na2SO4 and removal of solvents in vacuo. All yields are reported after purification by
column chromatography or crystallization.
Materials. Organic reagents and solvents were used as purchased from the following
commercial sources: Sigma-Aldrich: dimethyl sulfoxide (DMSO, anhydrous, 99.9%), (S)(+)-α-methoxy-α-trifluoromethylphenylacetyl chloride (Mosher’s acid chloride, 98%,
Aldrich); Fisher: acetone (HPLC grade), sodium hydroxide, potassium hydroxide,
hydrochloric acid, sodium sulfate (anhydrous), sodium chloride, sea sand (washed),
potassium carbonate (K2CO3, anhydrous), methyl iodide, toluene (HPLC grade), ethyl
acetate (EtOAc, HPLC grade), hexanes (HPLC grade), chloroform (CHCl3, HPLC grade),
dichloromethane (CH2Cl2, HPLC grade), methyl alcohol (MeOH, HPLC grade), ethyl ether
(Et2O,

anhydrous);

Acros

Organics:

4-dimethylaminopyridine

(DMAP),

N,N-

dimethylformamide (DMF, anhydrous, 99.8%), sodium hydride (NaH, 60% dispersion in
mineral oil), allyl bromide (99%), benzyl bromide (98%), propargyl bromide (80% solution
in toluene), 3,4-dihydroxybenzaldehyde (97%), fluorobenzene (99%), dichloromethane
(99.8%, extra dry, over molecular sieves), cesium carbonate (Cs2CO3, 99.5%), anhydrous
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dimethylsulfoxide (DMSO), anhydrous dimethylformamide (DMF), methyl sulfoxide-d6,
chloroform-d (CDCl3), acetone-d6, 4-hydroxy-3-methoxybenzyl alcohol (99%), 1,2dibromoethane,

sodium

borohydride

(NaHB4,

powder,

98%),

scandium(III)

trifluoromethanesulfonate (Sc(OTf)3, 95%); methyl alcohol (MeOH, extra dry, over
molecular sieves), tetrahydrofuran (THF, extra dry, over molecular sieves), acetonitrile
(CH3CN, anhydrous); Concord Specialty Gases: xenon gas (scientific grade).
Triethylamine (Et3N, Acros) was distilled from KOH under nitrogen prior to use.
Synthetic Procedures and Analytical Data
Trihydroxy cryptophane (1) was obtained in six steps with an overall yield of 9.5%.54
Cryptophane (2, diastereomeric mixture): An oven-dried flask was charged with
trihydroxy cryptophane 1 (0.201 g, 0.236 mmol, 1.0 equiv), DMAP (0.010 g, 0.078 mmol,
0.3 equiv), and triethylamine (2 mL) in DMF (12 mL). Finally, Mosher’s acid chloride
(0.197 g, 0.778 mmol, 3.3 equiv) was added and the reaction mixture was stirred at 70 ºC
for 2 days. The reaction mixture was cooled to rt followed by standard workup procedure
using dichloromethane for extraction. The diastereomers were purified and separated by
silica gel column chromatography (Et2O:CH2Cl2, 0.5:99.5, v/v) to yield 0.12 g (0.081
mmol, yield: 34%) 2a and of 0.12 g (0.081 mmol, yield: 34%) 2b as white solids. Typically
20-30% of the trihydroxy cryptophane starting material was recovered from the
chromatography column.
Diastereomer 2a-(S)-(−): mp >130 °C dec; TLC (silica gel, Et2O: CH2Cl2, 1:99, v/v): Rf(2a)
= 0.63; 1H NMR (CDCl3) δ (ppm): 7.73-7.55 (m, 15H), 6.78 (s, 3H), 6.67 (s, 3H), 6.65 (s,
3H), 6.59 (s, 3H), 4.67 (d, J = 13.8 Hz, 3H), 4.54 (d, J = 13.7 Hz, 3H), 4.37-3.91 (m, 12H),
74

3.82 (s, 9H), 3.50 (d, J = 12.6 Hz, 3H), 3.43 (s, 9H), 3.37 (d, J = 13.9 Hz, 3H); 13C NMR
(CDCl3) δ (ppm): 164.6, 149.0, 148.9, 144.6, 138.8, 138.2, 133.2, 132.3, 132.0, 131.2,
130.0, 128.5, 127.6, 122.6, 122.4, 117.0, 114.9, 68.8, 68.5, 56.0, 55.4, 36.2, 36.0; Shown
in Figure 2. 11. HRMS (m/z): [M+Na]+ calculated for C81H69F9O18Na, 1523.4238; found,
1523.4221. NMR spectra are shown in Appendix B.
Diastereomer 2b-(S)-(+): mp >220 °C dec; TLC (silica gel, Et2O: CH2Cl2, 1:99, v/v): Rf(2b)
= 0.60; 1H NMR (CDCl3) δ (ppm): 7.75-7.55 (m, 15H), 6.87 (s, 3H), 6.76 (s, 3H), 6.55 (s,
3H), 6.44 (s, 3H), 4.68 (d, J = 13.9 Hz, 3H), 4.51 (d, J = 13.7 Hz, 3H), 4.26-3.88 (m, 12H),
3.77 (s, 9H), 3.53 (d, J = 13.9 Hz, 3H), 3.48 (s, 9H), 3.31 (d, J = 13.9 Hz, 3H); 13C NMR
(CDCl3) δ (ppm): 164.5, 149.8, 149.5, 146.0, 139.1, 139.0, 133.9, 133.2, 132.2, 131.3,
130.0, 128.7, 128.1, 123.3, 122.4, 119.2, 114.7, 69.3, 69.2, 55.9, 36.6, 36.3; shown in
Figure 2. 12. HRMS (m/z): [M+Na]+ calculated for C81H69F9O18Na, 1523.4238; found,
1523.4202. NMR spectra are shown in Appendix B.
Trihydroxy cryptophane 3a-(−): A solution of 2 M KOH (4 mL) was added to the solution
of cryptophane 2a-(S)-(−) (0.051 g, 0.034 mmol) in THF (6 mL). The solution was stirred
overnight at 70 °C. THF was removed under vacuum. Water was then added and the
resulting solution was acidified with concentrated HCl and extracted with CH2Cl2. The
solution was washed with water and the organic layer was dried over Na2SO4. The solvent
was removed in vacuo and the crude mixture was purified by silica gel column
chromatography (MeOH: CH2Cl2, 1:99, v/v) to yield 0.022 g (0.026 mmol, yield: 77%).
TLC (silica gel, MeOH/CH2Cl2, 5:95, v/v): Rf(3a) = 0.33; mp >200 °C dec; 1H NMR and
13

C NMR spectra for 3a are identical to the spectra of the racemic (±) trihydroxy
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cryptophane previously reported in our lab;54,

56

HRMS (m/z): [M+Na]+ calcd for

C51H48O12Na, 875.3043; found, 875.3047.
Trihydroxy cryptophane 3b-(+): Following the procedure for the synthesis of 3a,
compound 2b-(S)-(+) (0.049 g, 0.033 mmol) in the presence of 2 M KOH (4 mL) in THF
(6 mL) afforded 0.023 g (0.027 mmol, 81 % yield) of 3b as a white solid. TLC (silica gel,
MeOH/CH2Cl2, 5:95,v/v): Rf(3b) = 0.33. mp >200 °C dec; 1H NMR and 13C NMR spectra
for 3b are identical to the spectra of 3a and the racemic (±) trihydroxy cryptophane
previously reported in our lab,54, 56 for confirmation, HRMS (m/z): [M+Na]+ calculated for
C51H48O12Na 875.3043; found, 875.3041.
Tripropargyl cryptophane 4a-(−): Compound 3a (0.041 g, 0.048 mmol, 1 equiv) and
K2CO3 (0.033 g, 0.24 mmol, 5 equiv) were added into dry acetone (10 mL) under nitrogen.
The mixture was stirred at rt for 30 min. The reaction mixture was cooled to 0°C and
propargyl bromide (0.05 mL, 0.48 mmol, 10 equiv) was then added dropwise followed by
stirring for 30 min at rt. Finally, the reaction mixture was refluxed for 2 days with stirring.
The solvent was removed in vacuo and the crude mixture was purified by silica gel column
chromatography (CH2Cl2→Acetone:CH2Cl2 5:95, v/v) to yield 0.024 g (0.025 mmol, 52%
yield) of 4a as a white powder. mp >200 °C dec; TLC (silica gel, acetone: CH2Cl2, 1:9,
v/v): Rf(4a) = 0.73; 1H NMR and 13C NMR spectra for 4a are identical to the spectra of the
racemic (±) tripropargyl cryptophane previously reported in our lab;54 HRMS (m/z):
[M+Na]+ calculated for C60H54O12Na, 989.3513; found, 989.3514.
Tripropargyl cryptophane 4b-(+): Following the procedure for the synthesis of 4a,
compound 3b (0.045 g, 0.053 mmol, 1 equiv) in the presence of K2CO3 (0.037 g, 0.27
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mmol, 5 equiv) and propargyl bromide (0.06 mL, 0.53 mmol, 10 equiv) in dry acetone (10
mL) afforded 0.028 g (0.029 mmol, 55% yield) of 4b as a white solid, mp >200 °C dec;
TLC (silica gel, acetone: CH2Cl2, 1:9, v/v): Rf(4b) = 0.73. 1H NMR and 13C NMR spectra
for 4b are identical to the spectra of 4a and the racemic (±) tripropargyl cryptophane
previously reported in our lab; HRMS (m/z): [M+Na]+ calculated for C60H54O12Na,
989.3513; found, 989.3533.
UVvis Spectroscopy. A stock solution of 20 mgs tripropargyl cryptophane in 1,4-dioxane
was prepared in a volumetric flask. Dilutions were made to generate a range of sample of
known concentration. The absorbance of these samples were measured and used to
calculate an extinction coefficient of 10,000 M-1cm-1, shown in Figure 2. 11.

Figure 2. 11. Representative UV-vis spectrum of tripropargyl cryptophane (a); and Beer’s Law
plot determining the extinction coefficient of tripropargyl cryptophane (b). Adapted with permission
from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A. Riggle; D.N. Haase; and I.J. Dmochowski.
Synthesis of Enantiopure, Trisubstituted Cryptophane-A Derivatives. Org Lett. 2012, 14, (14)
3580-3583. Copyright 2012 American Chemical Society.
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Cryptophane-A-(+): An excess of methyl iodide (0.035 g, 0.25 mmol, 10 equiv) was added
to 3b-(+) (0.021 g, 0.025 mmol, 1 equiv) and K2CO3 (0.017 g, 0.13 mmol, 5 equiv) in dry
acetone (5 mL) under nitrogen. The reaction mixture was refluxed for 2 days with stirring.
The solvent was removed in vacuo and the crude was purified by silica gel column
chromatography (CH2Cl2→Acetone:CH2Cl2 5:95, v/v) to yield 0.018 g (0.021 mmol, 85%
yield) of 5 as a white powder. TLC (silica gel, acetone:CH2Cl2, 1:9, v/v): Rf(5) = 0.82; 1H
NMR (CDCl3) δ (ppm): 6.77 (s, 6H), 6.68 (s, 6H), 4.61 (d, J = 13. Hz, 6H), 4.17 (m, 12H),
3.81 (s, 9H), 3.42 (d, J = 13.8 Hz, 3H); 13C NMR (CDCl3) δ (ppm): 149.9, 146.9, 134.4,
131.8, 121.0, 113.9, 69.6, 55.9, 36.4. HRMS (m/z): [M+Na]+ calculated for C54H54O12Na,
917.3513; found, 917.3517.
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§ 2.4 Enantiopure Cryptophane-129Xe NMR Biosensors Targeting Carbonic
Anhydrase**
Utilizing the synthetic strategies discussed in Section 2.3, we endeavored to
determine if the + and – enantiomers of the carbonic anhydrase targeting cryptophane,
C7B, bound CA in different ways and thus resulted in the observed multiple bound peaks.
As shown in Figure 1. 20, C7B demonstrated the largest chemical shift from free biosensor
(Δδ=7.5 pmm) and from the other bound peak (Δδ=4.2 ppm) and thus was selected for
initial attempts to elucidated how diastereomers formation affects biosensor binding.
Enantiopure C7B was achieved in two steps from enantiopure tripropargyl cryptophane as
shown in Figure 2. 12. Enantiopurity was confirmed by circular dichroism spectroscopy as
shown in Figure 2. 13.

**

This section summarizes work published by Taratula et al. and the data figures are
directly used from the paper in reference 86
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Figure 2. 12. Synthesis of enantiopure cryptophane biosensors (−) and (+) C7B from enantiopure
tripropargyl cryptophane.

We had demonstrated with hp 129Xe NMR that C7B in 50 mM Tris at pH 8, has a
chemical shift of 63.9 ppm. Upon addition of stoichiometric amounts of WT CAII, there
are three observable peaks. The first is at 63.7 ppm which we attribute to unbound
biosensor. The second and third are at 67.0 and 71.2 ppm, respectively. We attributed those
two peaks to biosensor binding or otherwise interacting with the protein.
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Figure 2. 13. Electronic Circular Dichroism for C7B-(─) and C7B-(+). Reproduced with
permission from Taratula et al.86

It is well documented in the literature that benzene sulfonamide binds CAII in 1:1
stoichiometry.85 Thus we hypothesized that the different diastereomers formed upon active
site binding was the most probable cause for the observed multiple peaks. We performed
129

Xe NMR with both the (+) and (−) C7B compounds at 0.5 and 1.0 equivalents. We

endeavored to both assign each bound peak to a given diastereomers and to ascertain if
they bound with equal affinity. The results, however, depicted a more convoluted binding
interaction, see Figure 2. 14. The (+) enantiomer appears to bind CAII with higher affinity,
at both 0.5 and 1.0 equivalents we observe no unbound peak. The (−) enantiomer, on the
other hand, seems to bind more weakly as there is observable unbound biosensor even with
1.0 equivalent of CAII but the (−) enantiomer gives the desired large (~7 ppm) chemical
shift upon binding. Reexamining racemic C7B binding to WT CAII (Figure 2. 15)
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definitively demonstrates that diastereomer formation does contribute to the presence of
multiple bound peaks but that it isn’t the only contributing factor.

Figure 2. 14. 129Xe NMR spectra of C7B-(─) and C7B-(+) in the before and after binding WT
CAII. Reproduced with permission from Taratula et al.86
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Figure 2. 15. 129Xe NMR spectrum of racemic C7B and WT CAII. Reproduced with permission
from Taratula et al.86

§ 2.5 Two-Site Hypothesis
The need to understand how we generate specific chemical shifts was not
completely resolved by the enantiopure C7B studies, thus we returned to the literature to
find anomalies in benezene sulfonamide binding to CA. One paper mentioned, as an aside,
that in crystallographic studies a benzenesulfonamide derivative was observed to bind to
the external protein surface which they termed a “b” site shown in Figure 2. 16.
The cause of this binding was attributed to the “relatively high concentrations of
inhibitors employed in the crystal soaking protocol…”114 Nonetheless, we wondered if the
cryptophane itself could be strengthening and thus promoting binding to this “b” site even
in stoichiometric concentrations of biosensor. To determine if this was the case we
produced two initial mutants, H94R--to abolish active-site binding and D19L--to abolish
“b” site binding, see Figure 2. 17. Following on the initial enantiopure work with C7B, we
decided to employ C8B for these studies as it is the only CA biosensor with which we
obtained a bound crystal structure.89 Initial

129
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Xe NMR and ITC experiments (Figure 2.

17b, ITC data not shown) demonstrated single site binding between the biosensor and
D19L CAII. However, attempts with H94R showed no signal by

129

Xe NMR (data not

shown) and the protein foamed extensively precluding any ITC measurements. Although
these preliminary data do not prove whether the biosensors can bind to the “b” site they do
show that removing the charged residue in the 19 position results in a single bound peak.
We made further attempts to determine whether our CA biosensors bind to the purported
“b” site. Benjamin Roose next expressed an H94A CAII mutant which was documented as
being more stable in the literature. ITC data showed no binding (data not shown) and 129Xe
NMR also showed no bound signal, while indicating biosensor free in solution, Figure 2.
17c. Thus, these experiments with H94A succeeded in negating the “b site hypothesis.” All
evidence for multi-site binding must result from biosensor binding in different
conformations and in different regions of the active-site (‘a site’) channel.

Figure 2. 16. Crystal structures of a benzenesulfonamide derivative bound to CAII i) enzyme
active site or Site A; and ii) an external binding site or Site B.
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Figure 2. 17. Depiction of the two purported benzene sulfonamide binding sites on CA II and the
proposed mutations, H94A in green and blue and D19L in magenta. 129Xe NMR shows A) two
bound peaks for C8B with WT CAII; B) one bound peak for C8B with D19L CAII; and C) only an
unbound peak for C8B with H94R CAII.
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Utilizing C8B and a variety of protein double and triple mutants we were able to
observe that the charged 19 residue is on a flexible portion of the protein and is in close
enough proximity with the biosensor as to interact with it, possibly via the cryptophane
propionates, and influence biosensor positioning relative to residues at the mouth of the
active site channel. These perturbations then result in changes in the 129Xe chemical shift.
Figure 2. 18 demonstrates the proximity of the two sites and demonstrates the
conformational flexibility of the tail containing D19. A manuscript detailing these results
is in preparation thus the data have been omitted from this dissertation.

Figure 2. 18. WT CAII bound to benzene-sulfonamide substrates. The “b site” is found on a
flexible loop of CA II which may facilitate D19 interaction with biosensor bound to the protein
active site.
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§ 2.6 Moving Forward
The final component to that manuscript will be to repeat some of the double and
triple protein mutant studies with enantiopure C8B. Although these specific compounds
have not been previously prepared, I am utilizing our previously published routes to C7B,
discussed in Sections 2-4 of this chapter. Studies comparing the results of racemic C8B to
(+) and (−) enantiopure C8B with the variety of prepared CAII mutants should resolve
many components that result in the observed multiple bound peaks. The synthesis will be
completed by Mara Greenberg, a talented undergraduate student who I trained.
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Chapter 3: Smart 129Xe NMR Biosensor for pH-Dependent Cancer Cell
Labeling

The content of this chapter was originally published in the Journal of the American
Chemical Society. It has been adapted here with permission from the publisher:
Reprinted with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart” 129Xe
NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 55425548. Copyright 2015 American Chemical Society.
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§ 3.1 Introduction
Magnetic resonance imaging (MRI) and spectroscopy (MRS) are versatile and
commonly employed techniques for the diagnosis and staging of disease.20 The
development of targeted and stimuli-responsive (i.e., “smart”) contrast agents improves the
capabilities of MRI/MRS for molecular imaging.115 Targeted therapeutic and diagnostic
imaging techniques are typically directed to one or more receptors associated with a disease
state. However, in cancer, as a result of large natural variations between cells and the
heterogeneous nature of tissue within a tumor, there is also need for more general
biomarkers.116, 117 For example, hypoxia and acidification occur in 90% of tumors and are
key microenvironmental factors in progression and treatment resistance in solid tumors.118,
119

The tumor microenvironment is acidified to levels approaching pH 6.0 from a normal

pH of 7.4, which increases metastasis, mutation rate, and cell viability.117, 120-122 Therefore,
being able to identify cells in acidic environments has practical importance in the design
of cancer therapies and controlled-release drug delivery mechanisms.121 Additionally,
acidic environments can mitigate the efficacy of weakly basic chemotherapeutics such as
doxorubicin, further necessitating methodologies to probe extracellular pH (pHe).123 Here,
we present an ultrasensitive xenon-based MR contrast agent that can identify and label cell
populations based on their acidic pHe.
A variety of pH-responsive MR contrast agents have been designed previously,
including Gd complexes,124,
compounds,126,

127

125

tunable micelle-encapsulated polymers and

and CEST agents,128-134 among others.135,

136

19

F

These probes enable

measurements of solution pH but do not selectively label cells in acidic environments, e.g.,
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as needed for identifying small populations of cancer cells or performing cell tracking
experiments. In parallel efforts over the past two decades, many strategies have been
developed for labeling cells with MRI contrast agents such as membrane-targeting Gd
chelates,23 monocrystalline iron-oxide particles (MIONs),137 micron-sized iron-oxide
particles (MPIOs),138 ultrasmall dextran-coated iron oxide particles (USPIOs),139 and
superparamagnetic iron oxide (SPIO) glycol chitosan.122,

140

Pioneering studies by the

Tsourkas lab and others have explored pH-dependent cell labeling with these reagents, but
there remain significant limitations, e.g., pH-responsive SPIO typically requires significant
incubation time (~24 h) between administration and imaging.122 More generally,
applications with conventional MRI contrast agents are limited by low detection sensitivity
on a per-monomer basis (i.e., low mM). One strategy for improving NMR detection
sensitivity involves the use of exogenously supplied “hyperpolarized” (hp) nuclei, e.g.,
129

Xe,

13

C, and 3He, with magnetic spin reservoirs that exceed the normal Boltzmann

distribution by several orders of magnitude. Xe binds void spaces in materials,141
proteins,142 and spores143 but shows highest affinity and useful exchange kinetics for a class
of host molecules known as cryptophane.48, 50, 55-57, 86, 144, 145 Perturbation of the large (~42
Å3 volume) 129Xe electron cloud can produce significant nuclear magnetic chemical shift
changes and results in a nearly 300 ppm chemical shift window when bound to different
cryptophanes in aqueous solution.50, 60, 61
Based on these principles, we and others have developed 129Xe-cryptophane NMR
biosensors66 for the sensitive detection of protein receptors,66-69, 73 enzymes,70 DNA,71 and
metal ions in solution.113 In one proof-of-concept experiment, Berthault et al. decorated
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cryptophane with six carboxylic acids to create a pH reporter: unique chemical shifts were
measured over the pH 3.5-5.5 range with a total Δδ of 3.55 ppm.146 However, solubility
issues precluded work near neutral pH.
Recent studies have moved xenon biosensing from buffer solutions to lipid
membrane suspensions and living cells. The Pines lab developed ultrasensitive methods
for detecting cryptophane in solution using hp 129Xe chemical exchange saturation transfer
(Hyper-CEST) NMR spectroscopy.95 They also discovered that cryptophane in association
with a dilute suspension of sub-micron Intralipid vesicles yielded a 129Xe NMR peak that
was shifted ~10 ppm downfield from the aqueous 129Xe-cryptophane peak;90 similar results
were later obtained with different lipid compositions.147 The Schröder lab subsequently
performed Hyper-CEST NMR spectroscopy and imaging studies in cells loaded with
lipophilic cryptophane and found a similar 9-11 ppm downfield chemical shift change,
likely due to membrane association.75, 97, 148 These studies highlight the large 129Xe NMR
chemical shift changes that can be achieved by engineering cryptophane-lipid membrane
interactions.
Building on these examples, we set out to develop an ultrasensitive

129

Xe NMR

contrast agent for labeling cells in acidic microenvironments. Recent work from our
laboratory96 and elsewhere149, 150 has demonstrated nM-to-pM detection of water-soluble
cryptophane using Hyper-CEST NMR spectroscopy. Most recently, Witte et al.
demonstrated effective contrast via Hyper-CEST by site-specific labeling of cell-surface
glycans with nM concentrations of cryptophane.91 Thus, Hyper-CEST NMR should enable
ultrasensitive detection of cryptophane-labeled cells that reside in acidic environments and
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differentiation from “normal” cells residing in neutral pH environments, provided that
cryptophane-cell interactions can be modulated over the pH range 5.5-7.5.

Figure 3. 1. Reaction scheme for the formation of water soluble EALA-cryptophane (WEC). a. 1
(1 eq), 2 (1 eq), CuSO4 (1 eq), TBTA (5 eq), 2,6-lutidine (1 eq), NaAsc (10 eq), 12 h; b. 3 (crude),
4 (10 eq), CuSO4 (1 eq), TBTA (5 eq), 2,6-lutidine (1 eq), NaAsc (10 eq), 12 h. Adapted with
permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart” 129Xe NMR Biosensor for pHDependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 5542-5548. Copyright 2015
American Chemical Society.

We hypothesized that modifying cryptophane with an EALA-repeat peptide,
WEAALAEALAEALAEHLAEALAEALEALAA,151 should modulate
chemical shift in response to physiologic pH changes. By our strategy,

129

Xe NMR

129

Xe NMR

chemical shift should vary both from pH-dependent peptide conformational changes as
well as pH-dependent peptido-cryptophane-cell membrane association. The synthetic
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EALA-repeat peptide was inspired originally by hemagglutinin (HA), which membrane
inserts in low-pH environments.151 The poly-glutamic acid nature of the EALA-repeat
peptide elevates the pKa to around 6, resulting in a conformational change from random
coil (pH 7.5) to mostly alpha helical (pH 5.5), over this biologically relevant pH range.152
As the glutamates are protonated, the EALA-repeat peptide becomes more helical and
hydrophobic, and it inserts into lipophilic membranes.153 This pH-dependent membrane
insertion has been used in living cells to facilitate endosomal escape of both nanocapsule
and gene payloads.154-156 Thus, by appending cryptophane to a membrane-inserting EALA
peptide, we endeavored to generate a xenon contrast agent capable of being “activated” in
acidic cell environments to label cell membranes and give large 129Xe NMR chemical shift
changes. We based the design on our previously reported tripropargyl cryptophane-A
derivative (with two cyclotriveratrylene units tethered by three ethylene linkers),45 which
should allow facile attachment of a pH-responsive peptide and also two water-solubilizing
moieties (Figure 3.1) to mitigate the potential for cryptophane aggregation.97
§ 3.2 Results and Discussion
Synthetic Procedures
Figure 3.1 shows the synthesis of the water-soluble EALA-cryptophane (WEC)
pH-responsive biosensor 5, the details of which are provided in the Materials and Methods
Section of this chapter. Briefly, the synthesis of tripropargyl cryptophane 1 was performed
in six non-linear steps with modifications to previously published methods,54 with an
overall yield of 6.4%. The yield for the five linear steps was 9.9%. The azido-EALA-repeat
peptide 2 was prepared with standard Fmoc synthetic methods. The peptide was attached
93

to the cryptophane via copper(I)-catalyzed [3+2] azide-alkyne cycloaddition (CuAAC) to
form 3.111, 112 The mono-peptide cryptophane was achieved in preference by controlling
reaction stoichiometry. The resulting triazole-hexyl spacer kept the peptide in close
proximity to the

129

Xe nucleus while minimizing steric clashes with cryptophane during

conjugation. Formation of compound 3 was confirmed by MALDI-MS and the yield
quantified by analytical reverse-phase HPLC to be 60-80%. A solubilizing linker, 3azidopropionic acid 4, was synthesized in one step from the commercially available βpropiolactone (see Material and Methods Section)

70, 74

and reacted with crude 3 via a

second CuAAC. Starting from tripropargyl cryptophane 1, WEC 5 was isolated in ~40%
yield after sequential CuAAC reactions with 2 and 4 and HPLC purification to remove
unreacted EALA peptide and unreacted cryptophane.

Figure 3. 2. pH titrations monitored by ECD spectroscopy for a. azido-EALA peptide and b.
water-soluble EALA-cryptophane (WEC). Samples (30 µM) were in 10 mM sodium phosphate
buffer over the pH range 5.5-7.5 at 298 K. Reprinted with permission from B.A. Riggle; Y. Wang;
I.J. Dmochowski. A “Smart” 129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem.
Soc. 2015, 137, (16) 5542-5548. Copyright 2015 American Chemical Society.
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Electronic Circular Dichroism (ECD) Spectroscopy
For ECD studies, all samples of azido-peptide 2 or WEC were prepared at 30 μM
concentration in 10 mM sodium phosphate buffer, as confirmed by UV-vis spectroscopy
(peptide: ε280 = 5,700 M-1cm-1, WEC: ε280 = 17,700 M-1cm-1) and pH adjusted with 1 M
HCl or 1 M NaOH. We used CD spectroscopy to confirm that azido-peptide 2 maintained
pH sensitivity (Figure 3.2a):151, 157, 158 indeed, percent helicity increased from 25% to 67%
as the pH was decreased from 7.5 to 5.5 (Table 3.1). The CD signal at pH 5.5 had
pronounced local minima at 208 and 222 nm, indicative of an alpha-helical secondary
structure. At pH 7.5, the spectrum approached a minimum at 204 nm while subsequently
decreasing in negative ellipticity at 222 nm, characteristic of a more disordered state. For
WEC (Figure 3.2b and Figure 3.3), we observed a similar increase in EALA helicity from
36% (pH 7.5) to 61% (pH 5.5) see Table 3.2. These data established that the peptide still
undergoes a significant conformational change when conjugated to the cryptophane.
Samples showed reproducible and reversible secondary structure changes between pH 5.5
and 7.5 (Figure 3.4).

Interestingly, WEC was more ordered at pH 7.5 than peptide alone, suggesting that
the cryptophane elevated the conjugated peptide pKa. Similar pKa elevation was previously
95

observed for the analogous tris-propionic acid cryptophane, due to the bulky, hydrophobic
cryptophane disfavoring ionization of the nearby propionates.55

Figure 3. 3. Change in helicity as a function of pH of the azido-peptide (red) and WEC (blue).
Reprinted with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart” 129Xe NMR
Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 5542-5548.
Copyright 2015 American Chemical Society.
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Figure 3. 4. pH reversibility experiment shows the peptide can transition from disordered (pH 7.5,
black) to alpha-helical (pH 5.5, blue), back to disordered structure (pH 7.5, red). Reprinted with
permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart” 129Xe NMR Biosensor for pHDependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 5542-5548. Copyright 2015
American Chemical Society.

Tryptophan Fluorescence
The EALA-repeat peptide contains a single N-terminal tryptophan that we
hypothesized should provide a useful local probe of peptide conformation, as well as
peptide-cryptophane interaction. Fluorescence studies (λex = 280 nm) with peptide 2
demonstrated blue-shifted and somewhat quenched Trp emission with decreasing pH: 352
nm (pH 7.5) to 343 nm (pH 5.5), Figure 3.5a. Trp maximum emission wavelength for the
WEC decreased from 336 nm to 322 nm over the same pH range (Figure 3.5b), which was
considerably blue-shifted relative to peptide 2 alone, consistent with the Trp experiencing
a less solvated environment near cryptophane. We note that the fluorescence signal for the
amino acid tryptophan is typically not perturbed by pH changes in the range of 4-8,159
97

whereas Trp incorporated within peptides can exhibit emission that is very sensitive to the
peptide folded state. Cryptophane fluoresces (λmax = 313 nm) with comparable intensity to
Trp, which further blue-shifts the observed emission spectrum.55,

67

At all pH values,

cryptophane quenched Trp emission, as compared to the free peptide (Figure 3.5c). Plots
of F/F0 vs. pH (Figure 3.5c, where F is the fluorescence emission at a given pH and F0 is
the maximal fluorescence emission at pH 7.5) confirmed that cryptophane quenching
increased from pH 7.5 down to pH 5.5, where cryptophane-Trp interactions were
presumably more prevalent with the relatively uncharged, alpha-helical peptide. This
analysis is in agreement to an earlier work with a peptide-cryptophane conjugate where we
examined the interaction between Trp-containing peptide and cryptophane with a
temperature-dependent quenching assay and Stern-Volmer analysis.67 These experiments
revealed that Trp(peptide)-cryptophane complex formation resulted in loss of Trp
fluorescence. Previous studies identified high-affinity interactions between C60 (an
aromatic molecule with similar dimensions and spherical shape to cryptophane) and Trpcontaining proteins, which also resulted in Trp fluorescence quenching and blue-shifted
emission.160-162 These results support a mechanism by which the EALA peptide can
mediate Trp-cryptophane complex formation in WEC (Figure 3.5d) and result in pHdependent Trp fluorescence quenching. Importantly, Trp-cryptophane pi-stacking
interactions have the potential to deshield 129Xe within the cryptophane cavity, and produce
a downfield chemical shift.163-165
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Figure 3. 5. pH titration monitored by Trp fluorescence for a. azido-EALA peptide; b. watersoluble EALA-cryptophane (WEC); c. plot of F/F0 for the λmax of peptide only (352 nm) and WEC
(336 nm) as a function of pH; and, d. representation of alpha-helical and disordered peptide(Trp)cryptophane interaction. Samples (30 µM) were in 10 mM sodium phosphate buffer over the pH
range 5.5-7.5 at 298 K. Reprinted with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A
“Smart” 129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137,
(16) 5542-5548. Copyright 2015 American Chemical Society.

129Xe

NMR Spectroscopy
We initially performed hp

129

Xe NMR studies to examine the sensitivity of the

cryptophane-encapsulated 129Xe chemical shift to the nearby peptide conformational state.
NMR samples were identically prepared at 30 μM concentrations in 10 mM sodium
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phosphate buffer. Repeated trials at 300 ± 1 K ([Xe] = 6.2 mM)26 with the WEC at pH 7.5,
6.5, and 5.5 gave reproducible chemical shifts (Figure 3.6). A single peak was observed at
both pH 5.5 (67.6 ± 0.5 ppm) and pH 7.5 (64.2 ± 0.5 ppm), with a chemical shift difference
of 3.4 ppm. Interestingly, although the cryptophane itself is a racemic mixture of
stereoisomers and the EALA-repeat peptide is chiral, we did not observe a pair of
diastereomeric peaks at pH 7.5 or pH 5.5 as we reported for previous peptide-cryptophane
xenon biosensors67, 69 and has been seen for various racemic xenon biosensors complexed
to protein active sites.113 We hypothesize that the two diastereomers provide a very similar
environment for the bound xenon atom, and produce what appears to be a single

129

Xe

NMR peak at both pH values. In this case, the inclusion of solubilizing propionates
promotes open, xenon-binding conformations of the cryptophane, regardless of peptide
conformation. Conversely, the equal-intensity peaks observed at pH 6.5 (δ = 67.0 and 64.4
ppm) may result from hp

129

Xe experiencing very different environments within the two

WEC diastereomers.

Figure 3. 6. HP 129Xe NMR spectra (average of 16 scans, line-broadening = 60 Hz) of WEC (30
µM) in 10 mM sodium phosphate buffer at 300 ± 1 K, with peak widths (FWHM) indicated in Hz:
a. pH 5.5, 211 Hz; b. pH 6.5, 317 and 214 Hz; c. pH 7.5, 154 Hz. Reprinted with permission from
B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart” 129Xe NMR Biosensor for pH-Dependent Cell
Labeling. J. Am. Chem. Soc. 2015, 137, (16) 5542-5548. Copyright 2015 American Chemical
Society.
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Hyper-CEST 129Xe NMR
To improve detection sensitivity of WEC over direct detection by nearly six orders
of magnitude, we employed Hyper-CEST NMR spectroscopy. This indirect detection
method took advantage of the exchanging 129Xe population between bulk aqueous solution
and the xenon host molecule (Figure 3.7) by selectively saturating the bound signal (Figure
3.7b). Because of xenon exchange, the selective depolarization resulted in a concomitant
signal loss from the

129

Xe@water peak, which was readily monitored (Figure 3.7a). This

signal was compared with a reference measurement where an “off resonance” saturation
was applied to account for the natural self-relaxation of hp 129Xe@water over time.

Figure 3. 7. Hyper-CEST detection scheme for WEC-encapsulated 129Xe. a. Representative
spectra are shown for i. the initial spectrum and ii. the resulting spectrum from selective “on
resonance” saturation of the WEC-encapsulated 129Xe and commensurate bulk 129Xe@ H2O
depolarization; b. selective radio frequency depolarization of WEC-encapsulated 129Xe. Reprinted
with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart” 129Xe NMR Biosensor for
pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 5542-5548. Copyright 2015
American Chemical Society.
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Figure 3. 8. Hyper-CEST signal decay of 34 pM WEC at pH 7.5, 310 K. Depolarization rates
were measured with radiofrequency pulses either on-resonance (64.2 ppm) or off-resonance
(320.6 ppm) with hp 129Xe@WEC. Reprinted with permission from B.A. Riggle; Y. Wang; I.J.
Dmochowski. A “Smart” 129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem.
Soc. 2015, 137, (16) 5542-5548. Copyright 2015 American Chemical Society.

Using 34 pM WEC (pH 7.5, 310 K, [Xe] = 0.15 mM) indirect detection via HyperCEST was performed by applying shaped radiofrequency saturation pulses at the
129

Xe@WEC resonant frequency and measuring the residual aqueous

129

Xe signal for

different saturation duration (Figure 3.8). WEC was observed to “catalyze” this
depolarization process through on-resonance (64.2 ppm) saturation rf pulses with
129

Xe@WEC in pH 7.5 buffer. In contrast, saturation pulses applied off-resonance (320.6

ppm) gave a depolarization time that approximated the natural T1 of hp 129Xe in water.
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Figure 3. 9. Hyper-CEST scan of WEC (1 µM) at 300 K. Full image was collected with 5-ppm
step and individual peaks with 1-ppm step at pH 7.5 and pH 5.9 (inset). Reprinted with permission
from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart” 129Xe NMR Biosensor for pH-Dependent
Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 5542-5548. Copyright 2015 American Chemical
Society.

We also investigated the pH sensitivity of WEC-hp

129

Xe NMR chemical shift to

look at “normal” (pH 7.5) and acidic (pH 5.9) buffer solutions, Figure 3.9. Because
depolarization efficiency is decreased with a narrower saturation pulse, WEC was
employed at 1 µM concentrations, which is still at least 103-fold more dilute than
demonstrated for 1H CEST pH reporters.166 Prior to detecting a free xenon signal, a loop
of selective Dsnob-shaped saturation pulses was scanned over the chemical shift range of
40-230 ppm in 5-ppm (700 Hz) steps, which corresponded to pulse length of 3748.6 µs and
power of 77 µT. Two saturation responses centered at 195 ppm (129Xe@H2O) and 65 ppm
(129Xe@WEC) were observed (Figure 3.9 full image). By decreasing the frequency
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scanning step size to 1 ppm (138.2 Hz), which corresponded to shaped pulse length of
19014 µs and power of 15 µT, we were able to distinguish the WEC-encapsulated

129

Xe

peak for pH 7.5 and pH 5.9 samples at 300 K (Figure 3.9, inset). The total time to record
the Hyper-CEST NMR spectra was composed of xenon delivery time (20 s) and data
collection time. For the latter, each data point required time T:
𝑇 = (𝑠𝑝6 + 𝑑12) ∗ 𝐿6 + 𝑑1 + 𝑝1
In the 5-ppm step scanning experiments, sp6 (saturation pulse length) = 3.748 ms, d12
(delay between saturation pulses) = 20 µs, L6 (number of saturation cycles) = 400, d1
(delay before acquisition pulse) = 0.5 s, p1 (acquisition pulse) = 22 µs. Thus, the total time
needed to acquire the whole spectrum was 860 s. In the 1-ppm step scanning experiments,
sp6 = 19.014 ms, L6 = 600, and the total time needed was 478 s. The observed pair of peaks
at pH 5.9 was similar to hp 129Xe NMR data collected for 30 µM WEC by direct detection
at pH 6.5 (Figure 3.6). As illustrated by these data, the Hyper-CEST 129Xe NMR spectrum
readily distinguished between physiologically normal and acidic pH values.
Cellular Hyper-CEST 129Xe NMR
Finally, we investigated the utility of WEC in a biological setting through

129

Xe

NMR cell studies. Human cervical carcinoma (HeLa) cells were grown in a flask to
confluency. Cells were washed and suspended in either pH 7.5 or 5.5 sodium phosphate
buffer containing 5-10 µM WEC to give 1 x 107 cells/mL concentrations. Pluronic L-81
(0.1% final conc.) was added to reduce foaming that can result from Xe bubbling.75 Cells
were incubated in these conditions for 45-60 min and then transferred to an NMR tube.
Spectra were acquired at both pH values with frequency scanning step size of 1 ppm (138.2
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Hz), 400 cycles, which corresponded to shaped pulse length of 19014 µs and power of 15
µT. Figure 3.10a shows xenon in cells (196.3 ppm, red trace) and xenon dissolved in
aqueous solution of HeLa cells suspended in pH 7.5 buffer with WEC (192.3 ppm, blue
trace). Figure 3.10b shows WEC-encapsulated xenon in the same sample. 129Xe@WECaq,
pH 7.5 gave a chemical shift of 65.0 ppm, which corresponds to free biosensor in buffer at
pH 7.5.
In pH 5.5 experiments, Figure 3.10c shows two peaks, one for Xe@cells (198.0
ppm, red trace) and one for Xe@aq (192.0 ppm, blue trace). Figure 3.10d shows the
biosensor region of the same sample and exhibits two peaks, one at 68.0 ppm
corresponding to free alpha-helical WEC in buffer (blue trace) and one at 78.4 ppm that
we assign to WEC inserted in cell membrane (red trace). Notably, upon biosensormembrane insertion at pH 5.5, we observed a 13.4 ppm downfield chemical shift compared
to biosensor-cell solutions at pH 7.5. Contrary to previous

129

Xe NMR cell studies

performed with a more lipophilic cryptophane, we did not observe cryptophane-membrane
association at pH 7.5.90 This result is also consistent with previous studies with the EALA
peptide that showed no membrane association at pH 7.5.167 By targeting acidic pHe as a
general cancer biomarker, along with membrane association, we increased the chemical
shift difference between Xe@biosensorcells and Xe@biosensoraq as compared to earlier
studies.75, 97, 147 We note that in living organisms there will be additional factors (beyond
pHe) that impact the 129Xe@biosensorcells chemical shift, including cell type and membrane
composition. Follow-up studies will be required to assess this variability.
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Figure 3. 10. Hyper-CEST 129Xe NMR spectra for 5-10 µM WEC in 10 mM sodium phosphate
buffer with 0.1% Pluronic L-81 in a suspension of 1 x 107 cells/mL. Data were collected at pH 7.5,
a. Xe@cells-red trace (196.3 ppm), Xe@aq-blue trace (192.3 ppm); b. Xe@WECaq (65.0 ppm);
and at pH 5.5, c. Xe@cells-red trace (198.0 ppm), Xe@aq-blue trace (192.0 ppm); d.
Xe@WECcells-red trace (78.4 ppm) and Xe@WECaq-blue trace (68.0 ppm). Exponential
Lorentzian fits are shown as colored, solid lines and the corresponding sums are shown as solid
black lines. Reprinted with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart”
129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 55425548. Copyright 2015 American Chemical Society.

§ 3.3 Conclusions
In summary, by attaching a pH-responsive, membrane-inserting peptide and two
water-solubilizing moieties to a tripropargyl cryptophane host, we were able to generate an
ultrasensitive 129Xe NMR biosensor capable of labeling cells in acidic microenvironments.
This xenon biosensor is unique for undergoing a rapid and reversible conformational
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change (over a range of physiologic pH values) as well as functional changes: at pH 5.5,
the pendant EALA-repeat peptide was mostly alpha-helical and gained membraneinsertion capabilities. This represents a “smart”

129

Xe MR contrast agent, and builds on

previous examples of xenon biosensors that bind specific targets (e.g., protein receptors,
DNA, cell-surface glycans) or undergo a modification event (i.e., enzyme-mediated
peptide cleavage).
Significantly, this study demonstrated that appending the peptide to the ~1 nm
diameter, hydrophobic cryptophane did not significantly reduce its ability to undergo a
conformational change. Circular dichroism, Trp fluorescence, and hp

129

Xe NMR

spectroscopies were employed to measure the change in helical character of the peptide in
the pH range 5.5-7.5. EALA peptide helix formation resulted in a

129

Xe NMR downfield

chemical shift change of 3.4 ppm, which was likely enhanced by significant cryptophane
interactions with the nearby, N-terminal Trp residue. This suggests a general strategy for
engineering larger chemical shift changes with xenon biosensors, particularly to monitor
molecular events occurring nanometers away from the xenon-cryptophane reporter. These
data represent a significant advance over the previous example of a peptido-cryptophane
biosensor, which monitored MMP-7 activity: only a 0.5 ppm chemical shift change was
observed upon enzyme-mediated peptide cleavage, perhaps because the Trp was positioned
much farther from the cryptophane.67 For some in vivo applications, it may be useful to
maintain the full range of pH-dependent conformational changes of the EALA-repeat
peptide, and it will be interesting to explore different peptides and conjugation strategies
that work to achieve this goal.
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The design of a cryptophane-EALA peptide conjugate capable of membrane
insertion at acidic pH advances our long-range goal of developing ultrasensitive 129Xe MR
contrast agents to aid in cancer diagnosis and treatment.153,

158

Picomolar (10-11 M)

concentrations of WEC were detected by Hyper-CEST NMR, making this approach 8-9
orders of magnitude more sensitive than commonly employed MR contrast agents. We
demonstrated a 13.4 ppm downfield chemical shift change from disordered-peptide
biosensor at pH 7.5 to the helical, membrane-inserted biosensor at pH 5.5. This represents
the largest chemical shift change that has been engineered to date for a
129

Xe@cryptophane-biomolecule interaction, the magnitude of which should facilitate

multiplexed detection in many experimental formats. The development and cellular
implementation of this “smart” xenon biosensor are important steps towards future
biomedical applications.
§ 3.4 Materials and Methods
General Information
Instrumentation and Methods. 1H NMR (500 MHz) data were obtained in deuterated
chloroform (CDCl3) or dimethyl sulfoxide (DMSO-d6) using a Bruker DMX 500 NMR
spectrometer. Column chromatography was performed using silica gel (60 Å pore size, 4075 µm particle size) from Sorbent Technologies. Thin layer chromatography (TLC) was
performed using silica gel plates (60 Å pore size, Silicycle) with UV light at 254 nm as the
detection method. MALDI-MS data were collected using a Bruker Ultraflex III TOF/TOF
mass spectrometer. All HPLC purifications were performed on a Varian Prostar 210 system
equipped with a quaternary pump and diode array detector. All air- and moisture-sensitive
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reactions were performed under inert atmosphere in glassware flamed under vacuum, using
anhydrous dry solvents. Standard workup procedures involved multiple (~3) extractions
with the indicated organic solvent, followed by washing of the combined organic extracts
with water or brine, drying over Na2SO4 and removal of solvents in vacuo. All yields
reported were determined after purification by column chromatography or reverse phase
HPLC, unless otherwise noted. All data were collected using instruments in the Chemistry
Department at the University of Pennsylvania.
Materials. Organic reagents and solvents were used as purchased from the following
commercial sources: Sigma-Aldrich: N,N-diisopropylethylamine (DIPEA); dimethyl
sulfoxide (DMSO, anhydrous, 99.9%); Sigmacote®. Fisher: acetone (HPLC grade);
chloroform (CH2Cl3, HPLC grade); dichloromethane (CH2Cl2, HPLC grade); ethyl acetate
(EtOAc, HPLC grade); hexanes (HPLC grade); hydrochloric acid; methyl alcohol (MeOH,
HPLC grade), perchloric acid (60%); Pluronic L-81; potassium carbonate (anhydrous); sea
sand (washed); sodium chloride (NaCl); sodium hydroxide (NaOH); sodium sulfate
(anhydrous). Novabiochem (currently EMD Millipore; Billerica, MA, USA): 6azidohexanoic acid; 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU). MarCor: deionized (DI) water filtered (18 MΩ). Acros Organics: βpropiolactone (90%); cesium carbonate (Cs2CO3, 99.5%); chloroform-d (CDCl3); 1,2dibromoethane; 3,4-dihydroxybenzaldehyde (97%); N,N-dimethylformamide (DMF,
99.8%, anhydrous, acrosseal); dimethylsulfoxide-d6, 4-hydroxy-3-methoxybenzyl alcohol
(99%); propargyl bromide (80% solution in toluene); scandium(III) trifluoromethanesulfonate (Sc(OTf)3, 95%); sodium borohydride (NaHB4, 98%); sodium hydride
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(NaH, 60% dispersion in mineral oil); tetrahydrofuran (THF, extra dry, over sieves);
triisopropylsilane (TIS). MG Industries (Linde Group, NJ): xenon gas (scientific grade).
Synthetic Procedures

Figure 3. 11. 6-step, non-linear synthesis of tripropargyl cryptophane (1). Yield = 9.9% for the five
linear steps. Reprinted with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart”
129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 55425548. Copyright 2015 American Chemical Society.

Cryptophane Synthesis. Tripropargyl cryptophane was achieved in a 6-step synthesis with
a

6.4%

overall

yield

from

two

commercially

available

compounds,

3,4-

dihydroxybenzaldehyde and vanillyl alcohol shown in Figure 3.11.
4-((2-bromoethoxy)-3-methoxyphenol) methanol (i): In a dry two-necked flask with a
nitrogen inlet, vanillyl alcohol (10.0 g, 64.9 mmol, 1 eq) was combined with potassium
carbonate (44.8 g, 324 mmol, 5 eq) in acetone (100 mL) and stirred at rt for 30 min. 1,2dibromoethane (56.3 mL, 650 mmol, 10 eq) was then added to the reaction via syringe.
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The reaction flask was then transferred to a pre-heated oil bath at 57 °C and refluxed
overnight. The organic components were isolated with EtOAc on aqueous workup and the
final product was purified by column chromatography (1:1 to 7:3 hexanes:EtOAc, gradient
method; TLC 1:1 hexanes:EtOAc Rf(i) = 0.43) to yield 10.2 g (39.1 mmol, 60% yield). The
spectroscopic data match those reported in the literature.54 1H NMR CDCl3: 6.96 (s, 1H,
aryl); 6.91 (d, 1H, aryl); 6.89 (d, 1H, aryl), 4.64 (s, 2H, CH2OH); 4.34 (t, 2H, OCH2CH2Br)
3.89 (s, 3H, OCH3); 3.66 (t, 2H, OCH2CH2Br).
2,7,12-Tris-(2-bromoethoxy)-3,8,13-trimethoxy-10,15-dihydro-2Htribenzo[a,d,g]cyclononene (ii, also known as cyclotriveratrylene) In a dry two-necked
flask 8 g of 4-((2-bromoethoxy)-3-methoxyphenol methanol was combined with 0.50 g of
scandium (III) trifluoromethanesulfonate and the reaction flask was put in vacuo for 1 h to
remove moisture. An oil bath was preheated to 40 ºC. Dry dichloromethane (200 mL) was
added to the reaction flask and the reaction was put to reflux overnight. Reaction progress
was monitored by TLC (98% DCM/2% Et2O, Rf(ii) = 0.67). The reaction was quenched
on completion with 1 M NaOH and extracted with DCM. The final product was purified
by flash column chromatography (isocratic method 1% Et2O in DCM) to a yield of 70%
(5.19 g, 7.12 mmol). The spectroscopic data match those previously described.54 1H NMR
CDCl3: 6.94 (s, 3H, cap aryl); 6. 86 (s, 3H, cap aryl); 4.72 (d, 3H, Hax); 4.31 (t, 6H, OCH2
CH2Br); 3.86 (s, 9, OCH3) 3.59 (t, 6H, OCH2CH2Br); 3.55 (d, 3H, Heq)
3-propargyloxy-4-hydroxybenzaldehyde (iii) To a flame or oven-dried round bottom flask
cooled under nitrogen, 7.24 g of 60% sodium hydride (2.5 eq, 302 mmol) was added under
argon. Dry DMF (50 mL)was added via syringe and the reaction was put to stirring at rt.
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In a separate dry flask, 10 g (1 eq, 72.4 mmol) of 3, 4-dihydroxybenzaldehyde was
dissolved in 40 mL dry DMF under argon and stirred until a homogenous solution was
achieved. The reaction flask containing NaH was put on ice and chilled to 0 ºC. The
solution of 3, 4-dihydroxybenzaldehyde was added to the NaH dropwise over a period of
~10 min. The flask was subsequently rinsed with an additional 10 mL of dry DMF and
added dropwise to the reaction flask while still on ice. The reaction was then allowed to
stir for 45 min or until gas ceased to evolve while slowly warming to rt. Subsequently, 6.44
mL of propargyl bromide, 80% in toluene (0.8 eq, ρ = 1.34 g/mL, 57.9 mmol) was added
dropwise to the reaction flask. The reaction was stirred for 4 h at rt and then placed on ice
to quench with the addition of 1 M HCl. The reaction was extracted with EtOAc and
purified by flash column chromatography with an isocratic method of 15% ethyl acetate in
hexanes. Note, the desired meta-substituted product (Rf(iii) = 0.48) is not well resolved
from the para substituted side product (Rf = 0.46). The final product was prepared in 65%
yield (8.29 g, 47.1 mmol) with the spectroscopic data following our published protocols.67
Product (meta): 1H NMR δ(ppm) CDCl3 (7.27): 9.84 (s, 1H, aldehyde); 7.53 (d, 1H, aryl);
7.49 (dd, 1H, aryl), 7.09 (d, 1H, aryl); 6.28 (bs,1H, -OH); 4.84 (d, 3H, OCH2CCH); 2.60
(t, 1H, OCH2CCH). Side product (para): 1H NMR CDCl3 (7.27): 9.86 (s, 1H, aldehyde);
7.47 (d, 1H, aryl); 7.45 (dd, 1H, aryl), 7.12 (d, 1H, aryl); 5.84 (bs,1H, -OH); 4.86 (d, 3H,
OCH2CCH); 2.62 (t, 1H, OCH2CCH).
2,7,12-Tris-[2-[4-formyl-2-propargyloxyphenoxy]ethoxy]-3,8,13-trimethoxy-10,15dihydro-2H-tribenzo[a,d,g]cyclononene (iv): An oil bath was preheated to 55 ºC. In a twonecked round bottom flask 2.72 g of propargyl linker (iii), (3.3 eq, 15.48 mmol) and 5.05
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g cesium carbonate (3.3 eq, 15.48 mmol) were combined and dried in vacuo for 1 h. Dry
DMF (50 mL) was added to the reaction flask and stirred at rt for 30 min. Dry CTV (ii), (1
eq, 4.69 mmol) was added to the reaction and the reaction flask was submerged in the
heated oil bath and stirred overnight. The reaction was diluted with brine and extracted
with DCM. Purified product was achieved from flash column chromatography, isocratic
method 3% acetone in 97% DCM, Rf (iv) = 0.63. Final product was obtained in 68% yield
(1.08 g, 1.06 mmol) and confirmed to agree with our previously published data.54 1H NMR
δ(ppm) CDCl3 (7.27): 9.87 (s, 3H, Ph-CHO), 7.56 (s, 3H, aryl), 7.50 (d, J = 8.2 Hz, 3H,
aryl), 7.05 (d, J = 8.2 Hz, 3H, aryl), 7.01 (s, 3H, aryl), 6.86 (s, 3H, aryl), 4.77 (d, 3H, Hax),
4.74 (q, 6H, -O-CH2-CCH), 4.40-4.44 (m, 12H, Ph-CH2-OH, -O-CH2-CCH), 3.75 (s, 9H,
-O-CH3), 3.57 (d, J = 13.8 Hz, 3H, Heq), 2.52 (t, J = 2.3 Hz, 3H, -O-CH2CCH).
2,7,12-Tris-[2-[4-(hydroxymethyl)-2-propargyloxyphenoxy]ethoxy]-3,8,13-trimethoxy10,15-dihydro-2H-tribenzo[a,d,g]cyclononene (v) Compound iv was dissolved in a 1:1
mixture of chloroform and THF. Next, MeOH was added slowly to ensure iv remained in
solution. The reaction as then chilled to -10 ºC with a salted ice bath. NaBH4 was then
added and the reaction stirred at 0 C for 20 min. The reaction was allowed to warm to rt
and stir for 4 h. Reaction progress was monitored by TLC (5% MeOH in CH2Cl2), Rf(v) =
0.25. Additional equivalents of NaHB4 were added as necessary, until quantitative
conversion was observed. No further purification was necessary after aqueous work-up. In
this manner, >90% yield (0.971 g, 0.951 mmol) was achieved. Spectroscopic data agreed
with our previously published work.54 1H NMR δ(ppm) CDCl3 (7.27): 7.03 (s, 3H, aryl),
6.98 (s, 3H, aryl), 6.89 (m, 6H, aryl), 6.82 (m, 3H, aryl), 4.74 (d, J = 13.6, 3H, Hax), 4.60
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(m, 12H, Ph-CH2-OH, -O-CH2-CCH), 4.34 (m, 12H, -O-CH2-CH2-O-), 3.71 (s, 9H, -OCH3), 3.52 (d, J = 13.8 Hz, 3H, Heq), 2.45 (t, J = 2.2 Hz, 3H, -O-CH2CCH).
Tripropargyl Cryptophane (1): Methanol (200 mL) was added to a 1 L reaction flask
containing compound v (50.0 mg, 0.0490 mmol, 1 eq). The reaction was put to stirring in
a salted ice bath (-10 °C) and fitted with an addition funnel. Perchloric acid (60%) (150
mL) was added drop-wise over several hours. Once addition was complete, the reaction
was allowed to slowly warm to rt and stir overnight. Afterwards, the reaction was again
placed on a salted ice bath and more perchloric acid (50 mL) was added. The reaction was
monitored by TLC (5% acetone in CH2Cl2) and subsequent 25 mL perchloric acid additions
were performed as necessary to drive the reaction to completion. The reaction was
quenched with the addition of dH2O and brine (200 mL each) and then extracted 3x with
CH2Cl2 (100 mL). The combined organics were then washed with dH2O, sat. sodium
bicarbonate, and brine (100 mL), dried over sodium sulfate and concentrated in vacuo. The
crude material was purified by silica gel flash column chromatography (5% acetone in
CH2Cl2, v/v) to yield 20.0 mg (0.0207 mmol, 40% yield) of 1 as a white powder. TLC
(silica gel, 5% acetone in CH2Cl2, v/v); Rf(1)= 0.47. The spectroscopic data match those
reported in the literature.54, 55 1H NMR δ(ppm) CDCl3 (7.27) : 6.91 (s, 3H, aryl), 6.80 (s,
3H, aryl), 6.78 (s, 3H, aryl), 6.71 (s, 3H, aryl), 4.71 (d, 3H, Hax), 4.70 (d, 3H, Hax), 4.62
(q, 9H, -O-CH2-CCH), 4.17 (m, 12H, -O-CH2-CH2-O), 3.83 (s, 9H, -O-CH3), 3.43 (d, J =
13.8 Hz, 3H, Heq), 3.42 (d, J = 13.9 Hz, 3H, Heq), 2.71 (t, J = 2.3 Hz, 3H, -O-CH2-CCH).
Peptide

Synthesis

and

Purification.

WEAALAEALAEALAEHLAEALAEALEALAA,

The

EALA-repeat

peptide,

sequence:

was synthesized (100 micromole scale) by
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solid-phase peptide synthesis, using Fmoc chemistry, on a Liberty 1 Automated Microwave
Peptide Synthesizer located in the UPenn Biological Chemistry Resource Center.
Piperidine (20%) in DMF was used as the deprotection agent, 0.5 M HBTU in DMF was
used as the activator, and 2 M DIPEA in N-methyl-2-pyrrolidone (NMP) was used as the
activator base. Five molar equivalents of the amino acid were used for each coupling on
Rink Amide MBHA resin (0.59 mmol/g substitution, Novabiochem). Residue Ala30 used
method 1 and His16 used method 3 and all other residues used method 2. Method 1: Initial
30 s microwave deprotection (35 W, 75 °C), followed by 3-min microwave deprotection
(35 W, 75 °C). Two consecutive coupling cycles were used. Both couplings were for 5 min
under microwave power (25 W, 75 °C). The instrument was then paused and taken off-line
while the unreacted resin was acetylated with a mixture of 2 mL acetic anhydride, 1.2 mL
of N-methylmorpholine (NMM), and 16.8 mL of DMF. Method 2: Initial 30-s microwave
deprotection (35 W, 75 °C), followed by a 3-min microwave deprotection (35 W, 75 °C).
Two consecutive coupling cycles were used. Both couplings were for 5 min under
microwave power (25 W, 75 °C). Method 3: Initial 30-s microwave deprotection (35 W,
75 °C), followed by a 3-min microwave deprotection (35 W, 75 °C). Two consecutive
coupling cycles were used. Both couplings were for 2 min at rt followed by 3 min under
microwave power (25 W, 50 °C). The peptide then underwent a final deprotection (initial
30 s microwave deprotection (35 W, 75 °C), followed by a 3 min microwave deprotection
(35 W, 75 °C) leaving the peptide on resin with a free N-terminus.
Azido-EALA peptide (2): The EALA peptide on resin in a sigmacoted vessel (0.1 mmol, 1
eq) was incubated in an excess (~10 mL) of DMF with magnetic stirring for 30 min to
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allow for resin swelling. DMF was subsequently removed by vacuum suction. The 6azidohexanoic acid (78.6 µL, 0.5 mmol, 5 eq) was combined with DMF (6 mL), HBTU
(190 mgs, 0.5 mmol, 5 eq) and DIPEA (175 µL, 1.0 mmol, 10 eq) and added to the resin
under magnetic stirring for 1 h. The reagent mixture was drained with vacuum suction and
the resin was iteratively washed with MeOH, DCM, and DMF and then drained with
vacuum. The resin was subjected to a second round of coupling with the same reagent
mixture. After rinsing extensively, the resin was dried over DCM for 30 min on vacuum.
The azido peptide was then dosed with a cleavage cocktail of 95% trifluoroacetic acid
(TFA), 2.5% triisopropylsilane (TIS), and 2.5% dH2O and stirred for 2.25 h. The vessel
was drained and the resulting solution was collected and reduced to approximately 1 mL
on a rotary evaporator. The peptide was then precipitated from solution with cold diethyl
ether and the resulting solid was isolated by centrifugation. The peptide was resuspended
in HPLC solvents (1:1 acetonitrile : dH2O with 0.1% TFA). The azido-EALA peptide was
purified using reverse-phase HPLC and monitored at 215 and 280 nm using a Zorbax RxC8
semi-preparative column (9.4×250 mm, 5µm beads). The elution gradient was composed
of two solvents: 0.1% aqueous TFA (solvent A) and a 0.1% solution of TFA in CH3CN
(solvent B). The purification method went from 65% A to 40% A over 5 min, then from
40% A to 25% A over 5 min, and then from 25% A to 0% A over 35 min at a flow rate of
4 mL/min and with a 1 mL injection volume. The peptide eluted at 21.04 min, Figure 3.12.
MALDI MS m/z calculated for N3-EALA C142H225N37O45 (M+H+) 3169.65; found
3169.51, Figure 3.13.
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Figure 3. 12. HPLC chromatogram of N3-EALA (2). UV absorbance monitored at 280 nm. Peak
assignment based on MALDI-MS. Reprinted with permission from B.A. Riggle; Y. Wang; I.J.
Dmochowski. A “Smart” 129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem.
Soc. 2015, 137, (16) 5542-5548. Copyright 2015 American Chemical Society.

Figure 3. 13. MALDI-MS spectrum of N3-EALA peptide (2). Expected mass [M+H+] 3169.65;
found 3169.51. Reprinted with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart”
129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 55425548. Copyright 2015 American Chemical Society.
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Solubilizing Linker Synthesis. 3-Azidopropionic acid was prepared from β-propiolactone
by literature procedure and matched the reported 1H NMR spectrum.168
3-azidopropionic acid (4). Briefly, sodium azide (4.5 g, 0.69 mmol, 1 eq) was dissolved in
ddH2O water. β-propiolactone (4.4 mL, 0.069 mmol, 1 eq) was added dropwise and the
reaction was allowed to stir at rt for 6 h. The reaction was neutralized with 1 M HCl and
then extracted 3 times with diethyl ether. The organic layer was then dried over sodium
sulfate and filtered through cotton. A clear oil in a 15% yield was recovered, requiring no
further purification.
WEC Biosensor Synthesis. The copper(I)-catalyzed [3+2] azide-alkyne cycloaddition
(CuAAC) between N3-EALA peptide and cryptophane and the subsequent cycloaddition
reaction between the cryptophane and 3-azidopropionic acid yielded the WEC biosensor.
EALA-cryptophane (3). To conjugate the azido-EALA peptide to the tripropargyl
cryptophane (1) CuAAC was utilized with modified conditions of those previously
employed.67, 68, 70, 73 Firstly, 4 mg (1.0 eq) of 1 and 13 mg of 2 (1 eq) were dissolved in 1
mL of dry methyl sulfoxide (DMSO) in a conical reaction vessel along with 1 cm of 18 g
copper wire. The reaction mixture was put to stirring and degassed. In a separate vial, 10
mg (5 eq) of tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methylamine (TBTA) copper ligand was
dissolved in 60 μL of DMSO. Separate solutions of 0.6 M copper (II) sulfate (CuSO4) and
4 M sodium ascorbate (NaAsc) in water were also prepared. To the TBTA solution, 6 μL
of CuSO4 (1 eq), 0.5 μL of 2,6-lutidine (1 eq), and 9 μL (+)-sodium-ʟ-ascorbate (10 eq)
were added sequentially, vortexing between additions. After addition of NaAsc, the
mixture turned clear indicative of Cu(I) formation. The entire reagent mixture was then
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added to the reaction vessel. The reaction vessel was again degassed and then covered with
foil and allowed to stir overnight under nitrogen at rt. A small aliquot of reaction was
removed (10 µL) and diluted in an HPLC solvent mixture, 50:50 mixture of acetonitrile
and water with 0.1% trifluoroacetic acid. To verify product formation, analytical reversephase HPLC was performed using a Zorbax RxC8 analytical column (4.6×150 mm, 5 µm
beads) and monitored at 215 and 280 nm. The elution gradient was composed of two
solvents: 0.1% aqueous TFA (solvent A) and a 0.1% solution of TFA in CH3CN (solvent
B). The purification method went from 65% A to 40% A over 15 min, then from 40% A to
18% A over 25 min, and then from 18% A to 0% A over 3 min at a flow rate of 1 mL/min
with a 1 mL injection volume. The EALA-cryptophane eluted at 36.50 min, Figure 3.14.
MALDI MS m/z calculated for EALA-cryptophane C202H279N37O57 (M+H+) 4136.01;
found 4136.84, Figure 3.15.
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Figure 3. 14. HPLC chromatogram of EALA-cryptophane (3). UV absorbance monitored at 280
nm. Peak assignment based on MALDI-MS. Reprinted with permission from B.A. Riggle; Y.
Wang; I.J. Dmochowski. A “Smart” 129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am.
Chem. Soc. 2015, 137, (16) 5542-5548. Copyright 2015 American Chemical Society.

Figure 3. 15. MALDI-MS spectrum of EALA-cryptophane (3). Expected mass [M+H+] 4136.01;
found 4136.84. Reprinted with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart”
129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 55425548. Copyright 2015 American Chemical Society.
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Water-soluble EALA-cryptophane (WEC) (5). The crude reaction (3) was then dosed with
4.6 μL 3-azidopropionic acid (4) (10 eq), and the same reagent mixture as in the previous
reaction and allowed to stir overnight while covered, to yield the water-soluble EALAcryptophane (WEC) biosensor. The reaction was diluted 10-fold in 50:50 ACN:H2O and
purified. Purification was achieved through reverse-phase HPLC employing the semipreparative version of the previous method by using a Zorbax RxC8 semi-preparative
column (9.4×250 mm, 5 µm beads) with 4 mL/min flow rate. The pH sensor eluted at 33.87
min, Figure 3.16. MALDI MS m/z calculated for WEC C208H289N43O61 (M+H+) 4366.08;
found 4366.36, Figure 3.17. The pure fractions were then collected and diluted with 0.1 %
ammonium hydroxide to 10% acetonitrile. Amicon-ultra-4mL 3K NMWL Centricon tubes
were used to concentrate and buffer exchange the final product 5 into 10 mM sodium
phosphate buffer at pH 7.5.
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Figure 3. 16. HPLC chromatogram of WEC (5). UV absorbance monitored at 280 nm. Peak
assignment based on MALDI-MS. Reprinted with permission from B.A. Riggle; Y. Wang; I.J.
Dmochowski. A “Smart” 129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem.
Soc. 2015, 137, (16) 5542-5548. Copyright 2015 American Chemical Society.

Figure 3. 17. MALDI-MS spectrum of WEC (5). Expected mass [M+H+] 4366.08; found 4366.36.
Reprinted with permission from B.A. Riggle; Y. Wang; I.J. Dmochowski. A “Smart” 129Xe NMR
Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137, (16) 5542-5548.
Copyright 2015 American Chemical Society.
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Characterization Methods
Electronic Circular Dichroism (ECD) Spectroscopy. All spectroscopy experiments were
performed on the Aviv 410 CD spectrometer. Data were collected at 25 °C from 260-190
nm, with a 30 s averaging time, 1 nm wavelength step, 1 s averaging time, and 1 nm
bandwidth. The samples were prepared by concentrating the purified WEC to 30 µM in 10
mM sodium phosphate at pH 7.5 and aliquoting the stock into five Eppendorf tubes and
adjusting the pH to 5.5, 6.0, 6.5, 7.0, and 7.5 with a few microliters of 1 M HCl. The
concentration was confirmed by measuring the absorbance at 280 nm, 𝜀280 =
17,700 𝑀−1 𝑐𝑚−1 and using an Agilent 89090A UV-visible spectrophotometer.
Data Analysis. The molar ellipticity was calculated from the observed ellipticity (mdeg)
and has the units of deg cm2 dmol-1. The molar ellipticity is given by equation 3.1 where C
is the concentration of the peptide or biosensor, ℓ is the path length of the cuvette-0.1 cm,
and 𝑛𝑟 is the number of residues-31.169

[𝜃] =

𝜃𝜆
(𝐶 ∗ ℓ ∗ 𝑛𝑟 ∗ 10)

(3.1)

The helical content of the peptide and biosensor was determined from circular dichroism
studies at 30 μM concentrations and in accordance with literature precedent. 170 Helicity
was calculated using the formulas 3.2 and 3.3 where 𝑛𝑟 is the number of amide bonds in
the peptide, in this case 31. Racemic cryptophane was employed for these experiments,
and thus did not contribute to the measured CD signal. Data are shown in Tables 3.1 and
3.2 and graphically in Figure 3.3.
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[𝜃]222
%ℎ𝑒𝑙𝑖𝑐𝑖𝑡𝑦 = 100 ∗ 𝑚𝑎𝑥
[𝜃] 222
𝑚𝑎𝑥

[𝜃]222 = −40000 ∗ [1 −

(3.2)

2.5
]
𝑛𝑟

(3.3)

pH Reversibility. Repeated trials with the azido-peptide alone and with WEC showed that
the peptide conformational change was reversible. Whether the sample was first prepared
at pH 5.5 or at pH 7.5 and titrated to higher or lower pH in this range, the ECD signal
confirmed the conformation aligned with what is shown in Figure 3.2. One example of this
reversibility is shown in Figure 3.4. In this experiment the peptide sample at pH 7.5 shown
in Figure 1a was titrated to pH 5.5 and the CD signal was measured. The same sample was
then titrated back to pH 7.5 (labeled pH 7.5R) and the CD signal was measured and found
to align with the original spectrum at pH 7.5.
Tryptophan Fluorescence Studies. All fluorescence studies were carried out on Photon
Technology International

(PTI)

QuantaMaster™
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fluorescence

spectrometer

(Birmingham, NJ, USA). The 30 µM samples at pH 5.5, 6.0, 6.5, 7.0, and 7.5 were removed
from the CD cuvettes and placed in the fluorimeter. Fluorescence spectra were collected at
25 °C in quartz cuvettes with a 1-cm path length. The samples were excited at 280 nm and
emission data were collected from 300-400 nm. For all spectra the slit widths were 5 nm,
scan rate was 60 nm/min, averaging time was 1 s, and the data interval was 1 nm.
Hyperpolarized

129Xe

NMR Spectroscopy. HP

129

Xe was generated using spin-exchange

optical pumping (SEOP) method with a home-built version of the previously commercially
available Nycomed-Amersham (now GE) model IGI.Xe.2000 129Xe hyperpolarizer. A gas
mixture of 89% helium, 10% nitrogen, and 1% natural abundance xenon (Linde Group,
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NJ) was used as the hyperpolarizer input. 795 nm circularly polarized diode laser was used
for optical pumping of Rb vapor.

129

Xe was hyperpolarized to 10–15% after being

cryogenically separated, accumulated, thawed, and collected in controlled atmosphere
129

valve NMR tubes (New Era). After hp

Xe collection, NMR tubes were shaken

vigorously to mix cryptophane solutions with hp Xe. All 129Xe NMR measurements were
carried out on a Bruker BioDRX 500 MHz NMR spectrometer (138.12 MHz frequency for
129

Xe), using a 10-mm BBO NMR probe. Sample temperature was controlled by VT unit

on NMR spectrometer to 300 ± 1 K. Eburp2 shaped pulse was used to selectively excite
Xe@WEC biosensor peak. Spectra were averaged over 16 scans. A delay of 0.5 s was
given between scans to allow for xenon exchange. All acquired NMR spectra were
processed with 60 Hz Lorentz broadening. Chemical shifts were referenced to free xenon
gas of 0 atm at 0 ppm, shown in Figure 3.6.
Hyper-CEST Frequency Scan Spectroscopy. Prior to applying saturation pulse, gas
mixture including hp

129

Xe was bubbled into a 10-mm NMR tube containing 2.5 mL

sample solution by a home-built continuous-flow gas delivery setup. For each data point
in the Hyper-CEST spectrum, the gas mixture was bubbled for 20 s, followed by a 3-s delay
to allow bubbles to collapse. All Hyper-CEST experiments were carried out using a Bruker
500 MHz NMR spectrometer, with 10-mm PABBO probe. A 90° hard pulse of this probe
has pulse length of 22 µs.
Hyperpolarized

129Xe

Chemical Exchange Saturation Transfer Depolarization Curve.

Saturation frequencies of Dsnob shaped pulse were positioned at (192.4 - 128.2) = 64.2
ppm and (192.4 + 128.2) = 320.6 ppm, for “on” and “off” resonance, respectively. In each
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experiment, pulse sequences of the following parameters were used: Pulse length tpulse =
3.748 ms, field strength B1,max = 77 µT, delay between pulse = 20 µs, maximum number of
saturation cycles = 6000. Data are shown in Figure 5. Sample temperature was controlled
by VT unit on NMR spectrometer to 310 ± 1 K. Xenon was introduced by continuous flow.
Cell Culture. Human cervical carcinoma (HeLa) cells in T-25 cell culture flasks in
Dulbecco’s Modified Eagle Medium (DMEM) with 10% fetal bovine serum and 1%
penicillin/streptomycin were grown to 80% confluency. The medium was then removed
and the cells were washed 3x with Dulbecco’s Phosphate Buffered Saline (DPBS). Cells
were suspended with 0.25% trypsin incubation for 5 min. The trypsin was quenched with
a 10-fold excess of DPBS. Cell suspension (10 µL) was removed and combined with 10
µL of Trypan Blue. Cells were counted with a hemocytometer after 5-min incubation. 1 x
107 cells/mL were used in all experiments. The cell suspension was then centrifuged for 7
min at 2 krpm and the cell pellet was isolated. Cells were resuspended in 10 mM sodium
phosphate buffer with 0.1% Pluronic L-8175 at either pH 5.5 or pH 7.5 and also 5-10 µM
WEC. The cell/biosensor solution was gently vortexed to mix. After < 1-h incubation, the
cell suspension was transferred to an NMR tube.
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Chapter 4: 129Xe as a Biophysical Probe of Protein Conformational Change

The content of this chapter has been submitted for publication. It has been adapted here:
Reprinted with permission from B.A. Riggle; M.L. Greenberg; Y. Wang; R.F. Wissner;
E.J. Petersson; and I.J. Dmochowski. A “Turn-On” xenon-129 Biosensor for Calmodulin.
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§ 4.1 Introduction
Calmodulin (CaM) is a small (17 kDa) calcium-binding messenger protein that is
expressed in all eukaryotic cells. CaM transduces calcium signals to mediate a wide variety
of processes from muscle contraction and metabolism to memory formation, inflammation
and immune response. Because of the diverse roles CaM plays it is ubiquitously expressed
throughout the body. CaM binds four Ca2+ ions, which activates binding to a variety of
helix-forming peptide sequences with µM to nM KD values.171 A solution structure of apoCaM was solved and revealed Ca2+ binding induces necessary conformational changes for
peptide binding.172

When CaM binds to cognate peptide it undergoes a dramatic

conformational change (Figure 4. 1), which has been probed using many spectroscopic
techniques.161, 171, 173-177 Here we investigate the potential for using sensitive

129

Xe NMR

spectroscopy to detect active CaM in solution.

Figure 4. 1. Conformational change of calmodulin with the addition of 4 Ca2+ ions and
subsequent folding in the presence of helical-peptido substrate.

Early work investigated the role of calcium-calmodulin and ion channel
modulation. Specifically, researchers looked at the interaction of the CaM complex with
cyclic nucleotide-activated cation channels that function to mediate olfactory and visual
signal transduction.178 They determined that CaM binds to a 26-amino acid N-terminal
129

portion of the transmembrane channel for rat (r), bovine (b), and fish (f) olfactory cyclic
nucleotide-activated channel (OCNC) but that Ca2+ is necessary for substrate binding.178,
179

The CaM binding region, despite a high degree of sequence flexibility, is characterized

by several attributes, namely, a basic amphiphilic structure, the ability to form helix, and
two aromatic or long chain aliphatic “anchor residues” 12 amino acids apart, shown boxed
in blue in Figure 4. 2.

178, 180, 181

From the original 26 amino acid sequence, later work

determined a 17-mer truncated peptide that also bound CaM, termed FRRIAR.173 The
CaM-FRIARR interaction is a model for many protein-protein interactions, based on the
burial of hydrophobic surface area and key electrostatic interactions, etc. CaM binds and
regulates more than 30 target enzymes.172

Figure 4. 2. Sequences of three in vivo substrates of CaM and the FRRIAR truncated substrate.

More recent work presented the NMR structure of calmodulin bound to αsynuclein.182 The role of Ca2+-CaM in the function of α-synuclein of is of particular interest
due to the role of α-synuclein in Parkinson’s disease.
Cryptophane xenon host-guest chemistry for use as targeted contrast agents in MRI
is an area of considerable research.183 Our lab and others have developed

129

Xe NMR

biosensors for detecting proteins and other biomolecules and metal ions in solution.113, 184
Less investigated is the potential for studying protein-protein interactions using
130

129

Xe

NMR spectroscopy.68, 73 Xenon-129 has a spin-½ nucleus and high isotopic abundance of
26.4%. Non-Boltzmann distributions of spins can be achieved by spin-exchange optical
pumping (SEOP) in a processes termed hyperpolarization (hp). This characteristic coupled
with the lack of endogenous xenon in vivo results in the potential for very large signal-tonoise ratios, compared to traditional proton MRI. Due to xenon’s polarizable electron
cloud, xenon exhibits appreciable affinity for small-molecule cryptophane hosts, and to a
lesser extent, cucurbit[6]uril.44, 185 Cryptophanes can be made water-soluble and provide a
hydrophobic cavity with internal volume well matched to that of Xe (D = 4.3 Å, V ~40
Å3).55-57, 65 Our lab68-70, 73, 77 and others49, 66, 75, 95, 97, 147, 149 have designed a wide variety of
cryptophane-xenon biosensors targeted to specific biomarkers indicated in cancer,
including integrin and folate receptors, MMP-7, carbonic anhydrase. . . In these previous
examples, cryptophane biosensor produced a specific hp 129Xe NMR chemical shift, which
then shifted downfield upon introduction of protein analyte.

Figure 4. 3. 129Xe “turn-on” NMR signal resulting from FRRIAR-TUC binding holo-calmodulin.

Cryptophane-based biosensors have been used to detect Zn2+ with xenon NMR113
as well as Pd2+ and Cd2+.184 In both of these cases the authors tethered cryptophane with a
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nitrilotriacetic acid group and relied on changes in the chemical shift to differentiate
between the three ions. We have chosen a different approach whereby we indirectly detect
the presence of Ca2+ ions through a protein conformational change and protein-peptide
interaction. Herein, we demonstrate a novel turn-on detection approach whereby we detect
biosensor binding to calmoduin protein through hp

129

Xe-cryptophane NMR signal is

absent until protein-peptide interaction occurs. We demonstrate a binary (ON/OFF) 129Xe
signal in the presence and absence of Ca2+-activated CaM, Figure 4. 3. Building on our
earlier work conjugating peptides to cryptophane, we present a synthetic route to conjugate
the CaM-binding peptide, FRRIAR, to our tripropargyl cryptophane host molecule, Figure
4. 4.
§ 4.2 Results and Discussion
Synthetic Procedures
Figure 4. 4 shows the synthesis of the FRRIAR peptide-trifunctionalized,
ultrasensitive cryptophane conjugate (FRRIAR-TUC) 5, the details of which are provided
in the Materials and Methods Section. Briefly, the synthesis of tripropargyl cryptophane 1
was performed in six non-linear steps with a yield for the five linear steps of 9.9%.77 AzidoFRRIAR peptide 2 was prepared with standard Fmoc synthetic methods. The peptide was
attached to the cryptophane via copper(I)-catalyzed [3+2] azide-alkyne cycloaddition
(CuAAC) to form 3 after a 3 h reaction.111, 112 Mono-peptide cryptophane conjugates were
achieved in preference by controlling reaction stoichiometry. The resulting triazole-hexyl
spacer kept the peptide in close proximity to the

129

Xe nucleus while minimizing steric

clashes with calmodulin during protein binding. Formation of compound 3 was confirmed
132

by MALDI-MS and the yield quantified by analytical reverse-phase HPLC to be
quantitative as all the azido-peptide was consumed (these data are provided in the Materials
and Methods section). A solubilizing linker, 3-azidopropionic acid 4, was synthesized in
one step from the commercially available β-propiolactone (see Material and Methods
Section)70, 74 and reacted with crude 3 without the addition of more copper catalyst. Starting
from tripropargyl cryptophane 1, FRRIAR-TUC 5 was isolated in ~70% yield after
sequential CuAAC reactions with 2 and 4 and HPLC purification to remove TBTA and
tris-triazole propionic acid cryptophane.
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Figure 4. 4. Reaction scheme for the formation of FRRIAR peptide-trisubstituted ultrasensitive
cryptophane (FRRIAR-TUC). a. 1 (1 eq), 2 (0.8 eq), CuBr (2 eq), TBTA (3 eq), 3 h; b. 3 (crude), 4
(10 eq), 12 h.

Initial attempts at synthesis were met with difficulty. [Note: all of the following
attempts, unless otherwise noted, utilized the copper ligand TBTA]. Building off the work
with EALA (see Chapter 3), 1.1 eq of FRRIAR were used. The reaction proceeded rapidly
and resulted in the formation of di- and tri- substituted peptido-cryptophane which wasn’t
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readily separable by HPLC. Subsequent attempts utilized reduced equivalents of FRRIAR
peptide; 0.8:1 peptide to cryptophane. This resulted in preferential formation of only the
mono-substituted product, however the reaction did not seem to proceed to completion
rather it stalled after 1 h. As time passed the product seemed to disappear, see Figure 4. 5.
Control studies in which FRRIAR peptide and cryptophane in DMSO but without reagents
and FRRIAR peptide in DMSO alone were monitored by HPLC over time. These time
course studies demonstrated that FRRIAR formed some sort of irreversible aggregate that
could not be resolubilized in mixtures of acetonitrile and water or in buffer after DMSO
was removed by lyophylization. Other reaction solvents were investigated. The
requirements were a solvent that could readily dissolve both the hydrophobic tripropargyl
cryptophane and hydrophilic FRRIAR peptide. Additionally, a copper source was needed
that would be compatible with the chosen solvent. The solubility of cryptophane and
FRRIAR was tested in trifluoroethanol (TFE) and both were found to be readily soluble.
Unfortunately, both copper sulfate and sodium ascorbate precipitated upon addition though
minimal product formation was observed. Next, TFE was employed as a co-solvent with
DMSO but aggregation was still observed. Copper(I) bromide was substituted for copper
sulfate with some success but the reaction precipitated over the timescale of the required
multitude of semi-preparative HPLC runs. Attempts were made in mixtures of acetonitrile
and water but afforded no product, possibly because acetonitrile coordinated the copper.
Finally, the stability of FRRIAR was investigated in N,N-dimethylformamide (DMF). The
peptide appeared to be stable long term in DMF but sodium ascorbate wasn’t soluble in
DMF. Following literature precedent copper (II) bromide was used in conjunction with
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triphenylphosphine to make a copper catalyst complex (in the absence of TBTA) which
has been seen to efficiently result in triazole formation. Alas, this complex resulted in no
product formation. Thus copper (I) bromide was again employed but this time in 100%
DMF and found to work with strong efficacy.

Figure 4. 5. Time-course HPLC of FRRIAR peptide degradation over time. Where the * denotes
peptide-cryptophane conjugate formation, the ◊ indicates tripropargyl cryptophane, and the □ is
FRRIAR peptide as confirmed by HPLC. No mass could be obtained on the increasing shoulder
that elutes right before FRRIAR nor on the broad humps between 20 and 30 min at 12 h.
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Gel Shift Assay
The binding of calmodulin protein to the peptide is readily observable by native gel
shift assay as shown by Liu et al.178 This assay was performed using polyacrylamide gel
electrophoresis (PAGE) and through it we are able to determine that binding is still
achieved and the binding stoichiometry of FRRIAR-TUC biosensor. This assay supports
the idea that the biosensor, FRRIAR-TUC binds in 1:1 stoichiometry with CaM in
agreement with the peptide alone.178 These data are depicted in Figure 4. 18. At 0.25, 0.50,
and 0.75 equivalents of FRRIAR-TUC biosensor two bands were observed--one band from
CaM-Ca2+ and a second that migrated to a lesser degree, representing a complex of
biosensor and CaM-Ca2+. This higher band increased in intensity with increasing
equivalents of FRRIAR-TUC until it was a single band at 1:1 CaM-Ca2+:FRRIAR-TUC.
This band migrated similarly to CaM-Ca2+:FRRIAR peptide.
Moving forward, we wanted to verify that FRRIAR-TUC would not bind to
calmodulin in the absence of Ca2+. Apo CaM was prepared and the native gel was repeated
with FRRIAR and FRRIAR-TUC. These data indicate FRRIAR-TUC induces CaM protein
folding only in the presence of Ca2+ ions, Figure 4. 6. Indeed, FRRIAR-TUC seems to
discriminate between apo and holo CaM more readily than FRRIAR alone.
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Figure 4. 6. Native gel shift assay, where sample are all 1:1 concentration of 10 µM CaM only or
10 µM CaM plus either 10 µM FRRIAR or 10 µM FRRIAR-TUC. 1) Apo CaM only; 2) Holo CaM
only; 3) Apo CaM + FRRIAR peptide; 4) Holo CaM +FRRIAR peptide; 5) Apo CaM + FRRIARTUC; and 6) Holo CaM + FRRIAR-TUC.

Tryptophan Fluorescence
The FRRIAR peptide contains a single tryptophan residue towards the C-terminus
that we hypothesized should provide a useful local probe of peptide and protein binding,
as well as changes in peptide-cryptophane interaction.186-188 Fluorescence studies (λex =
295 nm) with peptide 2 demonstrated a hypsochromic shift and increased Trp emission
intensity upon binding of calmodulin protein, Figure 4. 7a. Trp emission maximum
wavelength for the FRRIAR peptide decreased from 352 nm to 332 nm with increasing
concentrations of CaM protein. This quenching phenomenon was also observed in a much
narrower, and considerably blue shifted range with FRRIAR-TUC and CaM from 328 nm
to 325 nm (Figure 4. 7b), consistent with the Trp experiencing a less solvated environment
near cryptophane. Cryptophane fluoresces (λmax = 313 nm) with comparable intensity to
Trp, which further contributes significantly to the observed emission spectrum.55, 67
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Figure 4. 7. Calmodulin binding monitored by Trp fluorescence for a. FRRIAR peptide (30 µM)
with varying concentrations of CaM protein (0, 7.5, 15, 22.5, or 30 µM) and; b. FRRIAR-TUC (30
µM) with varying concentrations of CaM protein (0, 7.5, 15, 22.5, or 30 µM).

139

Figure 4. 8. Enthalpogram of FRRIAR-TUC (300 µM) titrated into CaM (30 µM).

Biosensor Binding Studies
The binding interaction between FRRIAR-TUC and CaM was characterized using
isothermal titration calorimetry as our laboratory has done with previous biosensors.70
Titration experiments were performed in 10 mM HEPES, 1 mM CaCl2 pH 7.2. We
determined ΔH = -18.1 kcal/mol, which gives a sub-micromolar dissociation constant of
0.65 µM at rt, see Figure 4. 8. These data were someone convoluted by the presence of an
initial dissociation process which may be the result of alleviating cryptophane-peptide
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interactions before calmodulin binding can take place. Reversible cryptophane-FRRIAR
association is not surprising as we have previously observed this phenomenon with other
peptide-cryptophane constructs.67, 77

Figure 4. 9. Electronic circular dichroism of FRRIAR (30 µM) and FRRIAR-TUC (10 µM) in 1:1
MeCN:H2O at 298 K. Data are normalized to molar ellipticity (see materials and methods)

Electronic Circular Dichroism
Although NMR178, 179 and crystallographic189 studies indicate FRRIAR peptide is
helical upon protein binding (Figure 4. 1), electronic circular dichroism studies
demonstrate the peptide is fairly disordered (Figure 4. 9, red trace) when free in solution.
Interestingly, after conjugating FRRIAR to cryptophane, the peptide exhibits a large
increase in helicity (Figure 4. 9, blue trace) from 11 to 37%, (see Materials and Methods).
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Because racemic cryptophane does not produce ECD signal, conjugation to the cage seems
to promote helicity in FRRIAR peptide. For ECD studies, samples of FRRIAR peptide (30
μM) and FRRIAR-TUC (10 µM) were prepared in 1:1 MeCN:H2O, as confirmed by UVvis spectroscopy (FRRIAR: ε280 = 6,970 M-1cm-1, FRRIAR-TUC: ε280 = 16,970 M-1cm-1).
HPLC solvents were used to minimize observed light scattering from DMSO and
HEPES.190 These data are in line with previous work where cryptophane was observed to
promote helicity in a helix forming peptide, likely through cryptophane-peptide pi-stacking
interactions.77 These data serve to further explain observations by ITC where there is an
initial “dilution” effect before CaM binding.

128Xe

NMR Spectroscopy
Finally, HP

129

Xe NMR spectroscopy was employed to further investigate the

biosensor-CaM interaction. Interestingly, the biosensor alone gave no hp

129

Xe-

cryptophane NMR signal; only the hp 129Xe@H2O resonance was observed, Figure 4. 10.
UV-Vis spectroscopy confirmed that significant quantity (~70 µM, ε280 = 16,970 M-1•cm1

) of biosensor was in solution. Upon addition of equimolar calcium-activated CaM,

FRRIAR-TUC produced strong

129

Xe NMR signal corresponding to cryptophane-CaM

complex formation Figure 4. 10. The two bound peaks (65.9, 67.6) were assigned to
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diastereomers, which are formed when racemic biosensor is conjugated to the chiral
peptide. Diastereomeric

129

Xe NMR peaks have been observed previously for peptide-

cryptophane conjugates as well as for xenon biosensors bound to protein active sites..66, 70
Only trace amounts of “free” biosensor was observed in the presence of calcium-bound
CaM (at 62.9 ppm), which was assigned from previous literature examples of water-soluble
cryptophane. The lack of hp

129

Xe NMR signal corresponding to free biosensor is thus

consistent in the presence or absence of CaM. Likewise, no hp

129

Xe NMR signal was

observed for biosensor in the presence of apo CaM, as FRIARR-CaM interaction is much
weaker in the absence of calcium (as confirmed by gel electrophoresis, Figure 4. 6). These
experiments demonstrate the first example of a “turn-on” xenon NMR biosensor, which
results from the binding of FRRIAR-TUC to calcium-activated CaM.
Our ECD and Trp fluorescence data suggest significant cryptophane-peptide
interactions as has been previously demonstrated.67, 77 Such interactions may contribute to
poor solubilisation of the cryptophane and should favour less xenon-accessible
conformations resulting in an “OFF” signal from the biosensor. Upon calcium-activated
CaM binding to the peptide, cryptophane-FRRIAR interactions are decreased and xenon
biosensor signal is turned “ON”.
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Figure 4. 10. 129Xe NMR spectra of CaM bound FRRIAR-TUC resulting in two bound signals, A.
and FRRIAR-TUC alone and in the presence of apo CaM resulted in no bound signal.

§ 4.3 Conclusions
In summary, we report a straightforward synthesis for the first “turn-on”
cryptophane biosensor, which was used to detect calcium-bound calmodulin protein. This
so called turn-on effect improves signal-to-noise especially in scenarios where there are
multiple biosensors with both “free” and “bound” signals. The observation of signal only
in the presence of target analyte will also facilitate ultrasensitive detection using
hyperpolarized chemical exchange saturation transfer (Hyper-CEST) NMR techniques.95
For example, large, high-powered pulse widths that increase detection sensitivity can be
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employed without interfering signal from untargeted biosensor(s). This work highlights a
new paradigm in xenon biosensing, and future studies will help to elucidate the nature of
peptide-cryptophane interactions that can produce the “OFF” state.
§ 4.4 Materials and Methods
General Information
Instrumentation and Methods. 1H NMR (500 MHz) data were obtained in deuterated
chloroform (CDCl3) or dimethyl sulfoxide (DMSO-d6) using a Bruker DMX 500 NMR
spectrometer. Column chromatography was performed using silica gel (60 Å pore size, 4075 µm particle size) from Sorbent Technologies. Thin layer chromatography (TLC) was
performed using silica gel plates (60 Å pore size, Silicycle) with UV light at 254 nm as the
detection method. MALDI-MS data were collected using a Bruker Ultraflex III TOF/TOF
mass spectrometer. All HPLC purifications were performed on a Varian Prostar 210 system
equipped with a quaternary pump and diode array detector. All air- and moisture-sensitive
reactions were performed under inert atmosphere in glassware flamed under vacuum, using
anhydrous dry solvents. Standard workup procedures involved multiple (~3) extractions
with the indicated organic solvent, followed by washing of the combined organic extracts
with water or brine, drying over Na2SO4 and removal of solvents in vacuo. All yields
reported were determined after purification by column chromatography or reverse phase
HPLC, unless otherwise noted. All data were collected using instruments in the Chemistry
Department at the University of Pennsylvania.
Materials. Organic reagents and solvents were used as purchased from the following
commercial sources: Sigma-Aldrich: N,N-diisopropylethylamine (DIPEA); copper(I)
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bromide; dimethyl sulfoxide (DMSO, anhydrous, 99.9%); Sigmacote®; Tris-[(1-benzyl1H-1,2,3-triazol-4-yl)methyl]amine (TBTA). Fisher: acetone (HPLC grade); chloroform
(CH2Cl3, HPLC grade); dichloromethane (CH2Cl2, HPLC grade); ethyl acetate (EtOAc,
HPLC grade); hexanes (HPLC grade); hydrochloric acid; methyl alcohol (MeOH, HPLC
grade), perchloric acid (60%); potassium carbonate (anhydrous); sea sand (washed);
sodium chloride (NaCl); sodium hydroxide (NaOH); sodium sulfate (anhydrous).
Novabiochem (currently EMD Millipore; Billerica, MA, USA): 6-azidohexanoic acid; 2(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate

(HBTU).

MarCor: deionized (DI) water filtered (18 MΩ). Acros Organics: β-propiolactone (90%);
cesium

carbonate (Cs2CO3, 99.5%); chloroform-d (CDCl3); 1,2-dibromoethane; 3,4-

dihydroxybenzaldehyde (97%); N,N-dimethylformamide (DMF, 99.8%, anhydrous,
acrosseal); dimethylsulfoxide-d6, 4-hydroxy-3-methoxybenzyl alcohol (99%); propargyl
bromide (80% solution in toluene); scandium(III) trifluoromethanesulfonate (Sc(OTf)3,
95%); sodium borohydride (NaHB4, powder, 98%); sodium hydride (NaH, 60% dispersion
in mineral oil); tetrahydrofuran (THF, extra dry, over molecular sieves); triisopropylsilane
(TIS). MG Industries (Linde Group, NJ): xenon gas (scientific grade).
Synthetic Procedures
Cryptophane Synthesis. Tripropargyl cryptophane was achieved in a 6-step synthesis with
a 6.4% overall yield from two commercially available compounds, 3,4-dihydroxybenzaldehyde and vanillyl alcohol. Spectroscopic data agreed with literature values.77
Peptide Synthesis and Purification. FRRIAR peptide was synthesized using standard solid
phase peptide synthesis as described previously,77 and then N-terminally capped with
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commercially available 6-azidohexanoic acid and purified by reverse-phase HPLC.77
Alternatively, azido-FRRIAR was purchased from Anaspec as a purified white powder
separated into 10 mg aliquots.
Solubilizing Linker Synthesis. 3-Azidopropionic acid was prepared from β-propiolactone
by literature procedure and matched the reported 1H NMR spectrum.168
3-azidopropionic acid (4). Briefly, sodium azide (4.5 g, 0.69 mmol, 1 eq) was dissolved in
ddH2O water. β-propiolactone (4.4 mL, 0.069 mmol, 1 eq) was added dropwise and the
reaction was allowed to stir at rt for 6 h. The reaction was neutralized with 1 M HCl and
then extracted 3 times. The organic layer was then dried over sodium sulfate and filtered
through cotton. A clear oil in a 15% yield was recovered, requiring no further purification.
FRRIAR-TUC Biosensor Synthesis. The copper(I)-catalyzed [3+2] azide-alkyne
cycloaddition (CuAAC) between N3-EALA peptide and cryptophane and the subsequent
cycloaddition reaction between the cryptophane and 3-azidopropionic acid yielded the
FRRIAR-TUC biosensor.
FRRIAR-cryptophane (3). To conjugate the azido-EALA peptide to the tripropargyl
cryptophane (1) CuAAC was utilized with modified conditions of those previously
employed.67, 68, 70, 73 Firstly, 5.3 mg (1.0 eq) of 1 and 10 mg of 2 (0.8 eq) were dissolved in
1 mL of dry N,N-dimethylformamide (DMF) in a conical reaction vessel. The reaction
mixture was put to stirring and degassed. In a separate vial, 16 mg (6 eq) of tris[(1-benzyl1H-1,2,3-triazol-4-yl)methylamine (TBTA) copper ligand was dissolved in 100 μL of
DMF. A separate solution of 0.35 M copper (I) bromide (CuBr) in DMSO was also
prepared. To the TBTA solution, 43 μL of CuBr (3 eq) was added, vortexing after addition.
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The reagent mixture was then added to the reaction vessel. The reaction vessel was again
degassed and then covered with foil and allowed to stir for 3 h under nitrogen at rt. A small
aliquot of reaction was removed (2 µL) and diluted in HPLC solvent mixture, 50:50
mixture of acetonitrile and water with 0.1% trifluoroacetic acid to 1 mL. To verify product
formation, analytical reverse-phase HPLC was performed using a Grace C18 analytical
column (250 × 4.6 mm, 5 µm beads) and monitored at 215 and 277 nm. The elution gradient
was composed of two solvents: 0.1% aqueous TFA (solvent A) and a 0.1% solution of TFA
in CH3CN (solvent B). The purification method went equilibrated at 90% A for 5 min.
Then went from 90% A to 60% A over 3 min, then from 60% A to 22% A over 32 min,
and finally decreased to 0% A over the next 5 min at a flow rate of 1 mL/min with a 1 mL
injection volume. The FRRIAR-cryptophane conjugate eluted at 28.00 min, Figure 4. 11.
MALDI-MS m/z calculated for FRRIAR-cryptophane C166H225N37O33 (M+H+) 3265.71;
found 3265.76, Figure 4. 12.
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Figure 4. 11. HPLC chromatogram of FRRIAR-cryptophane (3). UV absorbance monitored at 277
nm. Product eluted at 28.00 min. Peak assignment based on MALDI-MS.

Figure 4. 12. MALDI-MS spectrum of FRRIAR-cryptophane (3). Expected mass (M+H+) 3265.71;
found 3265.76.
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FRRIAR-trisubstituted ultrasensitive cryptophane (FRRIAR-TUC) (5). After 3 h the crude
reaction (3) was then dosed with 6 μL 3-azidopropionic acid (4) (11 eq) and allowed to stir
overnight while covered, to yield the FRRIAR-TUC biosensor. The reaction was diluted
10-fold in 50:50 ACN:H2O and purified. Purification was achieved through reverse-phase
HPLC employing a semi-preparative method and using a Grace C18 semi-preparative
column (10 × 250 mm, 5 µm beads). The purification method went equilibrated at 90% A
for 5 min. Then went from 90% A to 55% A over 3 min, then from 55% A to 51% A over
7 min, and then from 51% A to 47% A over 13 min. Next went from 47% A to 40% A over
6 min and finally decreased to 0% A over the next min at a flow rate of 4 mL/min with a 1
mL injection volume. The biosensor eluted at 20.30 min Figure 4. 13. MALDI-MS m/z
calculated for FRRIAR-TUC C208H289N43O61 (M+H+) 3496.02; found 3495.99, Figure 4.
14. The pure fractions were then collected and lyophilized to a white powder and dissolved
in a minimal amount of DMSO and then diluted to desired concentrations in 10 mM
HEPES at pH 7.5 with and without 1 mM CaCl2.
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Figure 4. 13. HPLC chromatogram of FRRIAR-TUC (5). UV absorbance monitored at 277 nm.
Product eluted at 20.30 min. Peak assignment based on MALDI-MS.

Figure 4. 14. MALDI-MS spectrum of FRRIAR-TUC (5). Expected mass (M+H+) 3496.02; found
3495.99.
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Calmodulin Protein Expression and Purification. Calmodulin (CaM) protein was
expressed and purified following previously established protocols.173 Briefly, Escherichia
coli BL21(DE3) cells were transformed with plasmid containing chicken CaM gene.
Transformed cells were selected on the basis of ampicillin resistance. M9 minimal media
(50 mL) supplemented with ampicillin (100 µg/mL) was inoculated with single colonies.
An M9 salts solution (42.3 mM Na2HPO4, 22.0 mM KH2PO4, and 8.5 mM NaCl) was
prepared and autoclaved. Autoclaved solutions of the following salts were added per liter
of M9 salts: 10 mL of 10% NH4Cl, 1 mL of 2 M MgSO4, 1 mL of 15 mg/mL FeCl2 (in 1.0
M HCl), 1 mL of 15 mg/mL ZnCl2 (in acidified H2O), and 2 mL of 10% Bacto™ Yeast
Extract. The primary 50 mL culture was incubated at 37 °C with shaking at 250 rpm
overnight. The cells were harvested at 5000 g for 15 min and the resulting pellet was
resuspended in 1 L of M9 minimal media supplemented with ampicillin. The 1 L culture
was incubated at 37 °C with shaking at 250 rpm until the absorbance at 600 nm reached an
OD of 0.9 AU. The culture was induced with isopropyl D-galactoside (IPTG), and then
incubated at 25 °C for an additional 12 h. The cells were again collected at 5000 g for 15
min and the resulting pellet was suspended in 15 mL of MOPS resuspension buffer: 50
mM

3-(N-morpholino)propanesulfonic

acid

(MOPS),

100

mM

KCl,

1

mM

ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol, pH 7.5. Cell were lysed with
lysozyme (150 µg/mL) for 1 h at room temperature followed by brief sonication. The cell
lysate was cooled on ice for 5 min. CaCl2 was added to the sonicated lysate to a final
concentration of 5 mM prior to centrifugation for 20 min at 30,000 g, 4 °C. CaM was
purified from the cleared cell lysate using a phenylsepharose CL-4B column (resin bed
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volume = 20 mL) with EDTA as eluent. The column was first equilibrated with 4 column
volumes of Buffer A (50 mM Tris base, 1 mM CaCl2, pH 7.5). After the clear cell lysate
was loaded and allowed to pass through the resin, the column was washed with 4 column
volumes of Buffer A, 4 column volumes of high-salt Buffer B (50 mM Tris base, 0.5 M
NaCl, 0.1 mM CaCl2, pH 7.5), and an additional 2 column volume washes of Buffer A to
restore low-salt conditions. CaM was eluted with Buffer C (10 mM Tris base, 10 mM
EDTA, pH 7.5) and collected in 4 mL fractions until absorbance at 280 nm was no longer
detected. A second column purification was performed on the first batch of eluted fractions
(re-saturated with CaCl2 to a concentration of 20 mM) to obtain CaM with high levels of
purity. Column fractions were dialyzed against 10 mM ammonium bicarbonate (pH 8.0)
and stored as a lyophilized powder at -20 °C. SDS-PAGE analysis was performed to
analyze dialyzed CaM elution fractions.
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Characterization Methods

Figure 4. 15. Electronic circular dichroism spectrum of FRRIAR peptide showing a disordered
conformation.

Electronic Circular Dichroism (ECD) Spectroscopy. All ECD spectroscopy experiments
were performed on the Aviv 410 CD spectrometer. Data were collected at 25 °C from 260190 nm, with a 30 s averaging time, 1 nm wavelength step, 1 s averaging time, and 1 nm
bandwidth. The sample in Figure 4. 15 was prepared by dissolving lyophilized FRRIAR in
10 mM HEPES, 1 mM CaCl2 pH 7.2 to 30 µM and serves as a control for peptide
conformation irrespective of solvent conditions. The concentration for all experiments was
confirmed by measuring the absorbance at 280 nm, 𝜀280 = 6,970 𝑀−1 𝑐𝑚−1 [FRRIAR]
and 𝜀280 = 16,970 𝑀−1 𝑐𝑚−1 [FRRIAR-TUC] and using an Agilent 89090A UV-visible
spectrophotometer.
Data Analysis. The molar ellipticity was calculated from the observed ellipticity (mdeg)
and has the units of deg cm2 dmol-1. The molar ellipticity is given by equation 4.1 where C
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is the concentration of the peptide or biosensor, ℓ is the path length of the cuvette-0.1 cm,
and 𝑛𝑟 is the number of residues-.169
[𝜃] =

𝜃𝜆
(𝐶 ∗ ℓ ∗ 𝑛𝑟 ∗ 10)

(4.1)

The helical content of FRRIAR and FRRIAR-TUC were determined from circular
dichroism studies at 30 and 10 μM concentrations, respectively, and in accordance with
literature precedent.170 The concentration variation is a result of the large difference in
extinction coefficients (6970 vs 16970 M-1 • cm-1), because data are normalized to molar
ellipticity they can be directly compared. Studies at various concentrations demonstrated
reproducible percent helicity values. Helicity was calculated using the formulas 4.2 and 4.3
where 𝑛𝑟 is the number of amino acids in the peptide, in this case 17. Racemic cryptophane
was employed for these experiments, and thus did not contribute to the measured CD
signal.145 Data are shown in Tables 4.1 and graphically in Figure 4. 9. These experiments
were performed in 1:1 MeOH:H2O because even samples with 0.25% DMSO contributed
to significant scattering below 210 nm as did the buffer to a lesser degree.190 Comparative
studies between FRRIAR in buffer and FRRIAR in 1:1 MeCN:H2O demonstrated
equivalent spectra.
[𝜃]222
%ℎ𝑒𝑙𝑖𝑐𝑖𝑡𝑦 = 100 ∗ 𝑚𝑎𝑥
[𝜃] 222
𝑚𝑎𝑥

[𝜃]222 = −40000 ∗ [1 −

(4.2)

2.5
]
𝑛𝑟

(4.3)

Tryptophan Fluorescence Studies. All fluorescence studies with the peptide and CaM
were carried out on Photon Technology International (PTI) QuantaMaster™ 40
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fluorescence spectrometer (Birmingham, NJ, USA). Samples containing 0, 7.5, 15, 22.5,
or 30 µM CaM and 30 µM FRRIAR peptide were prepared in 10 mM HEPES, 1 mM CaCl2
pH 7.2 and placed in the fluorimeter. Fluorescence spectra were collected at 25 °C in quartz
cuvettes with a 1-cm path length. The samples were excited at 295 nm and emission data
were collected from 300-400 nm. For all spectra the slit widths were 5 nm, scan rate was
60 nm/min, averaging time was 1 s, and the data interval was 1 nm. All fluorescence studies
with the biosensor and CaM were prepared in the same manner and carried out on Cary
Eclipse Fluorescence Spectrophotometer from Agilent (formally Varian).
Hyperpolarized

129Xe

NMR Spectroscopy. HP

129

Xe was generated using spin-exchange

optical pumping (SEOP) method with a home-built version of the previously commercially
available Nycomed-Amersham (now GE) model IGI.Xe.2000 129Xe hyperpolarizer. A gas
mixture of 89% helium, 10% nitrogen, and 1% natural abundance xenon (Linde Group,
NJ) was used as the hyperpolarizer input. 795 nm circularly polarized diode laser was used
for optical pumping of Rb vapor.

129

Xe was hyperpolarized to 10–15% after being

cryogenically separated, accumulated, thawed, and collected in controlled atmosphere
valve NMR tubes (New Era). After hp Xe collection, NMR tubes were shaken vigorously
to mix cryptophane solutions with hp Xe. All 129Xe NMR measurements were carried out
on a Bruker BioDRX 500 MHz NMR spectrometer (138.12 MHz frequency for

129

Xe),

using a 5-mm BBO NMR probe. Sample temperature was controlled by VT unit on NMR
spectrometer to 300 ± 1 K. Eburp1 shaped pulse was used to selectively excite
Xe@FRRIAR-TUC biosensor peak. Spectra were averaged over 16 scans. A delay of 0.15s
was given between scans to allow for xenon exchange. All acquired NMR spectra were
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processed with 25 Hz Lorentz broadening. Chemical shifts were referenced to free xenon
gas of 0 atm at 0 ppm.

Figure 4. 16. Temperature-dependent circular dichroism spectroscopy of 30 µM apo calmodulin

Thermal Melt of Calmodulin. To confirm that Apo CaM had been achieved temperaturedependent circular dichroism (CD) spectroscopy was performed following literature
protocol.173 Briefly, calcium containing CaM (holo-CaM) is thermostable (Tm > 90 ºC)
thus, we measured the thermal unfolding of the apo protein which has a reported Tm of 55
ºC.191 CD data were obtained from approximately 30 µM protein sample monitored at 222
nm between 0 and 95 ºC using the variable temperature module with the Aviv 410 CD
spectrometer. Data were collected every 1 ºC, using a 30 s averaging time, 2 min
temperature equilibrium, and 1 nm band width. The resulting ellipticity (θD) measurements
were converted to molar residue ellipticity values (θ) using equation 4.1, described above.
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The fraction folded (ff) for apo protein was determined using linear baselines to fit the low
(θF) and high (θU) temperature data, equations 4.4 and 4.5, respectively.
𝜃𝐹 = 𝑚𝐹 𝑇 + 𝑏𝐹

(4.4)

𝜃𝑈 = 𝑚𝑈 𝑇 + 𝑏𝑈

(4.5)

The entirety of the data range was then fit to equation S6 where K = e-(ΔH-TΔS)/RT, where ΔH
and ΔS are adjustable parameters and R = 8.3145 J•mol-1•K-1. The resulting plot is shown
in Figure 4. 16.
𝜃 = 𝜃𝐹 (𝑇)𝑓𝑓 (𝑇) + 𝜃𝑈 (𝑇)(1 − 𝑓𝑓 (𝑇))

(4.6)

Where: 𝑓𝑓 = 𝐾/(1 + 𝐾)
Our values agree quite favorably with the measured values associated with experiments
performed in Goldberg et al. (not published) and are shown in Table S2.173
Table 4.2: Calculated values for ΔH and ΔS from the thermal melt of apo calmodulin
Our Calculated Value

Literature Valuea

ΔH

1.43 x 105 kJ • mol-1

1.43 x 105 kJ • mol-1

ΔS

444 J • mol-1 • K-1

438 J • mol-1 • K-1

a

These values are associated with data analysis performed in Goldberg et al. while these values were not published in that
manuscript they were provided by the authors for comparison.

Gel Shift Assay. All gels were run on a Bio-Rad PowerPac™ Basic gel setup in 1x Trisglycine solution (prepared from a dilution of commercially available Tris-Glycine 10x
Solution for Electrophoresis in ddH2O). Mini-protean®TGX™ precast gels, 4-15%, 30
µL/well from Bio-Rad. Initial characterization of CaM gel shift upon binding was achieved
by preparing samples with 0, 10, or 20 µM FRRIAR (final concentration) with 10 µM CaM
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(final concentration) and is shown in Figure 4. 17. For the FRRIAR-TUC titration gel,
samples containing 0, 7.5, 15, 22.5, or 10 µM FRRIAR-TUC and 10 µM CaM were
prepared in 10 mM HEPES, pH 7.2 with 1% DMSO, Figure 4. 18. For the Apo/Holo
binding gel, 10 µM (final concentration) of either apo or holo CaM was combined with 10
µM FRRIAR (final concentration), 10 µM FRRIAR-TUC, or buffer, Figure 4. 6. Native
Tris-Glycine Sample Buffer 2x from Novex (25 µL) was combined with 25 µL of each
sample. Samples were incubated for 1 min after prep before being loaded onto a 4-15%
gradient gel. The gel box was put on ice and run at 120 V for 1.5 h before being stained
with Coomassie brilliant blue stain mixture (20 min) and then destained. The gel were
imaged on the Typhoon FLA 7000 gel imager.

Figure 4. 17. Native gel shift assay demonstrating retarded gel migration of CaM after binding
FRRIAR and that it does so in 1:1 stoichiometry.
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Figure 4. 18. Native gel shift assay, where sample are all 10 µM CaM (final concentration) plus 1.
buffer; 2. 0.25 µM FRRIAR-TUC; 3. 0.50 µM FRRIAR-TUC; 4. 0.75 µM FRRIAR-TUC; 5. 10 µM
FRRIAR-TUC; 6. 10 µM FRRIAR peptide; and 7. buffer.

Figure 4. 19. Enthalpogram of FRRIAR peptide injected into calmodulin protein.
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Isothermal Titration Calorimetry. All experiments were performed on a GE MicroCal™
ITC200 titration microcalorimeter at 298 K. Experiments were performed in high feedback
mode with 1000 rpm stir speed, an initial injection delay of 60 s, 180 s spacing between
injections, a differential power of 60, and a filter period of 5 s. An initial injection of 0.6
µL was measured and removed from subsequent data analysis due to initial drop dilution
this was followed by 19- 2 µL injections. Buffers were prepared in 1 L stock using ddH2O
water and were purified by vacuum filtration at 0.22 µM. CaM protein was dialyzed against
the desired buffer 2-3x. The buffer from the last dialysis was saved for subsequent use.
Protein concentration was determined using UVvis A280, ε = 3000 M-1 cm-1 and was diluted
in the buffer used for dialysis to a final concentration of 30 µM, 300 µL. Purified FRRIAR
peptide as a lyophilized powder was dissolved in the buffer from dialysis as well as to
ensure perfect buffer match to a final concentration of 300 µM, 100 µL as determined by
UV-vis: A280 with ε = 6970 M-1 cm-1. The heat of binding was measured for each injection
by measuring the power applied to the reference cell to maintain a temperature equal to
that of the sample cell and was measured in microcalories per second. Values for binding
enthalpy (ΔH), binding entropy (ΔS), binding stoichiometry (n), and association constant
(KA) were determined by peak integration and data fitting of the heat evolved per mole of
peptide injected using Origin software (version 7). Enthalpogram is shown in Figure 4. 19.
A control was performed of buffer injected into buffer and of peptide injected into buffer
(Figure 4. 20).
Repeated attempts were next made to calculate binding affinity between FRRIARTUC and CaM at various concentrations using ITC, however, no reliable data were
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achieved. Resulting enthalopograms were somewhat suggestive of a “two-site” binding
model which is likely reflective of an initial unfolding event to alleviate peptidecryptophane interactions or micelle disassembly to free up peptide for binding. Examples
are shown in Figure 4. 8.

Figure 4. 20. Enthalpograms of ITC controls. a. buffer titrated into buffer and b. FRRIAR titrated
into buffer. Buffer is 10 mM HEPES 1 mM CaCl2 pH 7.2.
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Chapter 5: Epilogue
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This thesis has explored the nature of cryptophane-based xenon biosensors and has
endeavored to elucidate design and synthesis strategies to generate biosensors with a high
degree of target specificity coupled with large changes in chemical shift. The long-term
goal is for this work to culminate in an array of targeted biosensors that can be employed
in animal models, and ultimately humans, as a means of accurately diagnosing cancer in
an ultrasensitive fashion.
§ 5.1 Carbonic Anhydrase as Cancer Biomarkers
Chapter 2 discussed our work with carbonic anhydrase targeting biosensors and our
studies attempting to explicate the chemical shift variation achieved from differing linker
lengths and the presence of multiple bound peaks. Our initial work was performed with
ubiquitously studied carbonic anhydrase isozymes I and II but as with all work in the
selective targeting and inhibition of specific carbonic anhydrase isozymes, we have also
considered isozymes indicated in cancer, CA IX and XII.

These membrane-bound

isozymes are upregulated in a multitude of cancers where they acidify the extracellular
milieu192-195 and have been challenging to express and work with in an “ex cellula” context.
However, there are a variety of cell lines that up-regulate these proteins. Thus, moving
forward we hope to generate fluorescent versions of our CXB (Figure 5.1) biosensors to
allow us to employ confocal microscopy and flow cytometry to visualize and quantify the
specificity of our biosensors. Because these proteins are membrane-bound we anticipate
an increase in the Δδ ppm as a result of bringing the cryptophane in close proximity to the
cellular membrane, as discussed in Chapter 3. Furthermore, there are a wide array of
targeting ligands for CA, some of which exhibit a degree of isozyme specificity that we
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plan to couple with our fluorescence strategies to develop biosensors highly specific for
CA IX and XII.80, 196 With these derivatives we plan to achieve large isozyme-dependent
chemical shifts that can be used in cellular NMR/MRI for ultrasensitive detection.

Figure 5. 1. Proposed synthesis of fluorescently labeled CXB derivatives where X=0, 1, or 2
carbon spacers.

§ 5.2 Stimuli-Responsive Cell Labeling as a Mechanism for Cancer Detection
Building on our work with carbonic anhydrase and its role in extracellular
acidification, Chapter 3 described a peptido-cryptophane that was used to label cells with
acidic local environments. This system was unusual in the field of targeted cryptophane
biosensors in that it targets a specific “stimulus” rather than an over-expressed receptor or
up-regulated enzyme. While the WEC biosensor does not provide a read-out of specific pH
values like some other studies have demonstrated,127, 134, 136 we were able to label cells only
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when placed in an acidic environment and detect cell labeling at 103-fold improved
concentration limits over other CEST reporters. Importantly, using the WEC biosensor we
achieved the largest chemical shift change published to date.
Moving forward this work could be improved by a peptide that undergoes a
conformational change over a narrower pH range and by studying if relative peak ratios of
the “bound” and “free” conformations can be utilized to provide a pH measurement. More
importantly, this work introduced a new paradigm to the field of cryptophane biosensors.
These methods can be applied to detect a wide range of stimuli in a wide variety of fashions.
One important aspect to bear in mind when designing stimuli responsive biosensors is to
generate a large change in chemical shift. Secondly, the biosensor can be targeted both
directly to the stimulus, such as enzymatic cleavage of a peptide-substrate or indirectly as
in the case of WEC where the xenon senses a change in conformation resulting in
membrane insertion rather than directly sensing pH change. In a living system, biosensors
that bind to receptors or proteins will either label the cells or be internalized via an
endocytotic mechanism. Stimuli-responsive biosensors may physically bind to the diseased
cell further necessitating a need to generate strong chemical shifts post targeting to
deconvolute the resultant signal. Our work targeting MMP-7, described in Section 1.9,
produced very small chemical shift variation pre- and post- enzymatic cleavage.67 Because
the chemical shift change is a result of shielding/deshielding effects, we propose to improve
the Δδ ppm for an enzymatic substrate tethered to cryptophane by using a highly
fluorinated version of the peptide. Finally, for many studies, an “on-off” response will be
sufficient, whereby cryptophane-labeled cells will produce observable hp 129Xe NMR/MRI
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signal. Accumulation of cryptophane at diseased cells should provide a useful diagnostic
agent, similarly to how FDG has enabled early cancer detection via PET imaging.
§ 5.3 Employing Xe as an Ultrasensitive Probe for Applications in Chemical Biology
Building on our work with WEC, Chapter 4 considers new uses of cryptophane129

Xe NMR spectroscopy to probe protein dynamics. In the field of chemical biology there

is a wide range of tools used to label proteins to study conformational changes and proteinprotein interactions. The development and use of these tools tends to be a tradeoff between
sensitivity and level of perturbation. X-ray crystallography and neutron diffraction can be
employed with macromolecular samples and can provide high-resolution structures but this
information is obtained from solid crystals and thus may not represent dynamic
information.197 Producing stable crystals can also require large screens to obtain ideal
conditions which can consume large quantities of protein. Time-resolved crystallography
helps to mitigate some of these concerns by generating molecular movies at atomic
resolution.198 This technique is limited, however, to conformational rearrangements that do
not disrupt crystal contacts and cannot be performed in vivo. Nuclear magnetic resonance
(NMR) can be used to study protein samples in solution to obtain both dynamic and
structural information through distance constraints determined by homo- and heteronuclear through-bond and through-space correlations.199,
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The limitation of this

technique is the difficulty to perform these experiments and that inferences, as opposed to
direct measurements, must made about line-broadening patterns. Importantly, the NMR
time scale is typically too slow to capture the full range of dynamic motions in large
conformational changes. Fluorescence spectroscopy methods require relatively small
168

amounts of protein and can be performed in live tissue and in complex solutions such as
cell lysates. Fluorescence spectroscopy can also be performed relying on intrinsic
characteristics of proteins such as tryptophan (W) signal. Conversely, proteins can be
labeled with a wide variety of fluorophores from Green Fluorescent Protein (GFP) to much
smaller molecules like fluorescein, acridone, coumarin, and Alexa Fluors.201 With smaller
molecules you potentially have much decreased perturbation of the native structure but the
fluorescence intensity is also reduced, thus precluding ultrasensitive detection. Thus the
use of cryptophane labeling for xenon monitoring of protein dynamics may provide a
complementary method to monitor protein dynamics in dilute solutions and in turbid
media.

Figure 5. 2. Synthesis of cryptophane labeled calmodulin protein.

Although our initial foray into this field involved labeling a peptide-substrate
involved in bringing about a conformational change, this method is not limited to labeling
peptides. Indeed through the incorporation of unnatural amino acids, bioorthogonal azides
can be introduced into proteins, allowing protein labeling as demonstrated by Wissner et
169

al.174 We have initiated studies directly labeling calmodulin protein with cryptophane,
following the reaction scheme in Figure 5.2 where the labeled protein was achieved as
confirmed by MALDI-MS, Figure 5.3. The reaction was complicated by the presence of
unlabeled protein as a result of aryl azide reduction, thus requiring further purification for
accurate concentrations of labeled protein to be determined. Moving forward, however, it
is reasonable to work with partially labeled batches of proteins as long as sufficient
concentrations are used to obtain xenon signal. More importantly, this system should be
optimized to increase xenon binding by first generating a cryptophane molecule that has
been solubilized to promote an open, xenon binding conformation.65 One possible method
to both improve solubility and improve labeling is to use a cryptophane such as the one
depicted in Figure 5.4.
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Figure 5. 3. MALDI-MS of cryptophane labeled calmodulin. Expected mass, M+H +=17702.5;
Found, M+H+=17749. The mass 16747 corresponds with para-amino-phenylalanine 16709.4
CaM. MALDI taken from crude reaction in DMSO and resulted in broad peaks.

Figure 5. 4. Proposed synthesis of water-soluble, azido cryptophane for labeling alkyneincorporated protein.
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§ 5.4 Final Remarks
In this thesis we have demonstrated the utility of xenon-129 as an ultrasensitive
contrast agent for NMR/MRI. Xenon hyperpolarization can be used to generate strong
signal enhancement (>105) over thermally equilibrated samples. The chemical environment
sensitivity of xenon can be exploited through host-guest chemistry using cryptophanes for
which xenon has a very high affinity. The cryptophane host molecules can be
functionalized with a wide variety of chemical handles to target any number of medically
relevant disease biomarkers. Further increases in sensitivity can be achieved through
indirect detection via hyperpolarized chemical exchange saturation transfer (HyperCEST). Indeed, through this technique we have demonstrated picomolar detection of
targeted biosensors. This host-guest system can also be applied as a biophysical probe in
chemical biology to facilitate the study of protein dynamics.
Moving forward, the field must demonstrate the utility of xenon biosensors in living
systems. Thus far, synthetic and equipment limitations have limited our ability to study the
efficacy of cryptophane in vivo. However, recent acquisition of a xenon polarizer and small
animal MRI at the medical school of the University of Pennsylvania may prove to facilitate
in vivo experiments in the near future. This will be a crucial test to ascertain the ultimate
applicability of this approach to disease imaging. In parallel with cryptophane biosensors,
the Dmochowski laboratory will continue to develop other small molecule (i.e.,
cucurbituril) as well as genetically encoded (i.e., protein) xenon biosensors, which will
expand the range of applications.
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Appendix A: List of Abbreviations
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H NMR spectra for 2a-(S)-(─). Reprinted with permission from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A.
Riggle; D.N. Haase; and I.J. Dmochowski. Synthesis of Enantiopure, Trisubstituted Cryptophane-A Derivatives.
Org Lett. 2012, 14, (14) 3580-3583. Copyright 2012 American Chemical Society.
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Appendix B: NMR Spectra
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C NMR spectra for 2a-(S)-(─). Reprinted with permission from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A.
Riggle; D.N. Haase; and I.J. Dmochowski. Synthesis of Enantiopure, Trisubstituted Cryptophane-A Derivatives.
Org Lett. 2012, 14, (14) 3580-3583. Copyright 2012 American Chemical Society.
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H NMR spectra for 2a-(S)-(+). Reprinted with permission from O. Taratula; M.P. Kim; Y. Bai; J.P.
Philbin; B.A. Riggle; D.N. Haase; and I.J. Dmochowski. Synthesis of Enantiopure, Trisubstituted
Cryptophane-A Derivatives. Org Lett. 2012, 14, (14) 3580-3583. Copyright 2012 American Chemical
Society.
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C NMR spectra for 2a-(S)-(+). Reprinted with permission from O. Taratula; M.P. Kim; Y. Bai; J.P. Philbin; B.A.
Riggle; D.N. Haase; and I.J. Dmochowski. Synthesis of Enantiopure, Trisubstituted Cryptophane-A Derivatives.
Org Lett. 2012, 14, (14) 3580-3583. Copyright 2012 American Chemical Society.
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NMR of trihydroxy cryptophane precursor from Route 1 in Chapter 2.
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Crude NMR of trihydroxy- aldehyde precursor to trihydroxy cryptophane from Route 3 in
Chapter 2.
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Crude NMR of trihydroxy- aldehyde precursor to trihydroxy cryptophane from Route 3 in
Chapter 2, zoom.
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